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iNtroductioN
Pain can be classified in several ways. The International Association for the Study of 
Pain (IASP) recommends describing pain according to five categories or axes, namely its 
anatomical location (neck, lower back, etc.), the body system involved (gastrointestinal, 
nervous, etc.), temporal characteristics (intermittent, constant, etc.), intensity and time 
since onset, and etiology (cause). The idea to discriminate between ‘nociceptive’ pain 
and ‘neuropathic’ pain only came into common clinical practice in the last decade. Since 
then, probably due to the therapeutic consequences of this classification, the proposal 
has become increasingly appreciated as a meaningful way to define pain.
In nociceptive or somatic pain, the initial stimulus of the peripheral nociceptor is 
produced chemically as a result of (potential) tissue damage. In contrast, neuropathic 
pain results from complex changes in the physiology of the nerve involved; this implies 
an affliction anywhere along the neuraxis from cortical neurons down to neurons in the 
anterior horn cell or in ganglia of the peripheral nervous system. The causes of neuro-
pathic pain include structural damage by disease, trauma, metabolic disturbance, and 
infection.1
Neuropathic pain is defined by the IASP as: pain arising from inflammation or injury to the 
peripheral or central nervous system, or from dysfunction of the nervous system.2 However, 
this definition has been an ongoing subject of debate. Some argue that inclusion of the 
term “dysfunction” makes this definition vague and far too broad.3,4 Moreover, a group 
of European neurologists have proposed a new definition for neuropathic pain, namely: 
pain arising as a direct consequence of a lesion or disease affecting the somatosensory 
system.5 This new insight emphasises the neurophysiological character of neuropathic 
pain and may help to overcome the current lack of progress in diagnostic classification.
Neuropathic pain occurs spontaneously (non-provoked), and responses to noxious 
and innocuous stimuli are pathologically amplified (provoked). The pain is caused by 
abnormal dysfunctional plasticity, i.e. repetitive neural action is re-focused to a disease 
state affecting the somatosensory system. Multiple alterations distributed widely 
across the nervous system contribute to different pain phenotypes. These alterations 
include ectopic generation of action potentials, facilitation and disinhibition of synaptic 
transmission, loss of synaptic connectivity and formation of new synaptic circuits, and 
neuroimmune interactions. Although neural lesions are necessary, the lesions alone are 
not sufficient to generate neuropathic pain; other factors influencing the risk to develop 
persistent pain include genetic polymorphisms, gender and age.6,7
The epidemiology of neuropathic pain has not been adequately studied, partly be-
cause of the diversity of the associated conditions. Current pooled data suggest that 
neuropathic pain may affect as much as 3% of the population.8–15
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Demonstrating a lesion of the nervous system that is compatible with particular signs 
and symptoms provides strong support for considering the pain to be neuropathic. 
However, when no lesion can be demonstrated the limits of current diagnostic technol-
ogy make it difficult to identify neuropathic pain. Furthermore, there is broad agree-
ment among pain clinicians and basic scientists that no suitable diagnostic tools are 
available to unambiguously identify which mechanisms cause neuropathic pain in any 
given patient. Moreover, in neuropathic pain no single mechanism, sign or symptom is 
pathognomonic.6,7,16. However, combinations of certain symptoms, pain descriptors, and 
bedside findings do increase the likelihood of a neuropathic pain condition.17,18
For the above-mentioned reasons, neuropathic pain is often under-diagnosed or 
recognised too late, which can result in ineffective pain management and therapeutic 
failure. This stimulated the development and validation of screening tools, in the form of 
questionnaires, based on verbal pain description with (or without) some bedside testing. 
A questionnaire format was selected because subjective pain experience, particularly 
the description of sensory pain, is often used in the identification of neuropathic pain 
mechanisms.19–23
One of the aims of this thesis is to validate and implement a questionnaire for reliable 
identification of specific signs and symptoms in order to accurately diagnose neuropathic 
pain. It is expected that this will also lead to a better understanding of the mechanisms 
involved in these signs and symptoms. Therefore, the DN4 (a questionnaire developed in 
France 23) was translated and validated for clinical use in the Netherlands.24,25
In the treatment of neuropathic pain, it is important to recognize that this pain con-
dition requires a new approach. For example, the ‘classic’ analgesics (e.g. NSAIDs) are 
generally of little benefit, 26 and none of the available pharmacological interventions 
produces meaningful pain relief in more than about 50% of the patients with neuro-
pathic pain.26 Although many medications with some evidence of efficacy are available 
for neuropathic pain, this condition remains under-recognized and therefore under-
treated.27
The most common pharmacological approaches to the management of neuropathic 
pain include antidepressants, anti-epileptics, SSRIs, SNRIs, opioids, and other treatments 
such as topical lidocaine patch and topical capsaicin.28
Double-blinded, placebo-controlled studies have been conducted to test the ef-
ficacy and tolerability of pregabalin in the treatment of peripheral neuropathic pain, 
in patients suffering from postherpetic neuralgia and post-traumatic pain, respectively. 
Pregabalin is an α2-δ ligand with demonstrated efficacy in epilepsy, neuropathic pain, 
and anxiety disorders.29 The results of two randomized controlled trials on neuropathic 
pain are presented in this thesis30,31.
A study in pain management clinics showed that patients with postherpetic neu-
ropathic pain and patients with non-neuropathic low back pain were similar in their 
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reports of pain, dysfunctional cognition, mood, and physical function.32 Two population-
based studies which used screening tools to identify neuropathic pain showed that it 
was associated with an excessive psychosocial burden compared to nociceptive pain, 
and that there is ample evidence that neuropathic pain impairs patients’ mood, quality 
of life, activities of daily living and performance at work.22,33
In this thesis we describe a cross-sectional survey among patients with postherpetic 
neuralgia which investigates health impairment and treatment patterns. Postherpetic 
neuralgia causes substantial patient burden expressed as interference with daily 
functioning and reduced health status associated with pain severity.34 Patient burden, 
expressed as impairment of function and reduced quality of life, was significantly as-
sociated with pain severity as indicated by poorer health status (EQ-5D) and increased 
pain interference with functioning (mBPI-SF Pain Interference scores) with increasing 
neuropathic pain severity.35,36
Understanding the relationship between pain severity and corresponding levels in 
patient-reported function can inform treatment decisions and guide assessment of out-
comes. We evaluated the relationship between pain (0–10 numerical rating scale, NRS), 
and patient-reported outcomes of function (Pain Interference Index from the modified 
Brief Pain Inventory), mood (Hospital Anxiety and Depression Scale), sleep (Medical 
Outcomes Study Sleep Scale), and sleep interference (0–10 NRS). 37
Postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) are 
common chronic neuropathic pain conditions. There is a complex relationship between 
chronic neuropathic pain and sleep, with pain often disturbing sleep and poor sleep 
exacerbating pain. We analyzed data of nine clinical trials investigating pregabalin for 
the treatment of PHN and DPN and showed that pregabalin has a beneficial effect on 
pain and sleep disturbances. 38
This thesis is based on clinical studies which focus on identifying and treating neuro-
pathic pain, co-morbidity and impairment of the patient’s quality of life.
14 Chapter I
refereNces
 1. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52:77–92.
 2. Merskey H, Bogduk N. Task Force on Taxonomy of the International Association for the Study of 
pain. IASP press 1994, Seattle, WA.
 3. Max MB. Clarifying the definition of neuropathic pain. Pain 2002;96:406–407.
 4. Backonja M. Defining neuropathic pain. Anesth Analgesia 2003;97:785–790.
 5. Treede RD, Jensen TS, Campbell JN et al. Neuropathic pain. Redefinition and a grading system for 
clinical and research purposes. Neurology 2008;70:1630–5.
 6. Woolf CJ, Max MB. Mechanism-based pain diagnosis: Issues for analgesic drug development. 
Anesthesiology 2001;95:241–249.
 7. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system 
to damage. Annu Rev Neuroscience 2009;32:1–32.
 8. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful 
diabetic neuropathy. Clin J Pain 2002;18:350–4.
 9. Werhagen L, Budh CN, Hultling C, et al. Neuropathic pain after traumatic spinal cord in-
jury–relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord 
2004;42:665–73.
 10. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiol-
ogy and management. CNS Drugs 2005;19:325–34.
 11. Sandroni P, Benrud-Larson LM, McClelland RL, et al. Complex regional pain syndrome type I: 
incidence and prevalence in Olmsted county, a population-based study. Pain 2003;103:199–207.
 12. Dieleman JP, Kerklaan J, Huygen FJPM, et al. Incidence rates and treatment of neuropathic pain 
conditions in the general population. Pain 2008;137:681–8.
 13. Bouhassira D, Lanteri-Minet M, Attal N, at el. Prevalence of chronic pain with neuropathic charac-
teristics in the general population. Pain 2008;136:380–387.
 14. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epide-
miological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer 
2008;99(4):604–610.
 15. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Bendow SJ. Chronic painful pe-
ripheral neuropathy in an urban community: a controlled comparison of people with or without 
diabetes. Diabet Med 2004; 21: 976–982.
 16. Natal N, Fermanian C, Fermanian D, et al. Neuropathic pain: Are there any distinct subtypes 
depending on the aetiology or anatomical lesion. Pain 2008;138: 343–53.
 17. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 
2007;127:199–203.
 18. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected 
neuropathic pain. Pain 2004;110:461–469.
 19. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to 
neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332–8.
 20. Bennett MI. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. 
Pain 2001;92:147–57.
 21. Bennett MI, Smith BH, Torrance N, et al. The S-Lanss score for identifying pain of predominantly 
neuropathic origin: validation for use in clinical and postal research. J Pain 2006: 149–58.
 22. Freyenhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify 
neuropathic components in patients with back pain.Curr Med Res and Opinions 2006;22:1911–20.
Introduction 15
 23. Bouhassira D, Attal N, Alchaar et al. Comparison of pain syndromes associated with nervous or 
somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain 
2005;114:29–36.
 24. Van Seventer R, Vos C, Meerding W, Mear I, Le Gal M, Bouhassira D, Huygen FJPM. Linguistic valida-
tion of the DN4 for use in international studies. Eur J Pain 2010 Jan;14(1):58–63. Epub 2009 Mar 
17.
 25. Van Seventer R, Vos CJ, Giezeman MJMM, Van Eerd M, Meerding WJ, Arnould B, Regnault A, Martin 
C, Huygen FJPM. Validation of the Dutch version of the DN4: A diagnostic questionnaire for neu-
ropathic pain. Submitted
 26. Gore M, Dukes E, Rowbotham DJ, Tai KS, et al. Clinical characteristics and pain management 
among patients with painful peripheral neuropathic disorders in general practice settings. Eur J 
Pain 2007;11:652–664.
 27. Attal N, Cruccu G, Haanpaa M, et al. EFNS Task Force: EFNS guidelines on pharmacological treat-
ment of neuropathic pain. Eur J Neurology 2006;13:1153–1167.
 28. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence 
based proposal. Pain 2005;118:289–305.
 29. Shneker BF, McAuley JW. Pregabalin: A new neuromodulator with broad therapeutic indications. 
Ann Pharmacother 2005;39(12):2029–2037.
 30. Van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of 
twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: 
a 13-week, randomized trial. Curr Med Res Opin 2006;22(2):375–84.
 31. Van Seventer R, Bach FW, Toth CC, Serpell M, Temple J, Murphy TK, Nimour M. Pregabalin in the 
treatment of post-traumatic peripheral neuropathic pain: A randomized double-blind trial. Eur J 
Neurol 2010;17(8):1082–9. Epub 2010 Mar 4.
 32. Daniel HC, Narewska J, Serpell M, et al. Comparison of psychological and physical function in 
neuropathic pain and nociceptive pain: implications for cognitive behavioural pain management 
programs. Eur J Pain 2008;12:731–741.
 33. Smith BH, Torrance N, Bennett MI, et al. Health and qualitiy of life associated with chronic pain of 
predominantly neuropathic origin in the community. Clin J Pain 2007;23:143–149.
 34. Van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of health state impairment 
and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35(2):132–7. 
Epub 2006 Jan 23
 35. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain 
2000;16 (2 Suppl.): S101–5
 36. Hoffman DL, Sadosky A, Dukes EM, et al. How do changes in average pain severity levels cor-
respond to changes in health status and functional outcomes in patients with painful diabetic 
peripheral neuropathy? Pain 2010, 149:194–201.
 37. Van Seventer R, Serpell M, Bach WB, Morlion BJ, Zlateva G, Bushmakin AG, Cappelleri JC, Nimour 
M. Relationships between changes in pain severity and patient-reported outcomes: An analysis in 
patients with posttraumatic peripheral neuropathic pain. Accepted for publication. 2011 March 
15. Health and Quality of Life Outcomes.
 38. Roth T, Van Seventer R, Murphy T.K. The effect of pregabalin on pain-related sleep interference 
in diabetic peripheral neuropathy or postherpetic neuralgia: A review of nine published clinical 
trials. Curr Med Res Opin 2010;26(10):2411–9.

 Chapter II
Linguistic validation of the DN4 for 
use in international studies
R. Van Seventer 1, C. Vos 2, W. Meerding 3, I. Mear 4, M. Le Gal 4, D. Bouhassira 5,6, F.J. 
P.M. Huygen 7
Author affi  liations:
1 Amphia Hospital, Department of Anaesthesiology, Breda, The Netherlands. 2 Department of General 
Practice, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands. 3 Pfi zer bv, Rivium 
Westlaan 142, 2909 LD, Capelle a/d IJssel, P.O. Box 37, 2900 AA Capelle a/d IJssel, The Netherlands. 
4 MAPI Group, 27, rue de la Villette, 69003 Lyon, France. 5 INSERM U-792, Boulogne-Billancourt 
F-92100, France. 6 Université Versailles-Saint-Quentin, Versailles F-78035, France. 7 Department of 
Anaesthesiology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
Published in: Eur J Pain 2010;14(1):58–63. Epub 2009 Mar 17.
18 Chapter II
AbstrAct
objectives
Traditionally, pain is divided into two main groups: nociceptive pain due to an excess 
of nociception and neuropathic pain associated with an injury or dysfunction of the 
central or peripheral nervous system. The French neuropathic pain group has devel-
oped a specific questionnaire, the DN4, to help clinicians in the differential diagnosis of 
neuropathic and non-neuropathic pain. In order to allow this questionnaire to be used 
in international studies, it has been translated and linguistically validated into Dutch, 
German, Greek and Hungarian, using a well-established procedure.
methods
The same method was used for each country and involved four stages: (1) two forward 
translations followed by comparison and reconciliation of the translations, (2) one back-
ward translation, (3) review by an expert clinician, and (4) cognitive testing of the first 
seven items on patients.
results
The translation work produced three types of situations. Either the original wording 
could be translated literally or semantic issues were discussed as the original wording 
was not always sufficiently clear and had to be clarified by adding an explanation, or, in 
the case of idiomatic phrases such as ‘‘pins and needles”, it was necessary to use differ-
ent expressions, the challenge being to retain the original concept while doing so. The 
versions proposed to patients and experts were well understood.
conclusion
The DN4 items were linguistically validated in each of the target languages, thus provid-
ing the means for standardising the diagnosis of neuropathic pain and pooling the data 
collected during clinical research in the different countries involved.
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1. iNtroductioN
The International Association for the Study of Pain (IASP) defines pain as ‘‘an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage”.
The IASP defines neuropathic pain as ‘‘initiated or caused by a primary lesion or dys-
function in the nervous system” (Backonja, 2003). Recently, the IASP’s special interest 
group proposed another definition: ‘‘pain arising as a direct consequence of a lesion 
or disease of the somatosensory system” (Treede et al., 2007). Neuropathic pain can be 
either peripheral or central, depending on where the lesion or dysfunction occurs (Attal 
and Bouhassira, 2004; Hansson, 2002).
The prevalence and incidence of neuropathic pain are difficult to assess given various 
origins and different ways of manifestation (Bowsher, 1991). Recent population-based 
studies in the UK and France based on screening tools have suggested that prevalence 
may be as high as 7–8% (Torrance et al., 2006; Bouhassira et al., 2008). Incidence rate in 
the Netherlands is estimated at 1% in the general population (Dieleman et al., 2008). 
This type of pain is under diagnosed and therefore not treated adequately (Hall et al., 
2006).
The lack of consensus on diagnostic criteria for neuropathic pain makes differential 
diagnosis and therefore adapted therapeutic approaches difficult in daily practice.
Early preliminary studies had suggested that some pain descriptors from the McGill 
Pain questionnaire could have a diagnostic value (Dubuisson and Melzack, 1976; 
Boureau et al., 1990). This notion was confirmed in a series of recent studies (Bennett, 
2001; Krause and Backonja, 2003; Bouhassira et al., 2005; Portenoy, 2006; Freynhagen et 
al., 2006a,b) showing that neuropathic pain has specific semiological characteristics. It 
was shown that, although no symptoms and/or signs were specific or pathognomonic, 
the combination of a relatively small number of selected symptoms and signs has a very 
high discriminative value for the identification of this category of pain. This was the basis 
for the development and validation of screening tools in the form of simple question-
naires based on verbal pain description.
Screening tools allow identification of potential patients with neuropathic pain, 
particularly in daily practice. This is probably their chief clinical strength. Their ease of 
use by professionals and patients makes them attractive. They provide immediate infor-
mation. Clinicians should then be alerted to undertake further assessment, which may 
subsequently influence management decisions. They fail to identify about 10–20% of 
patients with clinician-diagnosed neuropathic pain. They may offer guidance for further 
diagnostic evaluation and pain management but they do not replace clinical judgment 
(Bouhassira et al., 2004; Bennett et al., 2007).
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Epidemiology, in the general population and in specific clinical situations (e.g. Kaki et 
al., 2005; Torrance et al., 2006; Freynhagen et al., 2006a,b; Bennett and Bouhassira, 2007; 
Bouhassira et al., 2008) has been another major application of these tools.
Currently, five different screening tools are available for neuropathic pain including 
the DN4, developed by the French Neuropathic Pain Group (Bouhassira et al., 2005).
The aim being to use this new tool internationally, a linguistic validation process, 
described below, was required to ensure the equivalence of the concepts.
2. mAteriAls ANd methods
Interestingly, although screening tools were developed in parallel in different countries 
and into different languages (English, German, French), most of the items (i.e. pain 
descriptors) included in these clinical tools are similar, which strongly reinforces the 
relevance of this approach (Bennett et al., 2007). Thus, despite the specifities associated 
with the description of chronic pain in different cultures, the symptom-based approach 
for the diagnosis of neuropathic pain appears to be valid trans-culturally.
The DN4 was initially developed and tested in French, and then an English version 
was produced. This questionnaire consists of 10 items divided into two distinct sections: 
the patient interview (questions 1 and 2) and the standardised clinical examination of 
patients (questions 3 and 4) (Appendix A).
This questionnaire was tested, validated, and its psychometric properties verified 
during a study carried out in France involving 160 patients. It was noted that the 
seven items corresponding to the patients’ interview were sufficiently discriminating 
for the questionnaire to be used in large clinical studies with, for example, a telephone 
follow-up, or as part of epidemiological studies (Bouhassira et al., 2005, 2008). A recent 
psychometric study on 164 patients from Spain, further confirmed the high sensitivity 
of specificity of a Spanish translation of the DN4 questionnaire for the identification of 
neuropathic pain (Perez et al., 2007).
To obtain a translation of the DN4 original instrument in a target language that is both 
conceptually equivalent to the original and easily understood by the people to whom 
the translated questionnaire is administered, the Linguistic Validation followed an inter-
nationally-accepted translation methodology was performed using a well-recognized 
methodology which includes of the following standard steps (Figure 1) (Wild et al., 2005; 
Acquadro et al., 2004).
2.1. forward translation
The aim of this step is to produce a version in the target language that is close to the 
original questionnaire, both in meaning and conceptually.
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The process consists of different stages.
First, the concepts of each item in the original questionnaire are clearly defined in 
collaboration with the author. This ensures that translators in the different languages 
have a common understanding of the concepts and items, thereby ensuring that the 
translations remain faithful to the original meaning.
Two professional translators, native speakers of the target language and fluent in the 
source language, undertake independent forward translations of the original question-
naire into the target language. A reconciled language version is developed on the basis 
of the two forward translations.
2.2. backward translation
A backward translation of the reconciled language version is produced in the source 
language by a third professional translator, a native speaker of the source language and 
fluent in the target language. The back translation and the original version are then 
compared.
Any discrepancies encountered are analysed and, if necessary, changes are made to 
the reconciled translation in the target-language, leading to the production of a second 
target-language version.
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cifities associated with the description of chronic pain in different
cultures, the symptom-based approach for the diagnosis of neuro-
pathic pain appears to be valid trans-culturally.
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and easily understood by the people to whom the translated ques-
tionnaire is administered, the Linguistic Validation followed an
internationally-accepted translation methodology was performed
using a well-recognized methodology which includes of the fol-
lowing standard steps (Fig. 1) (Wild et al., 2005; Acquadro et al.,
2004).
2.1. Forward translation
The aim of this step is to produce a version in the target lan-
guage that is close to the original questionnaire, both in meaning
and conceptually.
The process consists of different stages.
First, the concepts of each item in the original questionnaire are
clearly defined in collaboration with the author. This ensures that
translators in the different languages have a common understand-
ing of the concepts and items, thereby ensuring that the transla-
tions remain faithful to the original meaning.
Two professional translators, native speakers of the target lan-
guage and fluent in the source language, undertake independent
forward translations of the original questionnaire into the target
language. A reconciled language version is developed on the basis
of the two forward translations.
2.2. Backward translation
A backward translation of the reconciled language version is
produced in he source language by a third professional translator,
• 1 Forward translation from the French original
•1 Forward translation from the English version Reconciliation
Target language version 1
Mapi Research Institute
Consultant
2 Translators
Backward translation into English Comparison
Target language version 2
Cognitive debriefing Discussion
Proof-reading
Discussion
Final target language version
Decision & Report Result Participants per language
Target language version 3
Linguistic Validation Certificate
Linguistic Validation Methodology
Original
Mapi Research Institute
Consultant
1 Translator
Mapi Research Institute
Consultant
5 Subjects
Mapi Research Institute
Consultant
1 Translator
Review by clinician Discussion
Target language version 3
Mapi Research Institute
Consultant
Clinician
Fig. 1. Linguistic validation methodology.  MAPI Research Institute, 1995. All Rights Reserved.
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2.3. Pilot testing
A clinician specialised in the treatment of neuropathic pain in the target country reviews 
the second target language version to obtain feedback from experts in the relevant 
medical field.
In the target country, the translated questionnaire is also administered to a small 
sample of five individuals with a low-to-average level of education, suffering from neu-
ropathic pain and who are native target-language speakers, in order to assess the clarity, 
appropriateness of wording and acceptability of the translated questionnaire. The third 
target-language version is produced based on the results of the clinician’s review and 
respondents’ feedback.
A summary report is compiled at each stage of the process.
The methodology used to translate the DN4 was adapted slightly as the questionnaire 
was originally developed in French, and then an English version was produced. For that 
reason, both the French original and the English version were used as starting points 
for the linguistic validation process. Therefore, the standard methodology needed to be 
revised slightly was as follows:
– One forward translation was based on the French original instrument and produced 
by a native-speaking translator from the target country, fluent in French; the second 
forward translation was based on the English version of the instrument and com-
pleted by a native-speaking translator from the target country, fluent in English.
– Although the original scale was developed in French, the backward translation was in 
English in order to facilitate the process and allow the consultant and MAPI Research 
Institute to perform a quality control.
– While the consultants primarily referred to the English version, MAPI Research Insti-
tute’s native French-speaking team provided input in the analyses and discussions 
based on the original French instrument, in order to reflect the original intended 
meaning.
This methodology was used to translate the DN4 into each of the four target languages.
The instructions and items 1 and 2 were translated using the complete process. In order 
for the Dutch version to be used both in the Netherlands and in Belgium, a harmonised 
version was produced after testing it on clinicians and patients both in the Netherlands 
and in Belgium. Items 3 and 4 were only tested on clinicians as these questions were 
only addressed to them.
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3. results
The cognitive debriefing step was carried out in each country on five patients suffer-
ing from neuropathic pain. Patient details and the average time spent filling in these 
questionnaires are presented in Table 1.
a native speaker of the source language and fluent in the target lan-
guage. The back translation and the original version are then
compared.
Any discrepancies encountered are analysed and, if necessary,
changes are made to the reconciled translation in the target-lan-
guage, leading to the production of a second target-language
version.
2.3. Pilot testing
A clinician specialised in the treatment of neuropathic pain in
the target country reviews the second target language version to
obtain feedback from experts in the relevant medical field.
In the target country, the translated questionnaire is also admin-
istered to a small sample of five individuals with a low-to-average
level of education, suffering from neuropathic pain and who are na-
tive target-language speakers, in order to assess the clarity, appro-
priateness of wording and acceptability of the translated
questionnaire. The third target-language version is produced based
on the results of the clinician’s review and respondents’ feedback.
A summary report is compiled at each stage of the process.
The methodology used to translate the DN4 was adapted
slightly as the questionnaire was originally developed in French,
and then an English version was produced. For that reason, both
the French original and the English version were used as starting
points for the linguistic validation process. Therefore, the standard
methodology needed to be revised slightly was as follows:
– One forward translation was based on the French original
instrument and produced by a native-speaking translator from
the target country, fluent in French; the second forward transla-
tion was based on the English version of the instrument and
completed by a native-speaking translator from the target coun-
try, fluent in English.
– Although the original scale was developed in French, the back-
ward translation was in English in order to facilitate the process
and allow the consultant and MAPI Research Institute to per-
form a quality control.
– While the consultants primarily referred to the English version,
MAPI Research Institute’s native French-speaking team provided
input in the analyses and discussions based on the original
French instrument, in order to reflect the original intended
meaning.
This methodology was used to translate the DN4 into each of
the four target languages.
The instructions and items 1 and 2 were translated using the
complete process. In order for the Dutch version to be used both
in the Netherlands and in Belgium, a harmonised version was pro-
duced after testing it on clinicians and patients both in the Nether-
lands and in Belgium. Items 3 and 4 were only tested on clinicians
as these questions were only addressed to them.
3. Results
The cognitive debriefing step was carried out in each country on
five patients suffering from neuropathic pain. Patient details and
the average time spent filling in these questionnaires are presented
in Table 1.
– The instruction sentence: ‘‘Please complete this questionnaire by
ticking one answer for each item in the 4 questions below:” was
translated literally in each target language, although a few slight
modifications were added. In Hungarian and German, the sen-
tence was split in two to make it easier to understand. In addi-
tion, as the term for ‘‘item” in German had not been well-
understood by patients, it was replaced by the equivalent of
‘‘point”. In Hungarian, the second part of the instructions were
translated using a colloquial expression ‘‘one–one square”,
which was confirmed to be understood well by patients, and
in the Greek version, it was specified that an ‘‘X” had to be used
to mark the answer (Table 2).
– During the translation process, it is easiest when the original
wording can be translated literally.
– Direct equivalents were found for items ‘‘burning” and ‘‘itching”
in each of the four languages, but the Hungarian translators felt
the need to add ‘‘sensation” after the word ‘‘burning” to make
the meaning clearer.
– The item ‘‘tingling” also had an equivalent in the four languages,
but the German translators decided to add the phrase ‘‘feeling of
ants crawling” to better reflect the original concept better. In
Greek, no additional phrase was necessary, as both translators
used the same word in their forward translations, meaning ‘‘like
when ants are walking on the skin”.
– No comments were made by the clinicians concerning the trans-
lations of these three items, and they were well-understood by
patients.
– The two items relating to sensory-deficit touch hypoesthesia
and pricking hypoesthesia provided no translation problems as
direct equivalents existed.
– Sometimes, semantic issues were discussed as the original
wording was not always sufficiently clear and had to be clarified
by adding an explanation.
– The items ‘‘painful cold” and ‘‘electric shocks” were modified
slightly during the forward translations, for example by adding
the word ‘‘sensation” or ‘‘like” to make their meaning clearer
and therefore easier to understand.
– For example, the item ‘‘electric shock” was translated in Hungar-
ian by the expression ‘‘sensation of electric-like shock” and for
the Greek version, patients themselves proposed the term ‘‘like
electric current” which seemed more idiomatic.
– When describing the ‘‘painful sensation of cold”, all five Greek
respondents spontaneously used the notion of ‘‘ice” and it was
therefore suggested that a reference to this should be added.
Table 1
Details of patients taking part in cognitive debriefing.
Number of patients
with neuropathic
pain
Age mean
(min–max)
Sex
male/
female
Completion time
mean (min–max)
Hungary 5 51.2 (29–69) 2/3 6.8 min (3–10)
Greece 5 71.4 (60–84) 1/4 1 min (0.5–1.5)
Germany 5 45.4 (34–63) 1/4 2.2 min (2–3)
Netherlands 5 54.6 (28–75) 2/3 2.2 min (1.0–4.5)
Belgium 4 67.3 (56–83) 1/3 10 min (5–15)
Table 2
Translations of the instruction sentence.
Backward translation
English
wording
‘‘Please complete this questionnaire by ticking one answer for each
item in the 4 questions below:”
Hungarian Please answer the following four questions. Answer all four
questions by marking one–one square
Greece Please complete this questionnaire by marking with a X one answer
for each item in the four questions below:
Germany Please answer the following four questions. Check only one answer
for each point:
Netherlands Please complete this questionnaire by crossing one answer for each
item of the four questions listed below:
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– The instruction sentence: “Please complete this questionnaire by ticking one answer for 
each item in the 4 questions below:” was translated literally in each target language, 
although a few slight modifications were added. In Hungarian and German, the 
sentence was split in two to make it easier to understand. In addition, as the term 
for ‘‘item” in German had not been wellunderstood by patients, it was replaced by 
the equivale t of ‘‘point”. In Hungarian, the second part of the instructions were 
translated using a colloquial expression ‘‘one–one square”, which was confirmed to 
be understood well by patients, and in the Greek version, it was specified that an ‘‘X” 
ad to be used to m rk the answer (Table 2).
a native speaker of the source language and fluent in the target lan-
guage. The back translation and the original version are then
compared.
Any discrepancies encountered are analysed and, if necessary,
changes are made to the reconciled translation in the target-lan-
guage, leading to the production of a second target-language
version.
2.3. Pilot testing
A clinician specialised in the treatment of neuropathic pain in
the target country reviews the second target language version to
obtain feedback from experts in the relevant medical field.
In the target country, the translated questionnaire is also admin-
istered to a small sample of five individuals with a low-to-average
level of education, suffering from neuropathic pain and who are na-
tive target-language speakers, in order to assess the clarity, appro-
priateness of wording and acceptability of the translated
questionnaire. The third target-language version is produced based
on the results of the clinician’s review and respondents’ feedback.
A summary report is compiled at each stage of the process.
The methodology used to translate the DN4 was adapted
slightly as the questionnaire was originally developed in French,
and then an English version was produced. For that reason, both
the French original and the English version were used as starting
points for the linguistic validation process. Therefore, the standard
methodology needed to be revised slightly was as follows:
– One forward translation was based on the French original
instrument and produced by a native-speaking translator from
the target country, fluent in French; the second forward transla-
tion was based on the E glish version of the instrument nd
complet d by a native-speaking translator from the target cou
try, fluent in English.
– Although the original scale was developed in French, the back-
ward translation was in English in order to facilitate the process
and allow the consultant and MAPI Research Institute to per-
form a quality control.
– While the consultants primarily referred to the English versio ,
MAPI Research Institute’s native French-speaking team provided
input in the analyses and discussions based on the original
French instrument, in order to reflect the o ig n intended
m aning.
This methodology w s u ed t translate the DN4 into each f
the four target languages.
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modifications were added. In Hungarian nd German, the s n
tence was split in wo to make it easier to understand. In addi-
tion, as the term for ‘‘item” in German had not been well-
understood by patients, it was replaced by the equivalent of
‘‘point”. In Hungarian, the second part of the instructions were
translated using a colloquial expression ‘‘one–one square”,
which was confirmed to be understood well by patients, and
in the Greek version, it was specified that an ‘‘X” ha t be used
to mark the answer (Table 2).
– During the translation process, it is easiest when the original
wording can be translated literally.
– Direct equivalents were found for items ‘‘burning” and ‘‘itching”
in each of the four languages, but the Hungarian translators felt
the need to add ‘‘sensation” after the word ‘‘burning” to make
the eaning clearer.
– The item ‘‘tingling” also had an equivalent in the four languages,
but the German translators decided to add the phrase ‘‘feeling of
ants crawling” to better reflect the original concept better. In
Greek, no additional phrase was necessary, as both translators
used the same word in their forward translations, meaning ‘‘like
when ants are walking on the skin”.
– No commen s we e made by the clinicians concerning the trans-
lations of these three items, and they were well-understood by
patients.
– The two items relating to sensory-deficit touch hypoesthesia
and pricking hypoesthesia provided no translation problems as
direct equivalents existed.
– Sometimes, semantic issues were discussed as the original
wording was not always sufficiently clear and had to be clarified
by adding an explanation.
– The items ‘‘painful cold” and ‘‘elect ic shocks” were modified
slightly during the forward tr nslations, for example by adding
the word ‘‘sensation” or ‘‘like” to make t eir meaning clearer
and therefore asier t understand.
– For example, the item ‘‘electric shock” was translated in Hungar-
an by the expression ‘‘sensation of elec ric-like shock” and for
he G eek version, patients themselves proposed the term ‘‘like
electric current” which seemed more idioma ic.
– When descri ing the ‘‘painful sensation of cold”, all five Greek
respondents spontaneously used th notion of ‘‘ice” and it was
th refore suggested that a referenc to this should be add d.
Table 1
Details of patients taking part in cognitive debriefing.
Number of patients
with neuropathic
pain
Age mean
(min–max)
Sex
male/
female
Completion time
mean (min–max)
Hungary 5 51.2 (29–69) 2/3 6.8 min (3–10)
Greece 5 71.4 (60–84) 1/4 1 min (0.5–1.5)
Germany 5 45.4 (34–63) 1/4 2.2 min (2–3)
Netherlands 5 54.6 (28–75) 2/3 2.2 min (1.0–4.5)
Belgium 4 67.3 (56–83) 1/3 10 min (5–15)
Table 2
Translations of the instruction sentence.
Backward translation
Engli h
wording
‘‘Please complete this questionnaire by ticking one answer for each
item in the 4 questions below:”
Hungarian Please answer the following four questions. Answer all four
questions by marking one–one square
Greece Please complete this questionnaire by marking with a X one answer
for each item in the four questions below:
Germany Please answer the f llowing four questions. Check only ne answer
for each point:
Netherlands Please complete this questionnaire by crossing one answer for each
item of the four questions listed below:
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– During the translation process, it is easiest when the original wording can be trans-
lated literally.
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– Direct equivalents were found for items ‘‘burning” and ‘‘itching” in each of the four 
languages, but the Hungarian translators felt the need to add ‘‘sensation” after the 
word ‘‘burning” to make the meaning clearer.
– The item ‘‘tingling” also had an equivalent in the four languages, but the German 
translators decided to add the phrase ‘‘feeling of ants crawling” to better reflect the 
original concept better. In Greek, no additional phrase was necessary, as both trans-
lators used the same word in their forward translations, meaning ‘‘like when ants are 
walking on the skin”.
– No comments were made by the clinicians concerning the translations of these three 
items, and they were well-understood by patients.
– The two items relating to sensory-deficit touch hypoesthesia and pricking hypoes-
thesia provided no translation problems as direct equivalents existed.
– Sometimes, semantic issues were discussed as the original wording was not always 
sufficiently clear and had to be clarified by adding an explanation.
– The items ‘‘painful cold” and ‘‘electric shocks” were modified slightly during the for-
ward translations, for example by adding the word ‘‘sensation” or ‘‘like” to make their 
meaning clearer and therefore easier to understand.
– For example, the item ‘‘electric shock” was translated in Hungarian by the expres-
sion ‘‘sensation of electric-like shock” and for the Greek version, patients themselves 
proposed the term ‘‘like electric current” which seemed more idiomatic.
– When describing the ‘‘painful sensation of cold”, all five Greek respondents spontane-
ously used the notion of ‘‘ice” and it was therefore suggested that a reference to this 
should be added.
 As this interpretation was found to be in line with the original concept, the item was 
consequently reworded as ‘‘painful sensation of cold as if it gets iced”, as the patients’ 
suggestion was approved by the clinician.
– The item ‘‘numbness” was translated into Hungarian and Greek using direct equiva-
lents, with no need for modification. In German, two alternatives, ‘‘stiffness” and 
‘‘numbness”, were suggested in the French to German translation. The latter wording 
was found to be closer in meaning to the original concept. However, the consultant 
explained that the German term ‘‘taubheit” can refer to both ‘‘numbness” and ‘‘deaf-
ness”. Consequently, to avoid any confusion, it was decided to use the alternative 
‘‘feeling of numbness” in the reconciled version.
– The term ‘‘numbness” was rendered in Dutch using a direct equivalent. The clinician 
suggested rewording the item as ‘‘deaf/dead sensation”. This change was implement-
ed in the Dutch translation. The item was correctly interpreted during the cognitive 
debriefing step and was therefore implemented in the final Dutch version. However, 
during the additional step when the Dutch translation was harmonized with the 
Belgian Dutch version, the term ‘‘dead” was deleted from the Dutch translation to 
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be in line with the Belgian Dutch version. The revised wording ‘‘deaf sensation” was 
tested on 4 patients in the Netherlands and the original meaning was confirmed to 
be correctly understood. The change was consequently implemented in the updated 
Dutch for the Netherlands version.
– On the other hand, ‘‘brushing”, the last item of the questionnaire, posed quite a few 
translation problems in each of the target languages.
A direct translation in Hungarian of ‘‘brushing” (dörzsölés) was found inappropriate in 
this context as this term refers to ‘‘brushing with strength”. The item was therefore ren-
dered as ‘‘touching (applying brush)” in the reconciled version. The clinician pointed out 
that a piece of cotton wool is more frequently used than a brush in neurological tests in 
Hungary. He therefore suggested rewording the item to read ‘‘touching (applying cotton 
wool or fine brush)”. This change was implemented in the final Hungarian version.
The term ‘‘brushing” was used by the English-to-Greek translator and the word ‘‘rub-
bing” by the French-to-Greek translator. The former was retained in the reconciled ver-
sion.
During the backward translation step, it was explained that the Greek noun for ‘‘brush-
ing” explicitly referred to the object ‘‘brush”. However, this word sounded too specific 
given that the original concept conveys a broader meaning and also implies rubbing 
with either the hand, a cloth, a brush or a piece of cotton wool. As a result, the term 
‘‘brushing” was replaced with ‘‘rubbing” and this alternative was to be carefully checked 
with the clinician. The clinician suggested adding ‘‘or caressing” after the word ‘‘rubbing” 
to fully convey the original concept. Since this part of the instrument is to be completed 
by the physician, the suggested alternative was retained.
The German word ‘‘bürsten” meaning ‘‘brushing” was retained in the reconciled ver-
sion but it was felt to be inappropriate in this context as it refers to actions requiring 
strength, such as cleaning shoes. The clinician suggested replacing the initial German 
wording with the phrase ‘‘caressing the skin with a brush”. As this alternative was found 
to be closer to the original concept, the reconciled version was reworded accordingly.
In the reconciled Dutch version, the item was rendered with an idiomatic term 
‘‘strijken”, literally meaning ‘‘stroking”. However, during the additional step when the 
Dutch translation was harmonized with the Belgian Dutch version, the Belgian Dutch 
version had used ‘‘wrijven”. The Dutch clinicians confirmed that the latter alternative 
(meaning ‘‘rubbing”) was closer to the original concept. The term ‘‘wrijven” was conse-
quently implemented in the updated Dutch for the Netherlands version.
– The idiomatic expression ‘‘pins and needles” was the item that proved to be the most 
difficult to translate because it was necessary to use different expressions.
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The expression ‘‘sensation of pins and needles” was preferred in Hungarian for the sake 
of clarity.
For the Greek version, both forward translators rendered this item with the noun 
literally meaning ‘‘pinnings”. This alternative was felt to be idiomatic and was therefore 
retained in the reconciled version. The clinician suggested replacing ‘‘pinnings” with 
‘‘needles and prickings”, as the latter expression is actually used in everyday practice and 
is better understood by Greek patients. This change was therefore implemented in the 
Greek version. In German, this item proved difficult to translate and generated extensive 
discussion. The English to German translator rendered it as ‘‘feeling of ants crawling on 
the skin”. However, this alternative was rejected as it was felt to be too close in meaning 
to item 4. The French-to-German forward translation used a German term ‘‘prickeln” 
(meaning prickling), which was explained to be slightly less intense than ‘‘stinging” but 
stronger than ‘‘tingling”. This wording was retained in the reconciled German version 
and the developer was contacted to clarify the original concepts. The original item was 
confirmed to refer to a prickling sensation; consequently, the initial German wording 
was replaced with ‘‘stechen”, a term generally used to describe a sharp pain as if caused 
by piercing. The clinician suggested adding the expression ‘‘like a thousand needles” in 
parentheses after the term ‘‘stechen”. Most participants found ‘‘stechen” inaccurate and 
pointed out that this term would generally be used to describe a stabbing pain rather 
than the kind of pain caused by thin needles. It was therefore suggested that the item 
be reworded as ‘‘pieksen (nadelstiche)” meaning ‘‘pricking (needles)”. However, to fully 
reflect the original concept, it was finally agreed to rephrase the item as ‘‘pricking (like a 
thousand needles)” as suggested by the clinician.
In the Dutch version, the term ‘‘prikkelingen”, meaning ‘‘pricking”, was found to be 
more appropriate and was consequently retained. However, it was discovered that the 
Dutch for ‘‘pricking” was confused with ‘‘tingling” by the patients. To avoid any misinter-
pretation, it was decided to replace the initial Dutch wording with ‘‘prikken”. This term, 
meaning ‘‘stinging”, was felt to better convey the original concept.
4. discussioN
The DN4 is a questionnaire developed to help clinicians, who are not pain specialists, 
to diagnose neuropathic pain in their daily clinical practice. This questionnaire consists 
of pain descriptors and items relating to bedside sensory examination (Bennett et al., 
2007).
When used in international studies, it is necessary to have language versions of this 
questionnaire available that are easily understood by patients and doctors in the dif-
ferent countries involved, and that measure the same concepts (Acquadro et al., 2004).
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Thus, the aim, when translating any document, is to transpose the text from the 
original language (source language) into another language (target language), while 
transmitting the message contained in it as faithfully as possible.
However, there is a difference between a translation, where the ideas expressed in one 
language are translated into another, and linguistic validation, whose objective is to ob-
tain a text that is conceptually equivalent without necessarily being a literal translation.
Item equivalents are found in different languages, yet it is necessary to ensure that 
they are correctly understood by users of the document. For example, in the DN4 
questionnaire, although an item such as ‘‘itching” posed no problem to translate, as an 
equivalent existed in the target language, it was necessary to add the word ‘‘sensation” 
after the item ‘‘burning”, to ensure in this case that the concept was clear and unambigu-
ous to patients.
The instruction sentence of the DN4 questionnaire ‘‘Please complete this question-
naire by ticking one answer for each item in the four questions below:” was, at first sight, 
very simple to translate, yet adaptations were made. Although equivalent words existed 
in each of the languages, slight modifications in sentence structure or vocabulary were 
necessary to make it easier to understand and to adapt it to the language structure 
found in each target country.
To ensure conceptual equivalence, it is essential to define the concepts precisely 
beforehand so that there is absolutely no ambiguity in interpretation, and the interpre-
tation is identical in every target language.
Few items in the DN4 questionnaire posed an interpretation problem, but the meaning 
is not easy to render in all languages. For the item ‘‘tingling”, although a direct equivalent 
was available in German, an explanatory phrase meaning ‘‘feeling of ants crawling” was 
added to reflect the defined concept more closely. During cognitive debriefing, patients 
validated this proposal, which eliminated any comprehension difficulties.
‘‘Brushing” posed a conceptual problem, as the concept conveyed by the word for 
‘‘brushing” in certain languages did not correspond to that initially foreseen by the 
questionnaire’s author. The point of this item was to evaluate whether stimuli that are in-
nocuous on normal skin can induce or increase pain for the patient. In some languages, 
such as Hungarian or German, the literal translation of the word was inappropriate, as 
the action suggested by this word was stronger than the author had intended.
In a straightforward translation, the direct equivalent of ‘‘brushing” would have been 
used, which would have been linguistically correct. However, the linguistic validation 
process allowed the concept of a gentler action to be transcribed more clearly, and 
which also happened to correspond to what clinicians normally do when they examine 
the patient. The risk of ambiguity was therefore eliminated.
This exercise is even more complex when the item is expressed by an idiomatic expres-
sion. In an ideal situation, it would be better for questionnaire developers to avoid using 
28 Chapter II
idiomatic expressions, although these often express the exact concept that is sought 
after. It is sometimes possible to find an equivalent expression in the target language, 
but it is often necessary to use a circumlocutory phrase. In the DN4 questionnaire, the 
expression ‘‘pins and needles” was translated in each of the target languages using a 
phrase linguistically remote from the original, but that still conveyed the same concep-
tual meaning.
The linguistic exercise is difficult as there are not one but several solutions that can usu-
ally be applied to different criteria. The question, therefore, is which criterion to adopt; 
either staying as close as possible to the original language structure or register, ensuring 
that there are no ambiguities by avoiding the risk of double meanings/double nega-
tives, or favouring the cultural aspect. Though the solutions retained in all languages 
are not identical, the fact that similar criteria are applied in the decision-making process 
ensures that the different target-language versions provide consistent and comparable 
results when applied in practice.
The results of the linguistic validation of the DN4 questionnaire clearly illustrate the 
importance of the various steps in the process.
The forward translation led to a consensus on the vocabulary, for example, with the 
item ‘‘tingling”, for which the two Greek translators used the same word in their forward 
translations, meaning ‘‘like when ants are walking on the skin”.
Backward translations avoid mistranslations and inaccuracies, although such prob-
lems did not arise in this case.
An adult’s understanding of a questionnaire is not affected by the patients’ age but 
rather by their level of education. Therefore, the age difference in the patients inter-
viewed in Greece, Belgium and in the other countries did not pose a problem. On the 
other hand, cognitive debriefing of subjects with a low-to-average level of education 
ensured that all items were understood correctly, using vocabulary suggested by the 
patients themselves. For example, the item ‘‘painful cold”, which they described as ‘‘cold 
as if it gets iced”, perfectly conveyed the concept sought and ensured the absence of 
ambiguity. Finally, the clinician-review step provides an extra quality control, validating 
the description of pain as expressed by patients and observed during clinical examina-
tion.
The linguistic validation process enabled items of the DN4 to be linguistically vali-
dated in each of the target languages. In clinical trials or epidemiological studies, the 
DN4 will provide the means for standardising the diagnosis of neuropathic pain and 
pooling the data from the different countries involved. It will be interesting to confirm 
the psychometric properties of each of these versions with the patient populations 
included in these studies, which is already the case for the Dutch version of the DN4, 
which is currently undergoing clinical validation in The Netherlands
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APPeNdiX A. dN4 QuestioNNAire (eNglish VersioN)
Item equivalents are found in different languages, yet it is nec-
essary to ensure that they are correctly understood by users of the
document. For example, in the DN4 questionnaire, although an
item such as ‘‘itching” posed no problem to translate, as an equiv-
alent existed in the target language, it was necessary to add the
word ‘‘sensation” after the item ‘‘burning”, to ensure in this case
that the concept was clear and unambiguous to patients.
The instruction sentence of the DN4 questionnaire ‘‘Please com-
plete this questionnaire by ticking one answer for each item in the
four questions below:” was, at first sight, very simple to translate,
yet adaptations were made. Although equivalent words existed in
each of the languages, slight modifications in sentence structure or
vocabulary were necessary to make it easier to understand and to
adapt it to the language structure found in each target country.
To ensure conceptual equivalence, it is essential to define the
concepts precisely beforehand so that there is absolutely no ambi-
guity in interpretation, and the interpretation is identical in every
target language.
Few items in the DN4 questionnaire posed an interpretation
problem, but the meaning is not easy to render in all languages.
For the item ‘‘tingling”, although a direct equivalent was available
in German, an explanatory phrase meaning ‘‘feeling of ants crawl-
ing” was added to reflect the defined concept more closely. During
cognitive debriefing, patients validated this proposal, which elimi-
nated any comprehension difficulties.
‘‘Brushing” posed a conceptual problem, as the concept con-
veyed by the word for ‘‘brushing” in certain languages did not cor-
respond to that initially foreseen by the questionnaire’s author. The
point of this item was to evaluate whether stimuli that are innoc-
uous on normal skin can induce or increase pain for the patient. In
some languages, such as Hungarian or German, the literal transla-
tion of the word was inappropriate, as the action suggested by this
word was stronger than the author had intended.
In a straightforward translation, the direct equivalent of ‘‘brush-
ing” would have been used, which would have been linguistically
correct. However, the linguistic validation process allowed the con-
cept of a gentler action to be transcribed more clearly, and which
also happened to correspond to what clinicians normally do when
they examine the patient. The risk of ambiguity was therefore
eliminated.
This exercise is even more complex when the item is expressed
by an idiomatic expression. In an ideal situation, it would be better
for questionnaire developers to avoid using idiomatic expressions,
although these often express the exact concept that is sought after.
It is sometimes possible to find an equivalent expression in the tar-
get language, but it is often necessary to use a circumlocutory
phrase. In the DN4 questionnaire, the expression ‘‘pins and nee-
dles” was translated in each of the target languages using a phrase
linguistically remote from the original, but that still conveyed the
same conceptual meaning.
The linguistic exercise is difficult as there are not one but sev-
eral solutions that can usually be applied to different criteria. The
question, therefore, is which criterion to adopt; either staying as
close as possible to the original language structure or register,
ensuring that there are no ambiguities by avoiding the risk of dou-
ble meanings/double negatives, or favouring the cultural aspect.
Though the solutions retained in all languages are not identical,
the fact that similar criteria are applied in the decision-making
process ensures that the different target-language versions provide
consistent and comparable results when applied in practice.
The results of the linguistic validation of the DN4 questionnaire
clearly illustrate the importance of the various steps in the process.
The forward translation led to a consensus on the vocabulary,
for example, with the item ‘‘tingling”, for which the two Greek
translators used the same word in their forward translations,
meaning ‘‘like when ants are walking on the skin”.
Backward translations avoid mistranslations and inaccuracies,
although such problems did not arise in this case.
An adult’s understanding of a questionnaire is not affected by
the patients’ age but rather by their level of education. Therefore,
the age difference in the patients interviewed in Greece, Belgium
and in the other countries did not pose a problem. On the other
hand, cognitive debriefing of subjects with a low-to-average level
of education ensured that all items were understood correctly,
using vocabulary suggested by the patients themselves. For exam-
ple, the item ‘‘painful cold”, which they described as ‘‘cold as if it
gets iced”, perfectly conveyed the concept sought and ensured
the absence of ambiguity. Finally, the clinician-review step pro-
vides an extra quality control, validating the description of pain
as expressed by patients and observed during clinical examination.
The linguistic validation process enabled items of the DN4 to be
linguistically validated in each of the target languages. In clinical
trials or epidemiological studies, the DN4 will provide the means
for standardising the diagnosis of neuropathic pain and pooling
the data from the different countries involved. It will be interesting
to confirm the psychometric properties of each of these versions
with the patient populations included in these studies, which is al-
ready the case for the Dutch version of the DN4, which is currently
undergoing clinical validation in the Netherlands.
Appendix A. DN4 Questionnaire (English version)
Question 1: Does the pain have any of the following
characteristics?
Yes No
Burning
Painful sensation of cold
Electric shocks
Question 2: Is the pain associated with any of the following
symptoms in the same area
Yes No
Tingling
Pins and needles
Numbness
Itching
Question 3: Is the pain located in an area where examination
reveals either of the following?
Yes No
Hypoesthesia to touch
Hypoesthesia to prick
Question 4: Is the pain provoked or increased by the following?
Yes No
Brushing
Bouhassira et al. (2005).
References
Acquadro C, Conway K, Giroudet C, Mear I. Linguistic validation manual for patient-
reported outcomes (PRO) instruments. Lyon: Mapi Research Institute; 2004. p.
15–7.
Attal N, Bouhassira D. Neuropathic pain: experimental advances and clinical
applications. Rev Neurol (Paris) 2004;160(2):199–203.
Backonja MM. Defining neuropathic pain. Anesth Analg 2003;97(3):785–90.
Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms
and signs. Pain 2001;92:147–57.
Bennett MI, Bouhassira D. Epidemiology of neuropathic pain: can we use the
screening tools? Pain 2007;132:12–3.
Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify
neuropathic pain. Pain 2007;127(3):199–203.
62 R. Van Seventer et al. / European Journal of Pain 14 (2010) 58–63

 Chapter III
VALIDATION OF THE DUTCH VERSION OF THE DN4 
DIAGNOSTIC QUESTIONNAIRE FOR NEUROPATHIC PAIN
Robert (R.) van Seventer 1, Kees (C.J.) Vos 2, Maurice (M.J.M.M.) Giezeman 3,Willem-
Jan (W.J.) Meerding 4, Benoit (B.) Arnould 5, Antoine (A.) Regnault 5, Maarten 
(M.J.P.G.) van Eerd 1, Carola (C.) Martin 6, Frank (F.J.P.M.) Huygen 6
Author affi  liations:
1 Amphia Hospital, Department of Anaesthesiology, Breda, Netherlands. 2 Erasmus Medical Center, 
Department of General Practice, Netherlands. 3 Diakonessen Hospital, Zeist, Netherlands. 4 Pfi zer bv, 
Netherlands. 5 Mapi Values, Lyon, France. 6 Erasmus Medical Center, Department of Anaesthesiology 
Pain treatment centre, Rotterdam, Netherlands
Submitted
34 Chapter III
AbstrAct
Difficulties in diagnosing neuropathic pain in routine clinical practice support the need 
for validated and easy-to-use diagnostic tools. The DN4 neuropathic pain diagnostic 
questionnaire aims to discriminate neuropathic pain from nociceptive pain, but needs 
clinical validation.
A total of 269 patients with chronic pain in three pain clinics were included in the study 
of which 248 had analyzable data. The mean duration of pain was 4.9 years. The most 
frequent etiologies were posttraumatic (36%), (pseudo) radicular (13%) and mechanical 
back (12%) pain. The mean intensity of patients’ pain at the moment of the visit was 5.6 
on a 0–10 scale.
196 out of 248 patients had an identical pain diagnosis from both physicians: 85 had 
neuropathic pain, 57 had nociceptive pain, and 54 had mixed pain. Among patients 
with identical diagnoses of neuropathic or nociceptive pain, using a receiver operat-
ing characteristic curve analysis, the area under the curve (AUC) was 0.81 for the DN4 
7-item and 0.82 for the 10-item version. A cut-off point of 5/10 for the full questionnaire 
resulted in a sensitivity of 75% and a specificity of 79%, while a cut-off point of 4/7 for 
the partial questionnaire resulted in a sensitivity of 74% and a specificity of 79%. The 
items “brushing”, “painful cold” and “numbness” were most discriminating.
The DN4 is an easy-to-use screening tool that is reliable for discriminating between 
neuropathic and nociceptive pain conditions in daily practice. Item-specific scores 
provide important information in addition to the total score.
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iNtroductioN
Pain can be classified in several ways. The International Association for the Study of 
Pain (IASP) recommends describing pain according to five categories or axes, namely its 
anatomical location (neck, lower back etc.), the body system involved (gastrointestinal, 
nervous etc.), temporal characteristics (intermittent, constant etc.), intensity and time 
since onset, and etiology (cause). From a therapeutic point of view a practical classifica-
tion between nociceptive and neuropathic pain is also advisable because each group 
requires a different treatment strategy.
Nociceptive pain is primarily treated with analgesics as described on the WHO ladder, 
for example with NSAIDs or weak and strong opioids. Neuropathic pain has to be treated 
with the so-called co-analgesics, drugs often originally not developed for the treatment 
of pain but which have a positive effect on this special kind of pain, for example tricyclic 
antidepressants and anti-epileptics [3].
Neuropathic pain is often difficult to diagnose and therefore possibly regularly under-
diagnosed or recognised too late, which may result in poor pain management strategies 
and therapeutic failures [9]. In a large primary care database study the incidence of neu-
ropathic pain was estimated to be 8.2 per 1000 person years translating to more than 
0.8% of the population per year or more than 130.000 cases in the Netherlands yearly [8].
In this study more than 50% of cases received pain medication within 6 months after 
diagnosis, mostly consisting of NSAIDs or aspirin. Anticonvulsants and tricyclic anti-
depressants were only used by 4.8 and 4.7% of cases respectively. Among every 1000 
patients registered with a general practitioner, about 60–80 patients will have symp-
toms of chronic neuropathic pain; 50% of these patients require medication and regular 
support [11]. The difficulties in identifying neuropathic pain support the need for diag-
nostic tools that can be used with, or even without, bedside testing [5]. The methods for 
developing and validating such tools are well defined [2]. Several screening tools are 
available in the form of questionnaires based on verbal pain descriptions. Regularly used 
screening questionnaires are the PainDetect [10] the S-LANSS [4] and the DN4 [7]. These 
screening tools allow identification of patients with neuropathic pain with a high degree 
of sensitivity and specificity. They can be used by pain specialists but also by general 
practitioners and nurses in daily practice [6]. DN4 stands for “douleur neuropathique 
4 questions” and was developed by the French Neuropathic Pain Group. The DN4 was 
designed as an easy to complete diagnostic questionnaire and is composed of 10 yes or 
no items. It was designed to compare signs and symptoms in patients with chronic pain 
associated with neurological (peripheral or central) or somatic tissue injuries [7]. The 
DN4 was linguistically validated in several languages including the Dutch and Spanish 
language [13,14].
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The primary objective of this study was to evaluate the diagnostic value of the Dutch 
version of the DN4 questionnaire. The secondary objectives were to evaluate the psy-
chometric properties and to compare these properties with those of the original French 
version.
methods
description of the dN4 questionnaire
The DN4 is a neuropathic pain diagnostic questionnaire built in two parts. The first 
part is based on symptoms estimated in an interview of the patient and can be self-
administered. The second part is based on a standardized clinical examination. The 
interview part includes 7 items corresponding to two domains. The questions initially 
assess pain characteristics (burning, painful cold and electric shocks), and subsequently 
assess associated symptoms of abnormal sensations in the same area (tingling, pins and 
needles, numbness, itching). The examination part includes two domains measured by 
3 items that address signs identified with a neurological examination: touch hypoes-
thesia, pricking hypoesthesia and pain caused or increased by brushing. Examination 
of sensitivity to touch and pricking is made by means of a soft brush and a von Frey hair 
respectively. In order to evaluate the tactile allodynia the soft brush is used once more. 
Every item is scored on a binary scale, with a no scoring as 0 and a yes scoring as 1. The 
sum of the item scores leads to a global score range between 0 and 10 when the 7 item 
interview part as well as the 3 item examination part are included. The total score ranges 
between 0 and 7 when only the 7 item interview part is utilised.
PAtieNts
Eligible patients were identified during referral and asked to participate in the study. 
Definite recruitment took place during the first visit in one of three participating pain 
clinics in the Netherlands, two general hospitals and one university hospital. All con-
secutive patients, men or women over 18 years old, with pain complaints were asked to 
participate in the study. Previously sent Data Privacy Statements were collected at the 
first visit, signed and dated.
Patients were included when their primary reason for consulting the doctor was 
chronic pain, defined as having pain for more than 3 months [12]. Other inclusion criteria 
were: suffering from moderate to severe pain (scoring 5 or higher on a 0–10 Numerical 
Rating Scale), being first time visitors and not yet previously diagnosed by the investiga-
tor. Exclusion criteria were major comorbidity (e.g. malignant disorders), fibromyalgia, 
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headache or visceral pain, communication or language issues, cognitive impairment, 
intellectual disorders, severe depression or psychosis (based on DSM IV) or participating 
in a clinical trial. Patients had to be able to speak and read the Dutch language.
desigN
The study was set up as a prospective observational study. At the first visit each pa-
tient was seen by a research nurse, and the same day was independently diagnosed 
for nociceptive, neuropathic or mixed pain by a physician. An independent diagnostic 
confirmation by a second physician took place the same day or at least within 72 hours 
after the first visit. All physicians were experienced pain anaesthesists or neurologists 
familiar with diagnosis and management of pain.
Prior to the first visit, patients were asked to complete the 7 self-assessment items of 
the DN4 questionnaire. On the day of the first visit the research nurse checked the 7 item 
questionnaire for completion and completed the demographic data of the patient (date 
of birth, gender, ethnic origin, medication for pain). The research nurse then adminis-
tered a second full 10-item DN4 questionnaire to the patient. Subsequently and without 
knowledge of the information from the patient and research nurse administered DN4 
questionnaires, the first physician completed the last 3 DN4 items of the patient admin-
istered questionnaire. The first physician also completed a diagnosis form in which the 
diagnosis (neuropathic, nociceptive or mixed pain) was stated. The second physician 
was asked to complete the same diagnosis form. Both physicians were blinded for the 
completed items of the DN4 and the second physician was blinded for the diagnosis 
of the first physician. Both physicians used whichever diagnostic tools they felt were 
appropriate.
In order to compare the results of this study with the results of the previously per-
formed validation study [7] we aimed for a comparable sample size of 70–80 patients in 
each of three diagnostic groups.
statistical analysis
Frequencies, standard deviation (SD) and total scores of all items were measured. All 
DN4 questionnaires were checked on completion. Questionnaires missing one or more 
items were not used in the analysis. The demographic data of patients removed from the 
analysis were compared with the remaining cohort.
The inter-rater reliability (i.e. agreement between the two assesments) of the last 
3 DN4 items and the reliability for self- and hetero-administrations of the first 7 DN4 
items were evaluated using Kappa coefficients. Strength of agreement is seen as poor 
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for values of Kappa <0.20; fair 0.21–0.40; moderate 0.41–0.60, good 0.61–0.80 and very 
good >0.81 [1].
The analysis of the discriminatory properties of the DN4 was limited to patients who 
were diagnosed with neuropathic or nociceptive pain by both physicians (n=142). 
In these patients the least doubt exists about the type of pain, and so they therefore 
provide the most appropriate groups to analyze the discriminatory properties. The 
discriminatory properties of the DN4 were assessed individually for each item as well as 
for the total scores of the 7-item and 10-item questionnaires. In this procedure, similar 
to the original French study, the diagnosis of neuropathic pain or nociceptive pain made 
by the physicians was considered as the gold standard. The ability of the DN4 items 
to discriminate between patients with nociceptive pain and patients with neuropathic 
pain was assessed using odds ratios (OR).
The predictive power of the DN4 diagnostic procedures was evaluated using the 
sensitivity, i.e. the ability of the diagnostic procedure to correctly identify patients with 
neuropathic pain, and the specificity, i.e. the ability of the diagnostic procedure to 
correctly identify patients without neuropathic pain. Receiving operator characteristic 
(ROC) curve was constructed and the area under the curve (AUC) calculated. A ROC 
curve is a plot of sensitivity as a function of 1–specificity for the possible cut-off points. 
This curve usually has a concave shape connecting the points (0,0) and (1,1). The AUC 
is a measure of the diagnostic power of the test, independent of cut-off points. An 
AUC <0.60 is considered ‘negative’, >0.60 and < 0.80 as ‘doubtful’, >0.80 and < 0.90 as 
‘good’ and >0.90 as ‘very good’ [1]. The Youden Index was calculated as the maximum of 
sensitivity plus specificity minus one for all possible cut-off points to identify the most 
relevant cut-off values [15]. All data processing and analyses were performed with SAS 
software for Windows (Statistical Analysis System, Version 9).
results
The study was performed in three different pain clinics from September 2006 until Sep-
tember 2008. In total 269 patients were eligible to enter the study. 19 patients did not 
complete all 7 DN4 self-assessment items. From the remaining 250 patients the diagno-
sis was missing from 1 patient, and baseline data were missing from 1 patient, resulting 
in 248 patients with analyzable data.Descriptions of socio-demographic characteristics 
in eligible patients are shown in Table 1.
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table 1 description of socio-demographic and pain characteristics in the eligible population (N=269)
Age, median (IQR Q1-Q3) 53.3 (41.2–63.1)
Gender, female (%) 68.0
Ethnic origin
Black (%) 0.7
Caucasian (%) 95.9
Other (%) 3.4
Pain characteristics
Duration of pain in years, median (IQR Q1-Q3) 2.0 (0.8–6.0)
Intensity of pain, mean (SD) 5.6 (2.2)
Acceptable pain intensity, mean (SD) 3.3 (2.1)
Results of sensory tests
Pinprick: decreased, normal, increased (%) 32.7, 33.5, 31.6
Cotton wool: decreased, normal, increased (%) 32.7, 43.5, 21.6
Cotton bud: decreased, normal, increased (%) 29.4, 42.8, 25.7
SD, standard deviation, IQR interquartile range.
The mean age was 52.3 years. A greater proportion of women entered the study (68%). 
The mean intensity of patients’ pain at the moment of the visit was 5.6 on a 0–10 scale, 
and the mean acceptable pain intensity was 3.3. The mean duration of pain was 4.9 
years. The most frequent etiologies of the pain were posttraumatic (36%), (pseudo) 
radicular (13%) and mechanical back pain (12%) as presented in Table 2.
table 2 Pain etiology ranked by frequency in the eligible population
Eligible population 
(n=269)
Patients with identical 
diagnosis of neuropathic 
pain (n=85)
Patients with identical 
diagnosis of nociceptive 
pain (n=57)
% % %
Posttraumatic 36.4 38.8 24.6
(Pseudo) radicular 12.6 11.8 8.8
Mechanical back 11.9 2.4 22.8
CRPS 9.7 23.5 3.5
Nerve damage 8.2 16.5 0.0
Lumbago 5.6 1.2 14.0
Soft tissue 3.7 2.4 8.8
Spinal stenosis 3.4 0.0 5.3
FBSS 2.6 0.0 0.0
Arthrosis 1.9 2.4 3.5
Cervicobrachial pain 1.9 0.0 7.0
Other 2.2 1.2 1.8
CRPS= Complex Regional Pain Syndrome
FBSS= Failed Back Surgery Syndrome
40 Chapter III
The 19 patients that did not complete all 7 DN4 self-assessment items were on average 
older and had a longer duration of pain but differences were small (data not shown).
From the 248 patients with analyzable data, the first and second physicians diagnosed 
identical types of pain in 196 patients: 85 patients with neuropathic pain, 57 patients 
with nociceptive pain and 54 patients with mixed pain. In the remaining 52 patients dif-
ferent diagnoses were made by the first and second physician. The diagnoses from both 
physicians were highly correlated, as demonstrated by a Pearson correlation coefficient 
of 0.82 for the scores on the specific 0–10 scale ranging from 0 nociceptive pain to 10 
neuropathic pain.
The majority of patients answered that pain was burning (62%) and painfully cold 
(52%), and that pain was associated with tingling (68%), pins and needles (61%) and 
numbness (66%). Only 38% answered that pain was like electric shocks and 21% that 
pain was associated with itching. Regarding the 3 examination items completed by the 
first physician, a majority answered that pain was not associated with touch hypoesthe-
sia (63%), pricking hypoesthesia (64%) or by brushing (60%).
The overall agreement between the patient-administered and nurse-administered 
information was very good for ‘burning’, ‘painful cold’ ‘and ‘itching’ (Table 3).
table 3 Inter-rater reliability for the DN4 items in patients with complete DN4 data (n=249)
Kappa coefficient
Patient — nurse
Kappa coefficient
Nurse — first physician
1. Burning 0.81  —
2. Painful cold 0.81  —
3. Electric shocks 0.69  —
4. Tingling 0.71  —
5. Pins and Needles 0.63  —
6. Numbness 0.67  —
7. Itching 0.82  —
8. Touch hypoesthesia  — 0.51
9. Pricking hypoesthesia  — 0.42
10. Brushing  — 0.56
Agreements for the other items were good. Inter-rater agreements for the last three 
items of the DN4 that were administered by the nurse and the first physician were mod-
erate, with Kappa coefficients between 0.42 and 0.56.
Because the aim of the study was to determine the discriminatory properties of the 
DN4, only patients with an identical diagnosis of neuropathic or nociceptive pain from 
both physicians were included in the analysis (n=142), using the scores from the patient 
administered questionnaire. The differences in DN4 item scores between neuropathic 
and nociceptive pain patients are shown in Table 4.
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table 4 Description of DN4 items in patients with neuropathic pain (n=85) and nociceptive pain (n=57)
Item answered with yes Neuropathic pain (%) Nociceptive pain (%)
1. burning 68.2 35.1
2. Painful cold 63.5 19.3
3. Electric shocks 42.2 29.8
4. Tingling 77.7 43.9
5. Pins and Needles 72.9 38.6
6.Numbness 74.1 31.6
7. Itching 29.4 19.3
8. Touch hypoesthesia 38.8 24.6
9. Pricking hypoesthesia 41.2 35.1
10. Brushing 50.6 8.8
Compared to nociceptive pain patients, neuropathic pain patients scored more posi-
tively on all the items, although not much higher on the itching and pricking hypoesthe-
sia items. Moreover neuropathic pain patients showed higher total scores on the DN4 
7-item and 10-item questionnaire compared to nociceptive patients (Figure 1a, 1b).
Six of the 10 DN4 items were individually and significantly able to discriminate between 
patients with neuropathic pain and those with nociceptive pain (Figure 2).
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figure 3a ROC curve for the 7-item DN4 score in the neuropathic and nociceptive pain groups (n=142)
 
 
figure 3b ROC curve for the 10-item DN4 score in the neuropathic and nociceptive pain groups (n=142)
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These items are: ‘burning’, ‘painful cold’, ‘’tingling’,’pins and needles’, ‘numbness’ and 
‘brushing’. The largest odds ratios observed were “brushing”, “painful cold” and “numb-
ness” (OR 10.6, 7.3 and 6.2, respectively).
We constructed two different ROC-curves, one for the 7-item and one for the 10-item 
questionnaire (Figure 3a, 3b).
Both the DN4 7-items and 10-items questionnaires showed good ability to discrimi-
nate between patients’ type of pain, with an AUC of 0.81 and 0.82, respectively. For the 
partial 7-item questionnaire the Youden index was 0.53, corresponding with a cut-off 
point of 4/7, a sensitivity of 74% and a specificity of 79%. Similarly, for the DN4 10-item 
questionnaire the Youden index was 0.54, corresponding with a cut-off score of 5/10, 
and the sensitivity and specificity of this cut-off score were 75% and 79%, respectively.
discussioN
Our study showed that the DN4 questionnaire is a diagnostic tool with a good ability to 
discriminate between neuropathic and nociceptive pain as shown by the ROC analysis, 
with an AUC of 0.81 and 0.82 for the 7-item and 10-item version, respectively.
There are two key characteristics of our study that strengthen the findings. Firstly, 
the patients in our study were a representative sample of a population presenting with 
chronic pain complaints in pain clinics. Secondly, we excluded patients with mixed 
pain and patients with noncorresponding diagnoses from two physicians. This enabled 
the analysis of the discriminatory ability of the DN4 in patients with a high likelihood 
of pain from a predominantly neuropathic or nociceptive origin. It is unlikely that 
the differences in diagnoses by two physicians were due to autonomous dynamics in 
pain symptoms because in practice all patients were seen by both physicians on the 
same day, although the protocol gave the opportunity for an interval of 72 hours. 
Our findings slightly differ from those of the French and Spanish validation studies [5,7]. 
For the 7-item version the cut-off score corresponding with the Youden index was higher 
than that defined on the original French data (4/7 vs. 3/7). For the 10-item DN4 we found 
a cut-off point of 5/10 while the French as well as the Spanish version both found a 
cut-off point of 4/10. Compared to the French study the diagnostic power was slightly 
lower as indicated by an AUC of 0.81 compared to 0.87 for the 7-item questionnaire and 
an AUC of 0.82 compared to 0.92 for the 10-item questionnaire. These differences may 
be explained by differences in the study design. As noted earlier, in our study patients 
with mixed pain were identified and excluded from the analysis of the diagnostic power. 
In addition, we used an unselected patient population of first time visitors with undiag-
nosed pain complaints that visited one of the three pain clinics involved in the study. 
The French study included patients who were already diagnosed. Also, patients with 
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a variety of chronic pain syndromes were included whereas these were more narrowly 
defined (e.g. CRPS patients were excluded) before inclusion in the French study. Finally, 
we used a Dutch translation of the DN4 that was derived from the French and English 
original. The Dutch version has been linguistically validated with a state-of-the-art 
methodology to solve semantic issues because of unclear wording in the original or 
because of equivalent alternative wordings in the target language with similar though 
slightly different meanings [14]. Nevertheless, slight differences in scoring because of 
different interpretations of items cannot be excluded.
The level of agreement between the patient-administered and nurse-administered 
questionnaire was good for the items “electric shocks”, ”tingling”, “pins and needles” and 
“numbness” and very good for the items “burning”, “painful cold” and “itching”. Except 
for the item “tingling”, Kappa coefficients were lower than those observed in the French 
study. This reflects a lower level of agreement between the Dutch physician and nurse 
than between the two French physicians. The agreement between the first physician 
and the nurse was considered moderate for the 3 items in the examination part. These 
three examination items did not add significantly to the sensitivity and specificity of the 
questionnaire. These findings are important in several ways. They support the idea that 
the DN4 produces reliable results with different modes of administration with no differ-
ences in diagnostic power, and can be applied in a flexible manner in clinical practice, 
in secondary as well as primary care settings. For daily practice the use of the 7-item 
questionnaire could be considered in order to make the DN4 also applicable outside 
the immediate physician consultation e.g. for pre-consultation and postal use. These 
applications could accelerate the use of the questionnaire. An easy-to-use questionnaire 
is also important for primary care settings. The findings also open the possibility that 
the three examination items are used as a second step if uncertainty remains for some 
patients with intermediate scores of 3 or 4 out of 7.
An alternative strategy for addressing uncertainty in diagnosis, particularly in patients 
with intermediate scores (e.g. 3 or 4 in the 7-item and 4 or 5 in the 10-item question-
naire), is provided by the differences in diagnostic power per item. In our study the 
examination item “brushing” and the items “painful cold” and “numbness” were identi-
fied as very discriminating between neuropathic and nociceptive pain. So the scores 
on these items may provide important information particularly when uncertainty exists 
about the diagnosis.
Compared to other neuropathic pain questionnaires the DN4 provided similar sensi-
tivity and specificity figures [6]. The choice as to which screening questionnaire is used 
also depends on the local acceptance of it. The DN4’s main advantages are that it is 
brief, and that a total score can be derived rapidly. It is also easy to apply any decision 
algorithm based on the total score, whereas the information on the discriminatory abil-
ity of the different items provides further flexibility in shaping these decisions.
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Of particular interest was the high level of acceptable pain in our study, with a mean 
score of 3.3 on a 0–10 numerical rating scale. It would be worth investigating the rela-
tionship between acceptable pain, pain intensity and the DN4 scores. Another issue for 
further research is whether DN4 response patterns would differ by age and sex, given the 
same type and level of pain. In our study we identified a substantial number of patients 
with mixed pain (n=54) and with different diagnoses (n=52) made by the two physicians. 
This indicates that it is important to provide physicians with reliable and validated tools 
to assist diagnosing. Now that the ability of the DN4 to discriminate between patients 
with clear neuropathic and nociceptive pain has been investigated and confirmed in 
several studies, a logical next step would be to investigate the performance of the DN4 
in patients with a less clear diagnosis or with mixed pain.
Whereas the DN4 has been identified as a useful tool to discriminate patients with 
neuropathic pain, it is worthwhile to investigate whether it is predictive for treatment 
response. Patients with a higher total score are hypothesized to be more responsive to 
therapy that is specific for the treatment of neuropathic pain.
We conclude that the DN4 is an easy-to-use screening tool that is reliable in daily prac-
tice to discriminate between neuropathic and nociceptive pain conditions. Item-specific 
scores provide important information in addition to the total score.
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AbstrAct
objective
This trial evaluated the efficacy andsafety of pregabalin dosed twice daily (BID) for relief 
of neuropathic pain associated with postherpetic neuralgia (PHN).
research design and methods
The 13-week, double-blind, placebo-controlled study randomized 370 patients with 
PHN to pregabalin (150, 300, or 600 mg/day BID) or placebo.
main outcome measures
Primary efficacy measure was endpoint mean pain score from daily pain diaries. The 
secondary efficacy measure was endpoint mean sleep-interference score from daily 
sleep diaries. Safety evaluations included adverse events (AEs), physical and neurologic 
examinations, 12-lead ECG, vital signs, and laboratory testing.
results
Pregabalin provided significant pain relief at endpoint: difference from placebo in mean 
pain score, 150 mg/day, –0.88, p = 0.0077; 300 mg/day, –1.07, p = 0.0016; 600 mg/day, 
–1.79, p = 0.0003. Weekly mean pain scores significantly improved as early as week 1. 
Sleep interference was also significantly improved at endpoint, compared with placebo 
( p < 0.001), beginning at week 1 ( p < 0.01). More patients in the 150 (22.6%, p = 0.02), 
300 (27.2%, p = 0.085), and 600 (36.5%, p = 0.003) mg/day pregabalin groups rated them-
selves ‘very much’ or ‘much’ improved than did patients in the placebo (16.2%) group.
Most AEs were mild or moderate. Among pregabalin-treated patients, 13.5% withdrew 
due to AEs, most commonly for dizziness (16 patients, 5.8%), somnolence (8, 2.9%), or 
ataxia (7, 2.5%).
conclusions
Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well 
tolerated. It also reduced the extent to which pain interfered with sleep. Pregabalin’s 
effects were seen as early as week 1 and were sustained throughout the 13-week study
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iNtroductioN
Ten to fifteen per cent of all patients with herpes zoster (HZ) have postherpetic neuralgia 
(PHN), persistent pain for > 3 months beyond the resolution of the HZ rash1. This often 
chronic pain resulting from HZ is neuropathic in nature. Neuropathic pain is differenti-
ated from nociceptive pain in that neuropathic pain is a direct result of damage to or 
dysfunction of the nervous system, while nociceptive pain is a neural response to injury 
to body tissues. PHN can be intensely painful, significantly interferes with sleep in > 50% 
of patients, and often impairs physical and psychosocial functioning2,3.
Treatment for PHN is often suboptimal. Tricyclic antidepressants have been first-choice 
therapy for PHN4–7, but their side-effects profiles may render their use in the elderly 
Problematic4,8,9. Some opioid analgesics10 and local anesthetic preparations (lidocaine 
patch)11 have shown some efficacy for relief of PHN. Drugs indicated for acute or noci-
ceptive pain, including non-steroidal anti-inflammatories, have been used to treat PHN 
with limited success. Gabapentin is approved for treatment of PHN in several countries12, 
however, gabapentin is relatively difficult to use clinically: it must be started at low doses, 
titrated to effective doses, and dosed three times daily (TID), adding complications for 
physicians and patients, which may affect compliance. There is a need for alternative 
treatments, the efficacy of which are supported by consistent clinical evidence. Pregaba-
lin is an alpha2-delta (α2-δ) ligand with analgesic, anxiolytic, and anticonvulsant activity. 
The compound binds potently to the α2-δ subunit protein of voltage-gated calcium 
channels13. Potent binding at this site reduces calcium influx at nerve terminals and 
reduces the release of several neurotransmitters, including glutamate, norepinephrine, 
and substance P, from activated neurons14–17. Pregabalin is inactive at GABAA and GABAB 
receptors, is not converted metabolically into GABA or a GABA antagonist, and does not 
alter GABA uptake or degradation18,19. Pregabalin’s Tmax is 1 h, its T. is 6 h, and it exhibits 
linear pharmacokinetics with low inter-subject variability. Pregabalin dosing does not 
require lengthy titration, and its starting dose of 150 mg/day significantly relieves pain 
in many patients.
Pregabalin — at dosages of 300 or 600 mg/day — has been shown to be safe and 
well tolerated, to reduce pain, and to improve sleep disturbance associated with chronic 
neuropathic pain in three studies totaling over 700 patients who had painful diabetic 
peripheral neuropathy20–22. Similarly, dosages of 150, 300, and 600 mg/day (TID) prega-
balin were shown to relieve pain and related sleep interference in two PHN studies of 
over 400 patients23,24. Most recently, in a study of 338 patients with either painful DPN 
or PHN who received 600 mg/day or flexibly-dosed (150–600 mg/day) pregabalin (BID) 
or placebo, treatment with pregabalin was associated with significant improvements 
in both pain and pain-related sleep interference25. In 2004, the American Academy of 
Neurology issued practice parameters for the treatment of PHN which identified prega-
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balin as a first-line treatment option for PHN1. This study was designed to evaluate the 
efficacy and tolerability of pregabalin dosed twice daily (BID) to enhance its ease of use 
in patients with PHN across its therapeutic dosing range.
PAtieNts ANd methods
Study 1008–196 was a randomized, double-blind, placebo-controlled, parallel-group, 
fixed-dose, multicenter, phase 3 trial, conducted from November 9, 2001 to October 30, 
2002. Patients were randomized to one of four treatments: placebo, 150, 300, or 600 mg/
day pregabalin, administered in two doses each day. Because pregabalin is renally ex-
creted (98% as unchanged drug), and because a doubling of exposure can be expected 
with a 50% reduction in creatinine clearance (CLcr)26, patients randomized to the 600 
mg/day group were stratified based on each patient’s CLcr: in this group, patients with 
CLcr > 60 mL/min received 600 mg/day pregabalin, while patients who had CLcr > 30 
and ≤ 60 mL/min received 300 mg/day, a dosage providing equivalent exposure to 600 
mg/day in patients with CLcr > 60 mL/min, based on pharmacokinetic modeling stud-
ies27. Creatinine clearance was estimated from serum creatinine, body weight, age, and 
sex using the Cockcroft and Gault equation.
The study consisted of three phases: 1-week baseline,13-week double-blind treatment 
(including 1-week titration and 12-week fixed-dose phases for patients receiving 300 or 
600 mg/day), and 1-week follow-up for patients not entering the open-label follow-on 
study. Patients were seen at six scheduled visits plus one follow-up visit (if not entering 
open label).
The study was conducted in accordance with the International Conference on Harmo-
nization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and US Food 
and Drug Administration regulations. Written informed consent was required from each 
patient (or their authorized representative) prior to enrolment. The protocol, consent 
documents, and protocol amendments were approved by each of the 76 participating 
centers’ Institutional Review Boards. Patients were eligible if they were ≥ 18 years old, 
had pain for > 3 months after healing of HZ lesions, had a visual analogue scale pain 
score ≥ 40 mm at baseline and at randomization, and had at least four daily pain diary 
entries with mean daily pain score ≥ 4 prior to randomization.
Patients were excluded for the following reasons: malignancy (with the exception 
of basal cell carcinoma) within the past 2 years; WBC < 2500 mm3, neutrophil count < 
1500 mm3, or platelet count < 100 × 103/mm3; clinically significant or unstable hepatic, 
respiratory, or hematologic illnesses or psychologic conditions; unstable cardiovascular 
disease; abnormal 12-lead ECG; history of chronic hepatitis B or C, hepatitis B or C within 
the past 3 months, or HIV infection; immunocompromise; history of alcohol or illicit drug 
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abuse within the last 2 years; or participation in a clinical trial for an investigational drug 
or agent within 30 days prior to baseline or participation in a previous trial of pregabalin. 
Patients with CLcr ≤ 30 mL/min were also excluded, as were patients who had previous 
surgical therapy for PHN, who had other severe pain or skin conditions in the affected 
dermatome that could alter sensation or that might compromise PHN assessment, or 
who had used prohibited medications, including long-acting benzodiazepines, skel-
etal muscle relaxants, steroids, capsaicin, mexiletine, dextromethorphan, amantadine, 
alpha-lipoic acid, hydroxychloroquine, thioridazine, deferoxamine, and antiepileptics 
(including carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topira-
mate, vigabatrin, and gabapentin) without appropriate washout (at least 7 days prior to 
entry to baseline phase). Stable regimens (of ≥ 30 days prior to study entry; therapy not 
to be initiated during study period) of non-narcotic analgesics, e.g., noramidopyrine and 
paracetamol, and stable regimens of opioids, anti-inflammatories, and antidepressants 
were allowed.
The primary efficacy parameter was endpoint mean pain score, based on the last 7 
days of patients’ daily pain diaries. Daily pain diaries consisted of an 11-point numerical 
rating scale (NRS), in which 0 = ‘nopain’ and 10 = ‘worst possible pain’. Each morning, 
patients rated the severity of their pain during the past 24 h by circling the appropriate 
number on the NRS. Supplemental analyses of the primary efficacy parameter included 
proportion of responders (patients with ≥ 50% reduction and patients with ≥ 30% reduc-
tion in mean pain score from baseline) and weekly mean pain scores. Secondary efficacy 
parameters included endpoint mean sleep-interference scores and weekly mean sleep-
interference scores. These measures were derived from daily sleep-interference diaries, 
consisting of an 11-point NRS, with 0 = ‘pain does not interfere with sleep’ through 10 
= ‘pain completely interferes with sleep’. At study termination, patients were also ad-
ministered the Patient Global Impression of Change (PGIC), a patient-rated instrument 
measuring change in patients’ overall health status on a 7-point scale ranging from 1 
(‘very much improved’) to 7 (‘very much worse’).
Efficacy analyses were performed on modified intent to-treat (ITT) patients — ran-
domized patients who took at least one dose of study medication and who had one or 
more post-baseline scores. Patients with no data for a parameter at baseline or at the 
time-point analyzed were excluded from that analysis. The sample size calculation was 
based on the primary efficacy parameter. Based on the results of previous pregabalin 
PHN trials, a common standard deviation of 2.15 was assumed23,24. Assuming two-sided 
testing at the 0.0167 level (to control for multiple comparisons), 88 patients per treat-
ment group would provide over 90% power to detect a difference of at least 1.3 between 
at least one pregabalin group and placebo. This difference from placebo is consistent 
with the design of other pregabalin PHN studies. Under the assumption of equal alloca-
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tion between the four treatment groups, a total sample size of 352 randomized patients 
is required.
The primary analysis of the primary parameter was an ANCOVA, including effects 
for treatment, cluster, CLcr stratum, and baseline mean pain score as the covariate. In 
addition, repeated-measures analysis was performed for the weekly mean pain scores 
and the weekly mean sleep interference scores. In each case, adjusted (leastsquares) 
means were obtained from the model and 95% confidence intervals on the difference in 
least-squares means between each pregabalin treatment group and placebo were con-
structed. p values were adjusted using the Hochberg procedure for the three pairwise 
comparisons versus placebo in order to protect the type I error rate at the 0.05 level. 
All statistical testing was done using SAS Version 6.12. Safety was assessed via adverse 
events (AEs) reporting (assessed as ‘mild’, ‘moderate’, or ‘severe’ by the investigators), 
laboratory testing, physical and neurologic exams, and 12-lead ECGs.
results
The four treatment groups were similar in gender (54% were female), age (mean = 
70.7 ±10.6 years), duration of PHN (mean = 40.7 months, median = 27 months), height, 
weight, and CLcr (Table 1). Four hundred and thirty-five patients entered the baseline 
phase, and 65 withdrew during the baseline phase: one patient experienced an adverse 
event, 48 patients (11%) did not meet the inclusion criteria, and 16 patients (4%) with-
drew due to other/administrative reasons.
Three hundred and seventy patients completed the baseline phase and were random-
ized (2 patients, one assigned to placebo and one to pregabalin 600 mg/day, did not 
receive study medication after randomization, Figure 1), and 368 patients were included 
in the modified ITT population. (The results and discussion below refer to this popu-
lation.) Despite concurrent use of pain-relief medications by 53% of patients — with 
paracetamol the most commonly reported (23%), followed by amitriptyline (12%) and 
tramadol (6%)– baseline mean pain scores for such patients were > 6 (as they were for 
patients not using concurrent medications), indicating continued moderate-to-severe 
pain. Thirty-four per cent of patients who received study medication withdrew during 
the double-blind phase: 13% because of an AE, 16% for lack of efficacy, 1% for lack of 
compliance, and 6% for other reasons (Figure 1). Two hundred and seventy-five patients 
(75%) entered the open-label, follow-on study: 63 (70%) from the pregabalin 600 mg/
day, 70 (71%) from the 300 mg/day, 68 (78%) from the 150 mg/day, and 74 (80%) from 
the placebo groups.
Endpoint mean pain score was significantly improved for each pregabalin dosage 
group compared with placebo (Table 2). Mean pain scores were also analyzed at each 
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Thirty‑four per cent of patients who received study 
medication withdrew during the double‑blind phase: 
13% because of an AE, 16% for lack of efficacy, 1% for 
lack of compliance, and 6% for other reasons (Figure 
1). Two hundred and seventy‑five patients (75%) 
entered the open‑label, follow‑on study: 63 (70%) 
from the pregabalin 600 mg/day, 70 (71%) from the 
300 mg/day, 68 (78%) from the 150 mg/day, and 74 
(80%) from the placebo groups.
Endpoint mean pain score was significantly 
improved for each pregabalin dosage group compared 
with placebo (Table 2). Mean pain scores were also 
analyzed at each study week, and, compared with 
placebo, all three pregabalin groups demonstrated 
significantly superior improvements in weekly mean 
pain score beginning at Week 1 ( p = 0.0005 for 
150 mg/day; p = 0.0002 for 300 and 600 mg/day). 
These significant improvements were maintained 
at every weekly timepoint and persisted throughout 
the study’s 13‑week duration (Figure 2), with 
maximum treatment effect beginning at approximately 
week 3.
The proportion of 50% responders (≥ 50% reduction 
from baseline) was 26.4% for the 150 mg/day, 26.5% 
for the 300 mg/day, and 37.5% for the 600 mg/day 
pregabalin groups versus 7.5% for the placebo group 
( p = 0.001 for each pregabalin group compared with 
placebo). The number needed to treat (NNT) based 
on ≥ 50% responder rates was 5.3 for the 150 mg/day, 
5.3 for the 300 mg/day, and 3.3 for the 600 mg/day 
pregabalin groups. The NNT for all pregabalin dosages 
combined (150–600 mg/day), was 4.4. The proportion 
 Placebo 
(n = 93) 
Pregabalin 
150 mg/day 
(n = 87) 
Pregabalin 
300 mg/day 
(n = 98) 
Pregabalin 
300/600 mg/day 
(n = 90) 
All patients 
(n = 368) 
Gender      
Male, n (%) 40 (43) 36 (41.4) 54 (55.1) 38 (42.2) 168 (45.7) 
Female, n (%) 53 (57) 51 (58.6) 44 (44.9) 52 (57.8) 200 (54.3) 
Premenopausal, n (%) 1 ( 1.9) 2 (3.9) 2 (3.9) 4 (7.7) 9 (4.5) 
Postmenopausal, n (%) 52 (98.1) 49 (96.1) 42 (95.5) 48 (92.3) 191 (95.5) 
Race      
White, n (%) 92 (98.9) 86 (98.9) 98 (100) 88 (97.8) 364 (98.9) 
Black, n (%) 0 1 (1.1) 0 1 (1.1) 2 (0.5) 
Other, n (%) 1 (1.1) 0 0 1 (1.1) 2 (0.5) 
Age categories      
18–64 years, n (%) 20 (21.5) 20 (23.0) 25 (25.5) 23 (25.6) 88 (23.9) 
 65, n (%) 73 (78.5) 67 (77.0) 73 (74.5) 67 (74.4) 280 (76.1) 
Age (years)      
Mean (SD) 70.9 (10.4) 70.5 (9.3) 70.7 (11.9) 70.7 (10.6) 70.7 (10.6) 
Median 72.0 73.0 73.0 72.5 73.0 
Min–max 42–89 38–88 18–92 38–90 18–92 
Weight (kg)      
Mean (SD) 73.03 (15.95) 72.27 (14.72) 73.72 (14.07) 72.71 (14.72) 72.96 (14.82) 
Median 72.00 72.00 74.35 71.45 72.00 
Min–max 36.0–154.0 44.8–111.1 45.0–111.0 44.5–105.8 36.0–154.0 
Baseline mean pain score      
Mean (SD) 6.85 (1.49) 6.44 (1.58) 6.72 (1.41) 6.65 (1.44) 6.67 (1.48) 
Median 7 6.57 6.93 6.71 6.79 
Min–max 1.71–10.00 2.57–10.00 3.71–9.71 3.86–10.00 1.71–10.00 
Duration of PHN (months)      
Mean (SD) 43.3 (44.8) 36.3 (43.1) 48.2 (53.1) 34.1 (37.3) 40.7 (45.3) 
Median 31 22 29 22.5 27 
Min–max 2–263 2–224 3–262 2–180 2–263 
Baseline CLcr (mL/min)      
Mean (SD) 76.80 (31.68) 74.34 (21.13) 75.33 (26.26) 76.34 (25.90) 75.71 (26.50) 
Median 68.00 71.00 70.50 72.50 71.00 
Min–max 32.0–229.0 36.0–126.0 37.0–201.0 33.0–152.0 32.0–229.0 
CLcr stratum      
Low (30‑60 mL/min), n (%) 31 (33.3) 26 (29.9) 33 (33.7) 26 (28.9) 116 (31.5) 
Normal (> 60 mL/min), n (%) 62 (66.7) 61 (70.1) 65 (66.3) 64 (71.1) 252 (68.5) 
Table 1. Patient characteristics (ITT population)
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Figure 1. Patient disposition cohort diagram
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(n = 435)
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(n = 87)
Pregabalin 300 mg/d
(n = 98)
Pregabalin 300/600 mg/d
(n = 90)
Completed study
(n = 59, 63.4%)
Completed study
(n = 61, 70.1%)
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(n = 62, 63.3%)
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(n = 60, 66.7%)
Entered open label
(n = 74, 79.6%)
Entered open label
(n = 68, 78.2%)
Entered open label
(n = 70, 71.4%)
Entered open label
(n = 63, 70.0%)
Not randomized (n = 65, 14.9%)
Did not meet criteria (n = 48, 11.0%)
Adverse event (n = 1, 0.2%)
Other/administrative (n = 16, 3.7%)
Withdrawn (n = 26, 29.9%)
Adverse event (n = 7, 8.0%)
Lack of compliance (n = 0, 0%)
(n = 16, 18.4%)
Other/administrative (n = 3, 3.4%)
Withdrawn (n = 36, 36.7%)
Adverse event (n = 15, 15.3%)
Lack of compliance (n = 1, 1.0%)
(n = 13, 13.3%)
Other/administrative (n = 7, 7.1%)
Withdrawn (n = 34, 36.6%)
Adverse event (n = 19, 21.1%)
Lack of compliance (n = 1, 1.1%)
(n = 6, 6.7%)
Other/administrative (n = 4, 4.4%)
Withdrawn (n = 34, 36.6%)
Adverse event (n = 5, 5.4%)
L
Lack of efficacy Lack of efficacy Lack of efficacy Lack of efficacy
ack of compliance (n = 0, 0%)
(n = 22, 23.7%)
Other/administrative (n = 7, 7.5%)
Treatment comparisons, pregabalin vs. placebo  N Least‑
squares 
means 
SE 
Difference 95% CI Unadjusted 
p value 
Adjusted† 
p value 
Pain        
Placebo 93 6.14 0.23     
PGB 150 87 5.26 0.24 –0.88 (–1.53, –0.23) 0.0077 0.0077 
PGB 300 98 5.07 0.23 –1.07 (–1.70, –0.45) 0.0008 0.0016 
PGB 600 88 4.35 0.24 –1.79 (–2.43, –1.15) 0.0001 0.0003 
Sleep        
Placebo 93 4.10 0.21     
PGB 150 87 3.07 0.22 –1.03 (–1.62, –0.44) 0.0007 0.0007 
PGB 300 98 2.84 0.21 –1.26 (–1.84, –0.68) 0.0001 0.0002 
PGB 600 88 2.17 0.22 –1.93 (–2.52, –1.34) 0.0001 0.0002 
SE = standard error; CI = confidence interval; PGB = pregabalin 
*Endpoint = last 7 available scores while on study medication, up to and including the day after the last dose. 
Based on LS Means using ANCOVA model (including effects for treatment, cluster, CLcr stratum, and the 
baseline sc re value as covariate) 
†Adjustment based on Hochberg’s procedure 
Table 2. Endpoint* mean pain and sleep interference scores for patients treated with placebo and three dosages  
of pregabalin (PGB)
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56 Chapter IV
study week, and, compared with placebo, all three pregabalin groups demonstrated 
significantly superior improvements in weekly mean pain score beginning at Week 1 ( p 
= 0.0005 for 150 mg/day; p = 0.0002 for 300 and 600 mg/day).
These significant improvements were maintained at every weekly timepoint and 
persisted throughout the study’s 13-week duration (Figure 2), with maximum pain relief 
(peak effect) beginning at week 3.
The proportion of 50% responders (≥ 50% reduction from baseline) was 26.4% for 
the 150 mg/day, 26.5% for the 300 mg/day, and 37.5% for the 600 mg/day pregabalin 
groups and 7.5% for the placebo group ( p = 0.001 for each pregabalin group compared 
withplacebo). Number needed to treat (NNT) based on ≥ 50% responder rates was 5.3 for 
the 150 mg/day, 5.3 for the 300 mg/day, and 3.3 for the 600 mg/day pregabalin groups. 
The NNT for all pregabalin doses combined (150–600 mg/day), was 4.4. The proportion 
of patients with ≥ 30% pain reduction from baseline, a clinically meaningful degree of 
improvement, as reported by Farrar et al.28, was 39.1% for the 150 mg/day, 40.8% for the 
300 mg/day, and 52.3% for the 600 mg/day pregabalin groups and 17.2% for placebo ( 
p ≤ 0.001, Figure 3).
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Mean sleep-interference scores at endpoint were significantly improved, compared 
with placebo, in all three pregabalin groups ( p = 0.0007 for 150 mg/day; p = 0.0002 for 
300 and for 600 mg/day, Table 2). Weekly mean sleep-interference scores were signifi-
cantly better than placebo beginning at week 1 and for every study week thereafter ( p 
< 0.01 for all pregabalin groups, Figure 4).
At study termination, more patients in the 150 mg/day (22.6%, p = 0.02), 300 mg/
day (27.2%, p = 0.085), and 600 mg/day (36.5%, p = 0.003) pregabalin groups rated 
themselves ‘very much’ or ‘much’ improved on the PGIC than did patients in the placebo 
(16.2%) group. At least minimal improvement was reported by 51.2%, 47.9%, and 67.1% 
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of patients with ≥ 30% pain reduction from baseline, 
a clinically meaningful degree of improvement, as 
reported by Farrar et al.28, was 39.1% for the 150 mg/
day, 40.8% for the 300 mg/day, and 52.3% for the 
600 mg/day pregabalin groups versus 17.2% for placebo 
( p ≤ 0.001, Figure 3).
Mean sleep‑interference scores at endpoint were 
significantly improved, compared with placebo, in all 
three pregabalin groups ( p = 0.0007 for 150 mg/day; 
p = 0.0002 for 300 and for 600 mg/day, Table 2). 
Weekly mean sleep‑interference scores were 
significantly better than placebo beginning at week 1 
Figure 2. Change from baseline in weekly mean pain scores, weeks 1–13. *p ≤ 0.01 vs. placebo. †600 mg/day arm stratified 
according to CL
cr
. Patients with CL
cr
 > 30 and ≤ 60 mL/min received 300 mg/day pregabalin; patients with CL
cr
 > 60 mL/
min received 600 mg/day. ‡Greater negative change from baseline indicates greater pain relief
Figure 3. Proportion of responders to treatment. *≥ 50% and ≥ 30% reduction from baseline. †p ≤ 0.001 vs. placebo. 
‡600 mg/day arm stratified according to CL
cr
. Patients with CL
cr
 > 30 and ≤ 60 mL/min received 300 mg/day; patients with 
CL
cr
 > 60 mL/min received 600 mg/day
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of pat ents with ≥ 30% pain duction f m baseline,
a clinicall  meaningful degree of imp ov ment, as 
reported by Fa rar et al.28, was 39.1% for the 150 mg/
day, 40.8% for the 300 mg/day, and 52.3% for the
600 mg/day pregabalin groups versus 17.2% for placebo 
( p ≤ 0.001, Figure 3).
Mean sleep‑interference scores a  endpoint were
significantly improved, compared with placebo, in all
three pregabalin groups ( p = 0. 07 for 150 mg/day;
p = 0.0002 for 300 and for 600 mg/day, Table 2).
Weekly mean sleep‑interference scores were
significantly better than placebo beginning at week 1 
Figure 2. Change from baseline in weekly mean pain scores, w eks 1–13. *p ≤ 0.01 vs. pl cebo. †600 mg/day arm stratified 
according to CL
cr
. Pati nts with CL
cr
 > 30 and ≤ 60 mL/min received 300 mg/day pregabalin; patients with CL
cr
 > 60 mL/
min received 600 mg/day. ‡Greater negative change from baseline indicates greater pain relief
Figure 3. P oportion of resp nders to treatment. *≥ 50% and ≥ % reduction from baselin . †p ≤ 0.001 vs. placebo. 
‡600 mg/day arm stratified according to CL
cr
. Patients with CL
cr
 > 30 and ≤ 60 mL/min received 300 mg/day; patients with 
CL
cr
 > 60 mL/min received 600 mg/day
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of patients treated with 150, 300, and 600 mg/day pregabalin, respectively compared 
with 35.6% of those treated with placebo.
sAfety ANd tolerAbility
The most commonly reported treatment-associated AEs (Table 3) for the pregabalin 
groups were dizziness (16.1%, 32.7%, 36.7% of patients in the 150, 300, and 600 mg/
day groups, respectively; 9.7% for placebo), somnolence (9.2%, 11.2%, 25.6% of patients 
in the 150, 300, and 600 mg/day groups, respectively; 4.3% for placebo), and periph-
eral edema (12.6%, 14.3%, 13.3% of patients in the 150, 300, and 600 mg/day groups, 
respectively; 10.8% for placebo). Most AEs were mild or moderate in intensity. There 
were no patient deaths reported during this double-blind study. Sixteen per cent of the 
275 patients in the three pregabalin groups and 13% of the 93 placebogroup patients 
had severe AEs. Serious AEs (defined as congenital anomaly/birth defect, persistent or 
significant disability/incapacity, any AE resulting in patient hospitalization or prolonga-
tion of existing hospitalization, immediately life-threatening, death, or any medically 
significant event, including laboratory abnormalities) occurred in 3.6% of pregabalin 
patients and 2.2% of placebo patients. A total of 13.5% of pregabalin patients and 4.3% 
of placebo patients withdrew because of AEs considered associated with treatment. 
Among pregabalin-treated patients, AEs most frequently leading to withdrawal were 
dizziness (5.8%), somnolence (2.9%), and ataxia (2.5%), while among placebo-treated 
patients, dizziness (3.2%) most frequently led to withdrawal (no patients in the placebo 
group withdrew because of somnolence or ataxia). Only 1.5% of pregabalin-treated 
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and for every study week thereafter ( p < 0.01 for all 
pregabalin groups, Figure 4).
At study termination, patients in the 150 (p = 0.02) 
and 600 mg/day (p = 0.003) groups were more likely 
to report global improvement than those in the 
placebo group. At least minimal improvement was 
reported by 51.2%, 47.9%, and 67.1% of patients 
treated with 150, 300, and 600 mg/day pregabalin, 
respectively compared with 35.6% of those treated 
with placebo. Much or very much improvement 
was reported by 22.6%, 27.2%, and 36.5% of 
patients treated with 150, 300, and 600 mg/day 
pregabalin, compared with 16.2% of those receiving 
placebo.
Safety and tolerability
The most commonly reported treatment‑associated 
AEs (Table 3) for the pregabalin groups were dizziness 
(16.1%, 32.7%, 36.7% of patients in the 150, 300, 
and 600 mg/day groups, respectively; 9.7% for 
placebo), somnolence (9.2%, 11.2%, 25.6% of 
patients in the 150, 300, and 600 mg/day groups, 
respectively; 4.3% for placebo), and peripheral edema 
(12.6%, 14.3%, 13.3% of patients in the 150, 300, and 
600 mg/day groups, respectively; 10.8% for placebo). 
Most AEs were mild or moderate in intensity. 
There were no patient deaths reported during this 
double‑blind study. Sixteen per cent of the 275 
patients in the three pregabalin groups and 13% of 
the 93 placebo‑group patients had severe AEs. Serious 
AEs (defined as congenital anomaly/birth defect, 
persistent or significant disability/incapacity, any AE 
resulting in patient hospitalization or prolongation of 
existing hospitalization, immediately life‑threatening, 
death, or any medically significant event, including 
laboratory abnormalities) occurred in 3.6% of 
pregabalin patients and 2.2% of placebo patients. 
A total of 13.5% of pregabalin patients and 4.3% of 
placebo patients withdrew because of AEs considered 
associated with treatment. Among pregabalin‑treated 
patients, AEs most frequently leading to withdrawal 
were dizziness (5.8%), somnolence (2.9%), and 
ataxia (2.5%), while among placebo‑treated patients, 
dizziness (3.2%) most frequently led to withdrawal 
(no patients in the placebo group withdrew because of 
somnolence or ataxia). Only 1.5% of pregabalin‑treated 
patients and 1.1% of placebo‑treated patients withdrew 
from the study because of peripheral edema. Of 
pregabalin‑treated patients, 6.9% reported weight 
gain as an AE that was considered associated with 
treatment. None of the AEs of weight gain was 
considered severe, and none led to withdrawal from 
the study.
Two patients had abnormal ECG findings that were 
present at termination, with no previous clinically 
significant findings detected at baseline. One patient’s 
abnormal ECG findings were considered unrelated to 
pregabalin (the patient had a history of hypertension 
and stroke and showed evidence of myocardial 
infarction at baseline); findings for the other patient 
(who was in the placebo group) were considered 
of unknown causality. Neither of these findings led 
to withdrawal.
Figure 4. Mean weekly pain‑related sleep‑interference scores in postherpetic neuralgia at all dosages. *p ≤ 0.01 vs. placebo. 
†600 mg/day arm stratified according to CL
cr
. Patients with CL
cr
 > 30 and ≤ 60 mL/min received 300 mg/day pregabalin; 
patients with CL
cr
 > 60 mL/min received 600 mg/day
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patients and 1.1% of placebo-treated patients withdrew from the study because of 
peripheral edema. Of pregabalintreated patients, 6.9% reported weight gain as an AE 
that was considered associated with treatment. None of the AEs of weight gain was 
considered severe, and none led to withdrawal from the study.
Two patients had abnormal ECG findings that were present at termination, with no 
previous clinically significant findings detected at baseline. One patient’s abnormal ECG 
findings were considered unrelated to pregabalin (the patient had a history of hyperten-
sion and stroke and showed evidence of myocardial infarction at baseline); findings for 
the other patient (who was in the placebo group) were considered of unknown causal-
ity. Neither of these findings led to withdrawal.
discussioN
In this 13-week study of patients with PHN — more than half of whom had high (> 6) 
baseline mean pain scores despite the use of pain-relief medications — all three BID 
dosages of pregabalin were associated with a statistically significant reduction in end-
point mean pain score versus placebo. Onset of statistically significant reduction of pain 
was rapid — beginning as early as Week 1, the first post-baseline time-point analyzed 
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Discussion
In this 13‑week study of patients with PHN – more 
than half of whom had high (> 6) baseline mean pain 
scores despite the use of pain‑relief medications – all 
three BID dosages of pregabalin were associated with a 
statistically significant reduction in endpoint mean pain 
score versus placebo. Onset of statistically significant 
reduction of pain was rapid – beginning as early as 
Week 1, the first post‑baseline time‑point analyzed 
– and remained statistically significant throughout 
the study’s 13 weeks. This finding is consistent with 
results reported from previous studies of pregabalin 
in both painful DPN and PHN. Pregabalin showed an 
increase in effect with increasi g dosage. At exposure 
equivalent to 600 mg/day BID, 37.5% of pregabalin‑
treated patients met the strict criterion for response 
(≥ 50% improvement). The NNT for this level of 
reduction in pain for the dosage range of 150–600 mg/
day was 4.4 (consistent with that observed in other 
studies of pregabalin for neuropathic pain), while 
the NNT to achieve a similar reduction in pain for 
gabapentin across a dosage range of 1800–3600 mg/
day has been calculated, from two studies, to be 5.0–
5.812,29. Further, 52% of patients in the 600 mg/day BID 
pregabalin group experienced ≥ 30% improvement, a 
level considered to indicate clinically meaningful pain 
relief28.
Improvement of sleep interference began by week 1 
for each of the three dosage groups, and it was signif‑
icantly superior to placebo at each weekly time‑point 
throughout the study. Because sleep interference is 
frequently co‑morbid with PHN (in > 50% of p tients)2, 
pregabalin’s effect on sleep interference represents an 
important benefit to patients being treated for PHN.
Pregabalin’s effect of reducing pain a d improving 
pain‑related sleep interference in patients with PHN 
has been established in two previous studies using TID 
dosing23,24 and in one study using BID dosing25. In this 
trial using BID dosing of longer duration (13 weeks 
versus 8 weeks in the two previous TID‑dosing PHN 
trials), pregabalin demonstrated similar efficacy 
and tolerability. Further, while the trial reported by 
Dworkin et al.23 had a single treatment arm (300 or 
600 mg/day based on creatinine clearance) and the 
trial reported by Sabatowksi et al.24 included 150‑ and 
300‑mg/day treatment arms, this is the first pregabalin 
PHN trial to include three treatment arms spanning 
Placebo 
(N = 93) 
Pregabalin 
150 mg/day
(N = 87) 
Pregabalin 
300 mg/day
(N = 98) 
Pregabalin 
600 mg/day
(N = 90) 
Adverse event/preferred 
term 
Number of patients (%) 
Dizziness 9 (9.7) 14 (16.1) 32 (32.7) 33 (36.7) 
Somnolence 4 (4.3) 8 (9.2) 11 (11.2) 23 (25.6) 
Peripheral edema 10 (10.8) 11 (12.6) 14 (14.3) 12 (13.3) 
Ataxia 0 (0.0) 3 (3.4) 6 (6.1) 11 (12.2) 
Dry mouth 0 (0.0) 5 (5.7) 4 (4.1) 11 (12.2) 
Constipation 2 (2.2) 1 (1.1) 8 (8.2) 8 (8.9) 
Weight gain 0 (0.0) 3 (3.4) 8 (8.2) 8 (8.9) 
Amblyopia 1 (1.1) 2 (2.3) 3 (3.1) 5 (5.6) 
Asthenia 5 (5.4) 4 (4.6) 3 (3.1) 5 (5.6) 
Edema 3 (3.2) 3 (3.4) 3 (3.1) 5 (5.6) 
Abnormal gait 0 (0.0) 1 (1.1) 2 (2.0) 4 (4.4) 
Abnormal vision 0 (0.0) 0 (0.0) 2 (2.0) 4 (4.4) 
Face edema 2 (2.2) 3 (3.4) 1 (1.0) 4 (4.4) 
Headache 3 (3.2) 4 (4.6) 1 (1.0) 4 (4.4) 
Thinking abnormal 1 (1.1) 2 (2.3) 2 (2.0) 4 (4.4) 
Confusion 1 (1.1) 3 (3.4) 3 (3.1) 3 (3.3) 
Diplopia 0 (0.0) 0 (0.0) 0 (0.0) 3 (3.3) 
Flatulence 2 (2.2) 1 (1.1) 0 (0.0) 3 (3.3) 
Incoordination 0 (0.0) 2 (2.3) 1 (1.0) 3 (3.3) 
Nausea 5 (5.4) 1 (1.1) 0 (0.0) 2 (2.2) 
Diarrhea 1 (1.1) 5 (5.7) 0 (0.0) 0 (0.0) 
Pain 2 (2.2) 2 (2.3) 3 (3.1) 0 (0.0) 
Sweating 3 (3.2) 1 (1.1) 0 (0.0) 0 (0.0) 
*AEs that were possibly, probably, or definitely related – and those for which the relationship was 
unknown – reported in at least 3% of patients in any treatment group. Events are sorted by 
decreasing frequency in the 600 mg/day pregabalin treatment group 
Table 3. Summary of associated* treatment‑emergent adverse events (ITT population)
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— and remained statistically significant throughout the study’s 13 weeks. This finding 
is consistent with results reported from previous studies of pregabalin in both painful 
DPN and PHN. Pregabalin showed a positive increase in effect with increasing dosage. 
At exposure equivalent to 600 mg/day BID, 37.5% of pregabalin-treated patients met the 
strict criterion for response (≥ 50% improvement). The NNT for this level of reduction in 
pain for the dosage range of 150–600 mg/day was 4.4 (consistent with that observed 
in other studies of pregabalin for neuropathic pain), while the NNT to achieve a similar 
reduction in pain for gabapentin across a dosage range of 900–3600 mg/day has been 
calculated, from two studies, to be 5.3–5.8. Further, 52% of patients in the 600 mg/day 
BID pregabalin group experienced ≥ 30% improvement, a level also considered to be 
clinically meaningful pain relief28.
Improvement of sleep interference began by week 1 for each of the three dosage 
groups, and it was significantly superior to placebo at each weekly timepoint through-
out the study. Because sleep interference is frequently co-morbid with PHN (in > 50% of 
patients)2, pregabalin’s effect on sleep interference represents an important benefit to 
patients being treated for PHN.
Pregabalin’s effect of reducing pain and improving pain-related sleep interference in 
patients with PHN has been established in two previous studies using TID dosing23,24 and 
in one study using BID dosing25. In this trial of BID dosing of longer duration (13 weeks 
versus 8 weeks in the two previous TID-dosing PHN trials), pregabalin demonstrated 
similar efficacy and tolerability. Further, while the trial reported by Dworkin et al.23 had 
a single treatment arm (300 or 600 mg/day based on creatinine clearance) and the trial 
reported by Sabatowksi et al.24 included 150- and 300-mg/day treatment arms, this is 
the first pregabalin PHN trial to include three treatment arms spanning pregabalin’s 
effective dosing range, 150–600 mg/day, each of which was associated with significant 
efficacy and favorable tolerability. Importantly, even at the high end of pregabalin’s dos-
ing range, using a BID as opposed to a TID schedule, most AEs were mild to moderate, 
and the low withdrawal rate due to AEs suggests the clinical benefit of treatment may 
have outweighed the discomfort of patients’ AEs.
coNclusioN
In addition to confirming previous data demonstrating pregabalin’s sustained, benefi-
cial effects for relief of neuropathic pain and associated sleep interference, this 13-week 
study supports a more convenient BID dosing schedule in PHN. Pregabalin represents 
a rapid-onset treatment option for PHN that is easy to use, shows low intersubject vari-
ability, and is well tolerated.
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AbstrAct
background
Pregabalin is effective in the treatment of peripheral and central neuropathic pain. This 
study evaluated pregabalin in the treatment of post-traumatic peripheral neuropathic 
pain (including post-surgical).
methods
Patients with a pain score ≥4 (0–10 scale) were randomized and treated with either 
flexible-dose pregabalin 150–600 mg/day (n=127) or placebo (n=127) in an 8-week 
double-blind treatment period preceded by a 2-week placebo run-in.
results
Pregabalin was associated with a significantly greater improvement in the mean 
endpoint pain score vs. placebo; mean treatment difference was -0.62 (95% CI -1.09 to 
-0.15) (P=0.01). The average pregabalin dose at endpoint was ~326 mg/day. Pregabalin 
was also associated with significant improvements from baseline in pain-related sleep 
interference, and the Medical Outcomes Study Sleep Scale sleep problems index and 
sleep disturbance subscale (all P<0.001). In the all patient group (ITT), pregabalin was 
associated with a statistically significant improvement in the Hospital Anxiety and De-
pression Scale anxiety subscale (P<0.05). In total, 29% of patients had moderate/severe 
baseline anxiety; treatment with pregabalin in this subset did not significantly improve 
anxiety. More patients reported global improvement at endpoint with pregabalin than 
with placebo (68% vs. 43%; overall P<0.01). Adverse events led to discontinuation of 
20% of patients from pregabalin and 7% from placebo. Mild or moderate dizziness and 
somnolence were the most common adverse events in the pregabalin group.
conclusion
Flexible-dose pregabalin 150–600 mg/day was effective in relieving neuropathic pain, 
improving disturbed sleep, improving overall patient status and was generally well 
tolerated in patients with post-traumatic peripheral neuropathic pain.
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iNtroductioN
Pregabalin demonstrated analgesic efficacy in the treatment of painful diabetic neu-
ropathy (DPN) [1–3], postherpetic neuralgia (PHN) [3–6] central neuropathic pain [7], 
and fibromyalgia [8]. The analgesic efficacy of pregabalin in peripheral and central neu-
ropathic pain models, as well as in fibromyalgia, a disorder in which central sensitization 
is thought to be an important component [10], has been linked to its ability to modulate 
neurotransmitter release from hyperexcited neurons via binding to the alpha-2-delta 
site, mediating calcium influx [9,10].
In addition to significant analgesic efficacy, pregabalin also improves pain-related 
sleep interference in neuropathic pain and is associated with significant patient-reported 
global improvement [1–7]. The anxiolytic activity of pregabalin has been demonstrated 
in several clinical trials in generalized anxiety disorder (GAD) in which pregabalin was 
associated with a significant improvement in the Hamilton Anxiety Rating Scale [11].
To date, the most rigorous evaluations of pregabalin in neuropathic pain have been 
undertaken in studies in patients with a single underlying cause. The study we report 
extends the findings from DPN and PHN studies by evaluating the efficacy of pregabalin 
in patients with post-traumatic peripheral neuropathic pain. A further objective was to 
evaluate the effect of pregabalin on anxiety in those patients with clinically relevant 
anxiety symptoms.
methods
Patients
Men or women aged 18 to 80 years with post-traumatic peripheral neuropathic pain, 
confirmed by a pain specialist, and which had persisted for at least 3 months following 
the traumatic event, were eligible. Patients with DPN, PHN, radiculopathy, trigeminal 
neuralgia, carpal tunnel syndrome, central neuropathic pain or Complex Regional Pain 
Syndromes I or II were excluded. Patients with creatinine clearance ≤60 mL/min or a 
positive urine illicit drug screen were also excluded. Women who were breastfeeding 
or pregnant were excluded and those able to conceive were required to use reliable 
contraception.
All patients were required to have a score greater than 40mm on the 100mm visual 
analog scale (VAS) of the Short-Form-McGill Pain Questionnaire [12] at screening (before 
a 2-week, single-blind, placebo run-in period) and at randomization. To be randomized, 
patients were also required to have completed a daily pain diary upon awakening in 
the 2 weeks before treatment in which pain in the last 24h was rated on an 11-point 
numerical rating scale (NRS) from 0=no pain to 10=worst possible pain, and to have 
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an average score of at least 4 based on at least four daily entries during the week prior 
to randomization. Patients were allowed to be taking non-steroidal anti-inflammatory 
drugs (NSAIDs) including cyclooxygenase-2 inhibitors (COX-2s), opioid and non-opioid 
analgesics, antiepileptic drugs (AEDs) and antidepressant medications concomitant pain 
medications if they had been stable for at least 1 month before the study and would 
remain so during the study. Those taking gabapentin were required to discontinue treat-
ment at the screening visit and those previously exposed to pregabalin were excluded.
All patients gave written, informed consent. Institutional review boards reviewed and 
approved the protocol and the study was conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines and local laws and regulations.
study design and treatment
This was an international, multicenter, parallel-group, double-blind, randomized clini-
cal trial comparing 8 weeks of flexible-dose pregabalin 150–600 mg/day with placebo, 
taken as two daily doses (Clintrial.gov Identifier: NCT00292188). Randomization was 
preceded by a 2-week, single blind, placebo run-in period; baseline data were collected 
at randomization. Patients who did not meet both pain entry criteria at randomization 
(i.e. NRS and VAS assessments) specified above were not randomized.
Study medication was initiated at 150 mg/day for the first week and was then in-
creased to 300 mg/day for the second week. Investigators were encouraged to have 
patients take their first dose in the morning. The 300 mg/day dose could be further 
increased to 600 mg/day from the beginning of week 3 if needed for efficacy. Only one 
dose reduction was allowed. A 450 mg/day dose increment was not included as 225 mg 
capsules had not been manufactured at the time of the study. Medication was blinded 
by using capsules of identical size, color, taste and smell for placebo and pregabalin. 
An Interactive Voice Recognition System was used to randomize patients. Clinic visits 
were scheduled for screening, baseline and the end of weeks 1, 2, 3, 4, 5 and 8, or upon 
discontinuation. There was a 1-week double-blind taper period at the end of the study.
efficacy assessments
The endpoint mean pain score was the primary efficacy variable and this was based on 
the last seven entries in the daily pain diary described above, which was completed by 
the patient during the placebo run-in and each day during the 8-week, double-blind 
treatment period. Patients also rated the extent to which pain interfered with sleep in 
a daily diary on an 11-point NRS from 0=pain does not interfere with sleep to 10=pain 
completely interferes with sleep.
Other secondary efficacy assessments included the Medical Outcomes Study (MOS)-
sleep scale [13] which was based on a 1-week recall period and was completed at 
baseline and week 8 or upon early discontinuation (endpoint) and the Hospital Anxiety 
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and Depression Scale (HADS) [14] which was completed at baseline, weeks 1 and 5 and 
at endpoint. The modified Brief Pain Inventory short-form (mBPI-sf ) [15] was completed 
at baseline and endpoint and the Patient Global Impression of Change (PGIC), in which 
patients rated their overall status on a 7-point scale from 1=very much improved to 
7=very much worse [16] was completed at endpoint.
tolerability and safety assessments
All spontaneously reported and observed adverse events, vital signs, and body weight 
were recorded at each clinic visit. Routine clinical laboratory tests were conducted at 
screening and endpoint. Peripheral edema was monitored.
data analysis
The sample size estimation, based on the between group comparison of the mean pain 
score at endpoint, assumed a two-sided comparison with a tolerance for type I error at 
alpha = 0.05. Based on the results of a previous flexible-dose study in PHN and DPN [4], 
the mean endpoint pain difference was estimated to be 1.2 with a standard deviation 
(SD) of 2.3. Because our study recruited patients with peripheral neuropathic pain of dif-
ferent etiologies, we sought to detect a smaller effect size than the previous study. It was 
calculated that 113 patients per group would provide 90% power to detect a treatment 
difference of 1.0 assuming the same SD. Assuming a dropout rate of 13% we estimated 
130 per patients group should be enrolled. We also estimated based on previous studies 
[7, 24] that to detect a mean difference (SD) of 2.3 (3.0) in the endpoint HADS anxiety 
subscale score in the subset of patients with a baseline score >10 (moderate to severe 
anxiety) that 39 patients (i.e. 30%) in each group would have to meet this criterion.
All analyses were based on the intention-to-treat population (ITT). In post-hoc analy-
ses, a model was fitted which also adjusted for gender and tested for a treatment by 
gender interaction. The proportions of patients with a ≥30% and ≥50% reduction in 
pain score between baseline and endpoint (responder analyses) were calculated. Mean 
changes from baseline to endpoint in the secondary efficacy variables were determined.
All analyses were based on two-sided tests using SAS procedures without adjustment 
for testing multiple measures. All continuous variables were analyzed using ANCOVA, 
controlling for pooled country, and baseline values. The analysis of weekly mean pain 
and sleep interference scores was based on a mixed model repeated measures (MMRM) 
analysis and least squares (LS) means were compared between groups each week. The 
MMRM analysis used all of the available data from sequential observations in patients to 
impute missing values. Categorical variables were analyzed using the Cochran-Mantel-
Haenszel test. Adverse events were coded using the Medical Dictionary for Regulatory 
Activities (MedDRA®) terminology.
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results
Patients
A total of 367 patients took single-blind placebo during the 2-week run-in period 
(Figure 1). Of the 367 treated in the single-blind run in, 254 were randomized and re-
ceived either placebo (n=127) or pregabalin (n=127). One patient from each group was 
excluded from the ITT analysis because they did not have post-baseline efficacy data. Of 
the 113 patients who were not randomized, 28 did not meet pain entry criteria.
Baseline demographic and clinical characteristics were generally similar in the two 
randomized treatment groups, except there was a greater proportion of women in the 
pregabalin group (60.6%) than in the placebo group (40.9%) (Table 1). All patients had post-
traumatic pain. The cause of pain was collected in an open field where the investigators 
table 1 Patient demographics and baseline characteristics
Placebo (n=127) Pregabalin (n=127)
Women, n (%) 52 (40.9) 77 (60.6)
Age, yr, mean (SD) 51 (13) 52 (14)
Aged ≥65–80 yr, n (%) 25 (19.7) 29 (22.8)
White race, n (%) 120 (94.5) 124 (97.6)
Weight, kg, mean 81 (17) 78 (15)
Mean duration of neuropathic pain, 
yr (range)
4.4 (0.2–29) 4.3 (0.3–26)
Primary neuropathic pain 
diagnosisa
Trauma 59 (46.5) 62 (48.8)
Surgical 41 (32.3) 44 (34.6)
Amputation 6 (4.7) 3 (2.4)
Nerve injury 12 (9.4) 8 (6.3)
Other 9 (7.1) 10 (7.9)
Concomitant pain medications, 
n (%)b
101 (79.5) 102 (80.3)
NSAIDs/Cox-2s 46 (36.2) 57 (44.9)
TCAs 39 (30.7) 41 (32.3)
SNRIs 7 (5.5) 2 (1.6)
Opioids 15 (11.8) 20 (15.8)
Tramadol 41 (32.3) 42 (33.1)
AEDsc 46 (36.2) 41 (32.3)
Abbreviations: NSAID — non-steroidal anti-inflammatory drug; COX-2 -cyclooxygenase-2 inhibitor; TCA 
— tricyclic antidepressant; SNRI selective norepinephrine receptor inhibitor, AEDs — anti-epileptic drugs.
 aCategorized based on the open field description on the cause of pain recorded by the investigator
 bMedications may not have been specifically prescribed for neuropathic pain
 cAEDs, excluding gabapentin, were allowed
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recorded what they felt was an appropriate description. Generally the statements in this 
field lacked sufficient detail to further classify the trauma causing the post traumatic pain 
precisely. Investigators recorded that almost half the patients had “trauma” as the cause of 
the neuropathic pain and a further one-third as having developed pain as a result of surgery.
The overall discontinuation rate from randomized treatment was similar in both treat-
ment groups (Figure 1). Lack of efficacy resulted in the discontinuation of 9.4% from 
placebo and 1.6% from pregabalin. Adverse events were given as the reason for the dis-
continuation of 7.1% and 19.7% from the placebo and pregabalin groups, respectively.
apparent at week 3 (P = 0.01) and then weekly from
week 5 to week 8 (P < 0.05). The mBPI-sf pain inter-
ference and severity indices, which were not subject to
formal statistical analysis, showed improvement in both
groups which were numerically greater in the pregaba-
lin group than the placebo group.
In total, 25.4% in the pregabalin group and 32.5% in
the placebo group had a baseline HADS anxiety sub-
scale score >10. In this subset of patients, there was
modest but insignificant difference between groups in
the change in the HADS anxiety score between baseline
and end-point. (Table 2). In the all-patient group, the
difference between groups did achieve statistical signif-
icance.
In the weekly analysis of pain-related sleep interfer-
ence, a statistically significant improvement in the pre-
gabalin group was apparent from week 1 onward and
(P < 0.05) and at end-point (Table 2). In the evalua-
tion of sleep using the MOS sleep scale, there was a
statistically significant improvement in the overall sleep
problems index in the pregabalin group (Table 2) as
well as in the sleep disturbance and sleep adequacy
subscales (both P < 0.001; data not shown). The mean
MOS sleep scale somnolence score at end-point was
33.6 in the placebo group and 35.4 in the pregabalin
and the adjusted mean end-point difference (2.31) was
not statistically significant (P = 0.32). At end-point,
Figure 1 Patient disposition. The other
protocol violations listed as the reason for
not completing the single-blind run-in
period/not being randomized included
medical and procedural reasons.
Table 1 Patient demographics and baseline characteristics
Placebo
(n = 127)
Pregabalin
(n = 127)
Women, n (%) 52 (40.9) 77 (60.6)
Age, year, mean (SD) 51 (13) 52 (14)
Aged ‡65–80, n (%) 25 (19.7) 29 (22.8)
White race, n (%) 120 (94.5) 124 (97.6)
Weight, kg, mean 81 (17) 78 (15)
Mean duration of neuropathic
pain, year (range)
4.4 (0.2–29) 4.3 (0.3–26)
Concomitant pain medications,
n (%)a
101 (79.5) 102 (80.3)
NSAIDs/Cox-2s 46 (36.2) 57 (44.9)
TCAs 39 (30.7) 41 (32.3)
SNRIs 7 (5.5) 2 (1.6)
Opioids 15 (11.8) 20 (15.8)
Tramadol 41 (32.3) 42 (33.1)
AEDb 46 (36.2) 41 (32.3)
NSAID, non-steroidal anti-inflammatory drug; COX-2, cyclooxygen-
ase-2 inhibitor; TCA, tricyclic antidepressant; SNRI, selective nor-
epinephrine receptor inhibitor; AEDs, anti-epileptic drugs.
aMedications may not have been specifically prescribed for
neuropathic pain.
bAEDs, excluding gabapentin, were allowed.
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The other protocol violations list d as the reason for not completing the single-blind 
run-in period/ not being randomized included medical and procedural reasons.
study medication
Pregabalin dosing at endpoint was as follows; 38 patients (30.2%) received 150 mg/day, 
58 (4 .0%) received 300 mg/day and 30 (23.8%) rec ived 600 mg/day. The correspo d-
ing percentages in the placebo group for these “dose groups” were 10.3%, 14.3% and 
75.4%, respectively. The mean endpoint pregabalin dose was 326 mg/day.
efficacy
In the evaluation of the primary endpoint, pregabalin was statistically significantly more 
effective than placebo in improving pain at endpoint (Table 2). The treatment by gender 
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interaction was not statistically significant and the findings of the primary efficacy analy-
sis were upheld when the model was adjusted for gender.
The percentage of patients with ≥30% reduction in pain from baseline to endpoint 
was significantly greater in the pregabalin group (39.7%) than in the placebo group 
(25.4%; P<0.05). In the MMRM analysis of weekly mean pain scores a statistically sig-
nificant difference in favor of pregabalin was first apparent at week 3 (P=0.01) and then 
weekly from week 5 to week 8 (P<0.05). The mBPI-sf pain interference and severity indi-
ces, which were not subject to formal statistical analysis, showed improvement in both 
groups which were numerically greater in the pregabalin group than the placebo group.
In total 25.4% in the pregabalin group and 32.5% in the placebo group had a baseline 
HADS anxiety subscale score >10. In this subset of patients there was modest but insig-
nificant difference between groups in the change in the HADS anxiety score between 
baseline and endpoint. (Table 2). In the all patient group, the difference between groups 
did achieve statistical significance.
table 2 Mean (SD) primary and secondary efficacy variables at baseline and endpoint, differences 
between treatment groups and statistical analysis.
Placebo Pregabalin endpoint comparison placebo 
— pregabalina
N Baseline Endpoint N Baseline Endpoint Adjusted 
difference
95% CI p value
Painb 125 6.3 (1.7) 5.5 (2.3) 126 6.0 (1.6) 4.6 (2.4) -0.62 -1.09;-
0.15
0.01
Sleep 
interferenceb
125 4.8 (2.6) 4.13 (2.8) 126 4.1 (2.4) 2.73 (2.4) -0.79 -1.25;-
0.34
0.001
MOS-sleep scale 
problems indexc
112 45.9
(21.9)
44.6
(21.0)
116 43.4 
(20.2)
35.9
(21.1)
-7.54 -11.52;
-3.56
<0.001
HADS Anxiety 
scored all 
patients
124 8.4 (4.9) 7.5 (4.9) 124 7.6 (4.5) 6.2 (4.5) -0.84 -1.6; 
-0.08
0.031
Patients with 
baseline HADS 
Anxiety subscale 
>10
41 14.3 (2.5) 12.1 (4.1) 32 13.7 (2.4) 10.3 (4.6) -1.68 -3.69; 
0.32
0.099
HADs 
Depression 
scored
124 6.8 (4.5) 6.5 (4.5) 124 6.3 (4.2) 5.1 (4.5) -0.97 -1.61; 
-0.33
0.003
Patients with 
baseline HADS 
Depression 
subscale >10
23 13.9 (2.7) 12.3 (4.1) 17 13.9 (2.8) 12.1 (4.5) 0.24 -1.87; 
2.34
0.819
Abbreviations: NSAID — non-steroidal anti-inflammatory drug; COX-2 -cyclooxygenase-2 inhibitor; TCA 
— tricyclic antidepressant; SNRI selective norepinephrine receptor inhibitor, AEDs — anti-epileptic drugs.
aCategorized based on the open field description on the cause of pain recorded by the investigator
 bMedications may not have been specifically prescribed for neuropathic pain
 cAEDs, excluding gabapentin, were allowed
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In the weekly analysis of pain-related sleep interference, a statistically significant 
improvement in the pregabalin group was apparent from week 1 onwards and (P<0.05) 
and at endpoint (Table 2). In the evaluation of sleep using the MOS sleep scale there 
was a statistically significant improvement in the overall sleep problems index in the 
pregabalin group (Table 2) as well as in the sleep disturbance and sleep adequacy 
subscales (both P<0.001; data not shown). The mean MOS sleep scale somnolence score 
at endpoint was 33.6 in the placebo group and 35.4 in the pregabalin and the adjusted 
mean endpoint difference (2.31) was not statistically significant (P=0.32). At endpoint, 
most patients in the pregabalin treatment group rated themselves as improved (Fig-
ure 2), with only 7.5% rating themselves as worse than baseline. In the placebo group 
over half the patients rated themselves as either unchanged or worse. The distribution 
of responses across the seven PGIC categories was statistically significant (P=0.006) in 
favor of improvement in the pregabalin group (Figure 2).
tolerAbility ANd sAfety
In total, treatment-emergent adverse events were reported in 58.3% of patients in the 
placebo group and 85.8% in the pregabalin group. Most adverse events were either mild 
or moderate in intensity; 9% in the placebo group and 10% in the pregabalin were rated 
as severe in intensity. The most common adverse events and the associated discontinu-
ation rates are summarized in Table 3.
Serious adverse events were reported in four patients in the pregabalin group, one 
of which was considered related to treatment, and two in the placebo group. The event 
most patients in the pregabalin treatment group rated
themselves as improved (Fig. 2), with only 7.5% rating
themselves as worse than baseline. In the placebo
group, over half the patients rated themselves as either
unchanged or worse. The distribution of responses
across the sev n PGIC categories was statistically
significant (P = 0.006) in favor of improvement in the
pregabalin group (Fig. 2).
Tolerability and safety
In total, treatment-emergent adverse events were
reported in 58.3% of patients in the placebo group and
85.8% in the pregabalin group. Most adverse events
were either mild or moderate in intensity; 9% in the
placebo group and 10% in the pregabalin were rated as
severe in intensity. The most common adverse events
and the associated discontinuation rates are summa-
rized in Table 3.
Serious adverse events were reported in four patients
in the pregabalin group, one of which was considered
related to treatment, and two in the placebo group. The
event considered related to pregabalin was a patient
with tremor and dyspnoea who was on 600 mg/day who
discontinued and recovered. Weight gain was reported
as an adverse event in five patients on pregabalin and
two on placebo. Four patients on pregabalin and two
on placebo had ‡7% weight gain. The mean weight
change at end-point was 1 kg in the pregabalin group
and 0.2 kg in the placebo group. No patterns of chan-
ges in vital signs or laboratory assessments were
observed.
Table 2 Mean (SD) primary and secondary efficacy variables at baseline and end-point, differences between treatment groups and statistical
analysis
Placebo Pregabalin
End-point comparison placebo –
pregabalina
N Baseline End-point N Baseline End-point
Adjusted
difference 95% CI P value
Painb 125 6.3 (1.7) 5.5 (2.3) 126 6.0 (1.6) 4.6 (2.4) )0.62 )1.09;)0.15 0.01
Sleep interferenceb 125 4.8 (2.6) 4.13 (2.8) 126 4.1 (2.4) 2.73 (2.4) )0.79 )1.25;)0.34 0.001
MOS sleep scale problems
indexc
112 45.9 (21.9) 44.6 (21.0) 116 43.4 (20.2) 35.9 (21.1) )7.54 )11.52; )3.56 <0.001
HADS anxiety scored all
patients
124 8.4 (4.9) 7.5 (4.9) 124 7.6 (4.5) 6.2 (4.5) )0.84 )1.6; )0.08 0.031
Patients with baseline HADS
anxiety subscale >10
41 14.3 (2.5) 12.1 (4.1) 32 13.7 (2.4) 10.3 (4.6) )1.68 )3.69; 0.32 0.099
HADS depression scored 124 6.8 (4.5) 6.5 (4.5) 124 6.3 (4.2) 5.1 (4.5) )0.97 )1.61; )0.33 0.003
Patients with baseline HADS
depression subscale >10
23 13.9 (2.7) 12.3 (4.1) 17 13.9 (2.8) 12.1 (4.5) 0.24 )1.87; 2.34 0.819
HADS, Hospital Anxiety and Depression Scale.
aPlacebo - pregabalin difference in least squares means from the ANCOVA model with treatment, pooled country, and baseline as factors.
Arithmetic mean values are presented with difference based on adjusted means.
bMean pain and sleep interference scores based on the average of each patients last 7 daily diary entries.
cThe 9-item MOS sleep scale problems index, derived from the MOS sleep scale, provides a broad summary of sleep problems (e.g., getting to sleep,
staying asleep, daytime sleepiness, feelings of being rested). Scores on the 9-item Index range from 0 to 100; higher scores indicate greater sleep
problems.
dThe HADS consists of 14 items on two subscales (seven anxiety and seven depression) and is self-administered. Ratings are made on four-point
scales representing the degree of distr ss during the previous week from 0 to 3. HADS subscales 0–7 = normal, 8–10 = mild, 11–14 = moderate,
15–21 = severe.
Figure 2 Patient Global Impression of Change (PGIC) of overall
change experienced by patients at end-point since receiving
randomized medication. PGIC rated on a seven-point scale
1 = very much improved; 2 = much improved, 3 = minimally
improved; 4 = no change, 5 = minimally worse, 6 = much
worse, 7 = very much worse; condensed into three categories for
presentation.
1086 R. van Seventer et al.
� 2010 The Author(s)
Journal compilation � 2010 EFNS European Journal of Neurology 17, 1082–1089
figure 2 Patient Global Impression of Ch nge (PGIC) of verall change experienced by patients at 
endpoint since receivi  randomized medic o
(PGIC) rated on a seven-po nt scal  1=very much improved; 2=much improved, 3=minimally improved; 
4=no change, 5=minimally worse, 6=much worse, 7=very much worse; conde sed into 3 categories for 
presentation
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considered related to pregabalin was a patient with tremor and dyspnoea who was on 
600 mg/day who discontinued and recovered. Weight gain was reported as an adverse 
event in five patients on pregabalin and two on placebo. Four patients on pregabalin 
and two on placebo had ≥7% weight gain. The mean weight change at endpoint was 1 
kg in the pregabalin group and 0.2 kg in the placebo group. No patterns of changes in 
vital signs or laboratory assessments were observed.
discussioN
This 8-week, placebo-controlled study of a heterogeneous group of patients with post-
traumatic peripheral neuropathic pain demonstrated that pregabalin was significantly 
effective in reducing pain. In addition, pregabalin was associated with significant im-
provement in disturbed sleep, and was generally well tolerated. The findings from the 
present study are largely consistent with results from previous studies of pregabalin in 
peripheral neuropathic pain [1–5].
This study, unlike previous studies of pregabalin in neuropathic pain, included a 
2-week placebo-run-in period. It has been suggested that this approach be explored as 
a means of minimizing the placebo-response rate in neuropathic pain trials [18]. In total, 
7.3% of those entered into the study were not randomized because they failed to meet 
both pain entry criteria (NRS and VAS assessments). The mean baseline pain score in this 
study (~6.1) was a little lower than the mean scores in pregabalin DPN (~6.4) and PHN 
(~6.7) pre-registration trials [24] in which no placebo-run-in was employed. The treat-
ment difference for pregabalin versus placebo in the primary pain endpoint in this study 
table3 most frequently reported adverse events; n(%)a
Placebo (n=127) Pregabalin (n=127)
Incidence Discontinuation Incidence Discontinuation
Dizziness 12 (9.4) 2 (1.6) 55 (43.3) 11 (8.7)
Somnolence 8 (6.3) 1 (0.8) 20 (15.7) 1 (0.8)
Headache 14 (11.0) 2 (1.6) 15 (11.8) 1 (0.8)
Fatigue 10 (7.9) 0 15 (11.8) 2 (1.6)
Dry mouth 6 (4.7) 0 14 (11.0) 0
Nausea 8 (6.3) 1 (0.8) 12 (9.4) 2 (1.6)
Constipation 4 (3.1) 0 9 (7.1) 0
Peripheral edema 3 (2.4) 0 9 (7.1) 2 (1.6)
Disturbance in attention 4 (3.1) 1 (0.8) 9 (7.1) 0
Blurred vision 3 (2.4) 0 8 (6.3) 1 (0.8)
aTreatment-emergent adverse events occurring in ≥5% of patients in either treatment group and with 
greater frequency in the pregabalin group than the placebo group.
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was modest (-0.62) but of statistical significance. The lower baseline score might in part 
explain the relatively modest improvement observed with pregabalin. The mean dose 
in this study was 326 mg/day. Compared with fixed doses of pregabalin such as with 300 
mg/day, the difference from placebo in primary pain endpoint in this study was gener-
ally less than other studies in DPN [1,2] and PHN [4], in which a significant improvement 
was observed, but similar to that in another PHN study [5]. A recent cross-over study of 
gabapentin up to 2400 mg/day in a similar patient population failed to find a significant 
difference from placebo on the primary endpoint, the mean change in pain intensity 
score, suggesting that this type of neuropathic pain may be more difficult to treat than 
the classic DPN and PHN models [19]. The placebo response rate in this study (14.3%), 
as shown by the proportion of patients with a ≥50% reduction in their pain score be-
tween baseline and endpoint was similar to or greater than in several other studies in 
peripheral neuropathic pain that did not employ a placebo run-in period [2,4,5]. Thus, 
it appears that the placebo run-in period with the use of an absolute entry threshold 
regardless of percentage improvement between screening and randomization did 
not demonstrate a marked impact on reducing the placebo response rate during the 
randomized treatment period.
Although the 50% responder rate with pregabalin was not significantly different from 
placebo, the difference between groups in the 30% response rate was significant. When 
putting the results from the assessment of pain in this study into context it is important 
to be cognisant of the population under study. This was a very heterogeneous group of 
patients with post-traumatic pain of many differing causes which had been present for, 
on average, 4.4 years. The refractory nature of the sample was evident when it is con-
sidered that 80% were taking concomitant pain medications, several classes of which 
have demonstrated efficacy in neuropathic pain, but nonetheless pain persisted at a 
level such they were able to enter the study. The very heterogeneity of the sample may 
also contribute to the fact that the effect size in this study was not as great as studies of 
pregabalin in more ”pure” DPN and PHN samples [1,2,4]. Rowbotham noted that clinical 
trials in specific disease cohorts have less variability than trials in relatively unselected 
groups with chronic pain [20], and this may be relevant to the heterogeneous popula-
tion in the present study.
A secondary objective of this study was to evaluate the effects of pregabalin on anxi-
ety in a subset of patient with clinically relevant baseline anxiety symptoms, defined as 
having a HADS anxiety subscale score >10. Slightly fewer patients than expected actu-
ally met this criterion, and therefore statistical power was lacking. Although a numerical 
difference that is likely to be clinically relevant was observed in favour of improvement 
in anxiety in the pregabalin group, the finding did not achieve statistical significance. 
The all patient group did reach statistical significant improvement despite the low 
overall baseline anxiety scores, which suggests very mild anxiety and little room for im-
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provement. Nonetheless, the significant improvement in the HADS anxiety subscale is 
consistent with a study in central neuropathic pain [6] and with the fact that pregabalin 
is effective in GAD [11]. Consistent with other studies in neuropathic pain, pregabalin 
was also associated with a rapid and significant improvement in pain-related sleep in-
terference [1–6], which was reflected in the significant improvements in the MOS sleep 
problems index, as well as in the sleep disturbance and sleep adequacy subscales.
Pregabalin was generally well tolerated with adverse events mostly mild or moderate 
in intensity and resulting in the discontinuation of 19.6% from pregabalin compared 
with 7.1% from placebo. Consistent with the broader pregabalin database [1–6], diz-
ziness and somnolence were the two most common adverse events. Dizziness among 
pregabalin-treated patients, at placebo-corrected incidence of 34%, was reported 
slightly more frequently than in pooled DPN studies [21] and more than 300 mg/day 
arms in PHN studies [4,5], but most patients who reported dizziness remained on 
treatment. The reason for the relatively higher incidence of mostly mild or moderate 
dizziness in this population is not known. Peripheral edema, which was proactively mea-
sured, was slightly more frequent with pregabalin than with placebo but only resulted in 
two patients discontinuing treatment. There were no remarkable findings in any of the 
laboratory or safety assessments.
The evaluation of change as rated by the PGIC reflected the overall benefits of pregabalin 
treatment as perceived by the patients. Two thirds of subjects receiving pregabalin rated 
themselves as improved at endpoint, and the distribution of PGIC responses was signifi-
cantly in favour of improvement in the pregabalin group versus placebo. This suggests that 
the improvement in pain and sleep disturbance, along with the fact that pregabalin was 
generally well tolerated, provided meaningful patient benefit. In conclusion, the results 
of this study in post-traumatic peripheral neuropathic pain are generally consistent with 
earlier studies in other peripheral neuropathic pain states, DPN and PHN, and underlie the 
effectiveness of pregabalin in the treatment of peripheral neuropathic pain.
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AbstrAct
background
Postherpetic neuralgia (PHN) develops in 8–24% of patients with herpes zoster. Few 
studies have evaluated the patient burden and treatment of PHN in general practice.
objectives
To determine the patient burden of PHN with respect to pain intensity and impact on 
patient functioning and to characterise treatment patterns and health resource utilisa-
tion in general practice.
methods
Eighty-four patients with PHN were identified in general practice settings during an 
observational survey of neuropathic pain syndromes in six European countries. Patients 
answered a questionnaire that included pain severity and interference items from the 
modified short form brief pain inventory (mBPI-SF), EuroQol (EQ-5D) survey and ques-
tions related to current treatment, health status and resource utilisation. Physicians pro-
vided information on medications prescribed for PHN and pain-related co-morbidities 
(anxiety, depression and sleep disturbance).
results
Mean patient age was 71.0 } 12.8 years, 76% were ≥65 years and 45% of patients had 
PHN ≥1 year. The mean pain severity index was 4.2, reflecting moderate pain despite 
89% of patients taking prescription medications for PHN. Few medications with dem-
onstrated efficacy against PHN (e.g. carbamazepine and gabapentin) were prescribed, 
often at suboptimal doses. Pain severity was associated with reduced EQ-5D health state 
valuation (P<0.001), greater pain interference on all domains (P<0.001) and increased 
health resource utilisation (P = 0.008).
conclusions
PHN causes substantial patient burden expressed as interference with daily functioning 
and reduced health status associated with pain severity. This burden may result in part 
from suboptimal management strategies and suggests a need for more effective pain 
management.
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iNtroductioN
Herpes zoster (HZ) is characterised by painful blisters that erupt along a nerve path after 
reactivation of latent varicella zoster virus. HZ has an estimated incidence in the United 
States and Europe of 3.9–11.8/1,000 person-years in persons aged ≥60 years [1]. The 
acute pain of HZ significantly impacts patient function and quality of life [2, 3].
Postherpetic neuralgia (PHN), the most common complication of HZ, is a neuropathic 
pain frequently reported as lancinating, burning, shooting, stabbing, paroxysmal or 
electrical. It is often associated with abnormal sensory perception (e.g. allodynia and/
or hyperalgesia) and may persist as chronic pain after resolution of the HZ rash. Because 
different criteria are used to define PHN (pain at rash healing, 1 month after rash onset 
or 3 months after rash onset), the estimated incidence varies from 8 to 24% [4, 5]. The 
prevalence of PHN increases with older age [6, 7]; 47 and 73% of untreated adults with 
HZ over 60 and 70 years of age, respectively, may have PHN [8]. With the ageing of the 
population, a larger proportion of persons are at a risk of developing HZ and PHN. Medi-
cal management of pain presents unique challenges in an older population, and care is 
needed in the choice of therapies for neuropathic pain conditions [9].
The high incidence of HZ in older persons combined with the recognised impact of 
PHN on patient functioning and quality of life [1, 4, 5, 10–13] suggests that PHN may 
present a significant patient burden in a population already impaired in health status. 
Patient functioning and quality of life have been incorporated as outcomes in several 
studies of PHN [14–16]. However, few studies evaluated the patient burden and treat-
ment of PHN in primary care, the usual locus of chronic pain management [17]. A US 
study conducted by postal questionnaire in patients recruited through advertisements 
showed substantial impact of PHN on health status domains related to patient func-
tioning [13]. A second US study, adapting the brief pain inventory to assess HZ pain in 
patients recruited from different health care settings, showed an association between 
PHN and reduced patient function and quality of life [18].
These considerations suggested a need to better understand treatment patterns 
and patient burden in general practice settings in Europe. The purpose of the present 
analysis was to evaluate the impact of PHN on patient functioning and to characterise 
associated treatment patterns in patients recruited from primary care settings in six 
European countries.
subjects ANd methods
The sample consisted of 84 patients with PHN identified during a larger observational, 
cross-sectional study of broad neuropathic pain syndromes [19]. Sampling was limited to 
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general practitioners and non-pain specialists. Patients were recruited from community-
based practices in France, Germany, Italy, the Netherlands, Spain and United Kingdom.
We assessed patient-reported functional health and wellbeing, pain experience, 
medication use and health resource utilisation specifically for PHN (e.g. physician visits 
and telephone consultations).
Physicians were screened for their interest in study participation, and a feasibility 
assessment was conducted to determine their ability to identify patients for inclusion. 
Physician training by teleconference included reviewing the study objectives, physician 
responsibilities, patient eligibility criteria and administrative procedures. The clinical 
case report form provided definitions of PHN with reference to patient-reported pain 
descriptors and pain location.
The study protocol was approved by local ethics committees. Participating physicians 
invited patients to participate in the study during routine care visits. Eligible patients 
were identified by physicians based on the presence of neuropathic pain and report of 
symptoms consistent with allodynia (pain in reaction to non-noxious stimuli such as the 
light touch of a cotton ball) and hyperalgesia (exaggerated pain reaction to mild pain 
stimuli) and/or the patient’s use of specific words (e.g. burning, shooting, stabbing or 
tingling) that typically describe neuropathic pain. PHN was defined as neuropathic pain 
in the area of a spinal nerve dermatome or cranial nerve tract lasting >3 months after 
crusting of the skin lesions associated with HZ. Symptom duration of ≥3 months and up 
to the week before the survey was required.
Exclusion criteria were participation in an investigational drug study within the past 
30 days, presentation with or a history of a serious or unstable medical or psychological 
condition that would compromise participation in the study and presence of a concomi-
tant illness unrelated to PHN (e.g. neurological disorder or other pain condition) that 
would likely confound the assessment of PHN.
Patients were eligible if they had other chronic pain conditions such as osteoarthritis 
or migraine headaches, provided they could distinguish between PHN pain and the 
other conditions. Patients who consented completed a questionnaire as described 
below. Physicians provided clinical information regarding the duration of disease and 
prescribed medications for PHN and common pain-related co-morbid conditions (e.g. 
anxiety, depression or sleep disturbance).
PAtieNt QuestioNNAire
The questionnaire included 11 items from the modified short form brief pain inventory 
(mBPI-SF) [20–22], the EuroQol (EQ-5D) [23] and additional questions as described below. 
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Validated translations of the mBPI-SF and EQ-5D survey were used, and the remaining 
questions were translated and reviewed for accuracy by native speakers.
modified short form brief pain inventory
Pain severity, assessed using the mBPI-SF, was measured using an 11-point numeric rat-
ing scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Items included 
current pain, worst, least and average pain over the previous 24 hours. The pain severity 
index was calculated as the average of the four ratings. Pain severity cut-points were 1–3 
for mild pain, 4–6 for moderate pain and 7–10 for severe pain [24].
The remaining items measured pain-related interference over seven health status 
domains using 11-point numeric rating scales ranging from 0 (does not interfere) to 10 
(completely interferes). The mean of these seven ratings measured the patient’s overall 
level of pain interference (pain interference index).
euroQol survey
The EQ-5D survey assessed the overall functioning and well-being with respect to 
mobility, self-care, usual activities, pain or discomfort and anxiety or depression [23]. 
Domains were rated using a 3-point ordinal scale, and the resulting profile was used to 
calculate health state valuations based on precalculated scoring coefficients [25]. We 
used scoring coefficients generated in the United Kingdom to assign health state valua-
tions to patients. Health state valuations ranged from –0.59 (worst health state) to 1.00 
(best health state).
AdditioNAl QuestioNs
Specific questions addressed patients’ overall health rating and health resource utilisa-
tion. Patients rated their current health on a scale of 0–100, where 0 represented ‘worst 
possible health’ and 100 represented ‘perfect health’; patients also provided a health 
rating under the hypothetical scenario of having complete relief of PHN pain.
Physicians provided information about current prescription medications for PHN, 
and patients provided information about the use of non-prescription medications and 
other therapies including acupuncture, topical lotions, herbs or vitamins, devices such 
as those for electroneural stimulation (e.g. transcutaneous electroneural stimulation 
[TENS] or spinal cord stimulation) and exercise. Patients also evaluated the efficacy of 
prescription medications (extremely effective, very effective, somewhat effective, a little 
effective and not effective) including information on treatment adherence and medica-
tion satisfaction. Other questions included the frequency of neuropathic pain-related 
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physician visits and telephone consultations during the past 4 weeks and evaluation by 
pain specialists.
stAtisticAl ANAlyses
Summary statistics were utilised to describe the study sample: means ± standard devia-
tions were provided for continuous variables and frequency distributions for categorical 
variables.
One-way analysis of variance models for continuous outcomes and chi-square tests 
for categorical outcomes were used to evaluate the association between pain severity 
(categorized as mild, moderate or severe) [24] and other outcomes.
Statistical significance was evaluated at the 0.05 level, with no adjustments for mul-
tiple comparisons, given the descriptive nature of the study. All analyses were performed 
using PC-SAS version 8.0 (SAS Institute, Cary, NC, USA).
results
The sample consisted of 84 patients: 48% males and 52% females. The mean age was 
71.0 ± 12.8 years: 76% of patients were ≥65 years of age. Sixty-five percent of patients 
were retired, 12.6% employed at least part-time and the rest disabled (3.8%), full-time 
homemakers (17.5%) or other (1.3%). Almost half the patients (45%) had PHN for >1 year.
The mean pain severity index was 4.2 indicating moderate pain. Fifty-nine per cent of 
patients reported moderateto- severe pain as their overall pain within the prior 24 hours 
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pain or discomfort and anxiety or depression [23]. Domains
were rated using a 3-point ordinal scale, and the resulting
profile was used to calculate health state valuations based on
precalculated scoring coefficient  [25]. We used scoring
coefficients generated in the United Kingdom to assign
health state valuations to patients. Health state valuations
ranged from –0.59 (worst health state) to 1.00 (best health
state).
Additional questions
Specific questions ddressed patients’ overall health rating
and health resource utilisation. Patients rated their current
health on a scale of 0–100, where 0 represented ‘worst pos-
sible health’ and 100 represented ‘perfect health’; patients
also provided a health rating under the hypothetical sce-
nario of having omplete relief of PHN pain.
Physicians provided information about current prescrip-
tion medications for PHN, and patients provided informa-
tion about the use of non-prescription medications and
other therapies including acupuncture, topical lotions, herbs
or vitamins, devices such as those for electroneural stimulation
(e.g. transcutaneous electroneural stimulation [TENS] or
spinal cord stimulation) and exercise. Patients also evaluated
the efficacy of prescription medications (extremely effect-
ive, very effective, somewhat effective, a little effective and
not effective) including information on treatment adherence
and medication satisfaction. Other questions included the
frequency of neuropathic pain-related physician visits and
telephone consultations during the past 4 weeks and evalua-
tion by pain specialists.
Statistical analyses
Summary statistics were utilised to describe the study sample:
means ± standard deviations w re provi ed for continuous
variables and frequency distributions for categorical variables.
One-way analysis of variance models for continuous
outcomes and chi-square tests for categorical outcomes were
used to evaluate the association between pain severity (cate-
gorised as mild, moderate or severe) [24] and other out-
comes. Statistical significance was evaluated at the 0.05 level,
with no adjustments for multiple comparisons, given the
descriptive nature of the study. All analyses were performed
using PC-SAS version 8.0 (SAS Institute, Cary, NC, USA).
Results
The sample consisted of 84 patients: 48% males and 52%
females. The mean age was 71.0 ± 12.8 years: 76% of
patients were ≥65 years of age. Sixty-five percent of patients
were retired, 12.6% employed at least part-time and the rest
disabled (3.8%), full-time homemakers (17.5%) or other
(1.3%). Almost half the patients (45%) had PHN for >1 year.
The mean pain severity index was 4.2 indicating moder-
ate pain. Fifty-nine per cent of patients reported moderate-
to-severe pain as their overall pain withi  the prior 24 hours
as indicated by their pain index severity scores; 78% of
patients reported their worst pain within the prior 24 hours
as moderate or severe in intensity.
Patients reported pain interference on all seven health sta-
tus domains that was significantly associated with greater pain
severity (Figure 1; P<0.001). The most affected domains were
mood, sleep and general activity; the least affected domains
were walking ability and relations with other people.
Most patients (89%) received at least one prescription
medication for neuropathic pain, and polypharmacy was
common (Table 1). More than half of the patients (52%)
were prescribed antiepileptic medications (Table 1) includ-
ing gabapentin (38%) and carbamaz pine (23%), which are
recommended for neuropathic pain [9]. Mean daily doses
were low; 1032.3 ± 508.2 mg of gabapentin and 500.0 ±
309.1 mg of carbamazepine. Other commonly prescribed
medications for PHN included anti-inflammatory and opi-
oid agents (64%), sedat ve or hypnotic medicatio s (32%),
amitriptyline (21%) and other antidepressants (26%). More
than one-third of patients (37%) received some form of
prescription medication for PHN for >1 year, and a similar
Figure 1. Mean pain interference scores for domains of daily functioning on the modified short form brief pain inventory (mBPI-
SF) by pain severity; *P<0.001 for the association between pain severity and interference.
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figure 1. Mean pain interference sc res for domains of daily functioning on the modified short form 
brief pain inventory (mBPISF) by pain severity; *P<0.001 for the association between pain severity and 
interference.
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as indicated by their pain index severity scores; 78% of patients reported their worst 
pain within the prior 24 hours as moderate or severe in intensity.
Patients reported pain interference on all seven health status domains that was sig-
nificantly associated with greater pain severity (Figure 1; P<0.001). The most affected 
domains were mood, sleep and general activity; the least affected domains were walk-
ing ability and relations with other people.
Most patients (89%) received at least one prescription medication for neuropathic 
pain, and polypharmacy was common (Table 1). More than half of the patients (52%) 
were prescribed antiepileptic medications (Table 1) including gabapentin (38%) and 
carbamazepine (23%), which are recommended for neuropathic pain [9]. Mean daily 
doses were low; 1032.3±508.2 mg of gabapentin and 500.0 ±309.1 mg of carbamaze-
pine. Other commonly prescribed medications for PHN included anti-inflammatory and 
opioid agents (64%), sedative or hypnotic medications (32%), amitriptyline (21%) and 
other antidepressants (26%). More than one-third of patients (37%) received some form 
of prescription medication for PHN for >1 year, and a similar proportion (37%) received 
concomitant prescription medications for anxiety, depression or sleep disturbance 
related to PHN (Table 1).
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proportion (37%) received concomitant prescription medi-
cations for anxiety, depression or sleep disturbance related
to PHN (Table 1).
Eighty-five per cent of patients reported taking their
prescription medication for PHN ‘all’ or ‘most of the time’.
Only 39% of patients reported their prescription medica-
tion as ‘extremely effective’ or ‘very effective’.
Many patients reported using other medications/treat-
ments for their PHN (Table 1); 37% reported taking over-
the-counter medications (e.g. paracetamol or aspirin), and
similar proportions r por ed us  of topi al lot ns or creams
(43%), physical treatments (29%) or herbs/vitamins/supple-
ments (25%).
Pain had a significant impact on health status including
functioning and well-being. Patients reported an overall
mean EQ-5D health state valuation of 0.60 ± 0.29 (–0.59 to
+1.00 scale), and a significant association was observed
between increasing pain severity and decreasing EQ-5D
health state valuation (Figure 2; P<0.001). Similarly, a signi-
ficant association was observed between increasing pain
severity and pain interference; pain interference index
scores were 1.3, 3.8 and 6.2 for mild, moderate and severe
pain, respectively (P<0.001).
Patients placed significant value on obtaining relief from
their PHN. On a 0–100 scale, patients estimated a 29%
increase in their health-rating score (improvement from
61.7 ± 20.3 to 79.7 ± 19.8; P<0.0001, paired t-test) if they
could experience complete relief from their PHN.
PHN directly impacted medical resource utilisation
within the past 4 weeks; 68% of patients visited their physi-
cian at least once, 30% had telephone consultations for their
PHN and 30% saw a pain specialist. A significant association
was observed between increasing pain severity and greater
number of telephone consults (P = 0.008), with a similar
trend between pain severity and physician visits (P = 0.078).
Discussion
These findings demonstrate a substantial patient burden of
PHN, consistent with previously reported neuropathic pain
conditions including diabetic peripheral neuropathy [12, 19, 26]
and PHN [13]. Patient burden, expressed as impairment of
function and reduced quality of life, was significantly associ-
ated with pain severity as indicated by poorer health status
(EQ-5D) and increased pain interference with functioning
(mBPI-SF Pain Interference scores) with increasing neuro-
pathic pain severity. Additionally, a substantial proportion
of patients were prescribed medications for depression,
anxiety and sleep disturbance related to PHN, conditions
considered co-morb d with chronic pain including neuro-
pathic syndromes [11, 27].
The sustained moderate-to-severe pain levels suggest
suboptimal pain management. This is supported by the con-
siderable patient burden observed despite most patients
receiving prescription medications for their PHN. This
finding may in part be attributed to the use of agents having
no demonstrated efficacy for the treatment of neuropathic
Table 1. Patterns of treatment for postherpetic neuralgia
NP, neuropathic pain; NSAIDs, non-steroidal anti-inflammatory drugs.
aNeither the treatment categories nor the subcategories are mutually exclusive.
bPrescribed either antidepressants, sedatives/hypnotics (benzodiazepines,
buspirone or other hypnotics) or analgesics (tramadol, any opioids or opioid
compounds, non-steroidal anti-inflammatory drugs or COX-2 inhibitors) for
concomitant anxiety, depression or sleep disturbance.
Treatmenta n (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . .
Physician-reported NP prescription medications
Current NP prescription medication 75 (89.3)
Amitriptyline 18 (21.4)
Other antidepressants 22 (26.2)
Sedatives/hypnotics 27 (32.1)
Analgesics 54 (64.3)
Opioids and opioid compounds 17 (20.2)
NSAIDs or COX-2s 28 (33.3)
Antiepileptic medications 44 (52.4)
Gabapentin 32 (38.1)
Carbamazepine 19 (22.6)
Duration of NP prescription medication use
<3 months 24 (29.6)
3–6 months 19 (23.5)
7–12 months 8 (9.9)
13–35 months 17 (21.0)
≥36 months 13 (16.0)
Physician-reported concomitant prescription medications
Current concomitant prescription medicationsb 31 (36.9)
Prescribed medications for anxiety 12 (14.3)
Prescribed medications for sleep disturbance 14 (16.7)
Prescribed medication for depression 5 (6.0)
Patient-reported other NP medications
Non-prescription medications 31 (36.9)
Physical treatments 24 (28.6)
Topical lotions/creams 36 (42.9)
Herbs, vitamins and supplements 21 (25.0)
Devices 16 (19.0)
Exercise 14 (16.7)
Figure 2. Association between pain severity and EuroQol
(EQ-5D) health state valuation. P<0.001 using one-way
ANOVA.
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Eighty-five per cent of patients reported taking their prescription medication for PHN 
‘all’ or ‘most of the time’. Only 39% of patients reported their prescription medication as 
‘extremely effective’ or ‘very effective’.
Many patients reported using other medications/treatments for their PHN (Table 1); 
37% reported taking overthe-counter medications (e.g. paracetamol or aspirin), and 
similar proportions reported use of topical lotions or creams (43%), physical treatments 
(29%) or herbs/vitamins/supplements (25%).
Pain had a significant impact on health status including functioning and well-being. 
Patients reported an overall mean EQ-5D health state valuation of 0.60±0.29 (–0.59 to 
+1.00 scale), and a significant association was observed between increasing pain sever-
ity and decreasing EQ-5D health state valuation (Figure 2; P<0.001). Similarly, a signifi-
cant association was observed between increasing pain severity and pain interference; 
pain interference index scores were 1.3, 3.8 and 6.2 for mild, moderate and severe pain, 
respectively (P<0.001).
Patients placed significant value on obtaining relief from their PHN. On a 0–100 scale, 
patients estimated a 29% increase in their health-rating score (improvement from 
61.7±20.3 to 79.7±19.8; P<0.0001, paired t-test) if they could experience complete relief 
from their PHN.
PHN directly impacted medical resource utilization within the past 4 weeks; 68% of 
patients visited their physician at least once, 30% had telephone consultations for their 
PHN and 30% saw a pain specialist. A significant association was observed between 
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tion as ‘extremely effective’ or ‘very effective’.
Many patients reported using other medications/treat-
ments for their PHN (Table 1); 37% reported taking over-
the-counter medications (e.g. paracetamol or aspirin), and
similar proportions reported use of topical lotions or creams
(43%), physical treatments (29%) or herbs/vitamins/supple-
ments (25%).
Pain had a significant impact on health status including
functioning and well-being. Patients reported an overall
mean EQ-5D health state valuation of 0.60 ± 0.29 (–0.59 to
+1.00 scale), and a significant association was observed
between increasing pain severity and decreasing EQ-5D
health state valuation (Figure 2; P<0.001). Similarly, a signi-
ficant association was observed between increasing pain
severity and pain interference; pain interference index
scores were 1.3, 3.8 and 6.2 for mild, moderate and severe
pain, respectively (P<0.001).
Patients placed significant value on obtaining relief from
their PHN. On a 0–100 scale, patients estimated a 29%
increase in their health-rating score (improvement from
61.7 ± 20.3 to 79.7 ± 19.8; P<0.0001, paired t-test) if they
could experience complete relief from their PHN.
PHN directly impacted medical resource utilisation
within the past 4 weeks; 68% of patients visited their physi-
cian at least once, 30% had telephone consultations for their
PHN and 30% saw a pain specialist. A significant association
was observed between increasing pain severity and greater
number of telephone consults (P = 0.008), with a similar
trend between pain severity and physician visits (P = 0.078).
Discussion
These findings demonstrate a substantial patient burden of
PHN, consistent with previously reported neuropathic pain
conditions including diabetic peripheral neuropathy [12, 19, 26]
and PHN [13]. Patient burden, expressed as impairment of
function and reduced quality of life, was significantly associ-
ated with pain severity as indicated by poorer health status
(EQ-5D) and increased pain interference with functioning
(mBPI-SF Pain Interference scores) with increasing neuro-
pathic pain severity. Additionally, a substantial proportion
of patients were prescribed medications for depression,
anxiety and sleep disturbance related to PHN, conditions
considered co-morbid with chronic pain including neuro-
pathic syndromes [11, 27].
The sustained moderate-to-severe pain levels suggest
suboptimal pain management. This is supported by the con-
siderable patient burden observed despite most patients
receiving prescription medications for their PHN. This
finding may in part be attributed to the use of agents having
no demon trated efficacy for the treatment f neur pathic
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buspirone or other hypnotics) or analgesics (tramadol, any opioids or opioid
compounds, non-steroidal anti-inflammatory drugs or COX-2 inhibitors) for
concomitant anxiety, depression or sleep disturbance.
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Physician-reported NP prescription medications
Current NP prescription medication 75 (89.3)
Amitriptyline 18 (21.4)
Other antidepressants 22 (26.2)
Sedatives/hypnotics 27 (32.1)
Analgesics 54 (64.3)
Opioids and opioid compounds 17 (20.2)
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Non-prescription medications 31 (36.9)
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figure 2. Association between pain severity and EuroQol (EQ-5D) health state valuation. P<0.001 using 
one-way ANOVA
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increasing pain severity and greater number of telephone consults (P = 0.008), with a 
similar trend between pain severity and physician visits (P = 0.078).
discussioN
These findings demonstrate a substantial patient burden of PHN, consistent with previ-
ously reported neuropathic pain conditions including diabetic peripheral neuropathy 
[12, 19, 26] and PHN [13]. Patient burden, expressed as impairment of function and 
reduced quality of life, was significantly associated with pain severity as indicated by 
poorer health status (EQ-5D) and increased pain interference with functioning (mBPI-
SF Pain Interference scores) with increasing neuropathic pain severity. Additionally, a 
substantial proportion of patients were prescribed medications for depression, anxiety 
and sleep disturbance related to PHN, conditions considered co-morbid with chronic 
pain including neuropathic syndromes [11, 27].
The sustained moderate-to-severe pain levels suggest suboptimal pain management. 
This is supported by the considerable patient burden observed despite most patients 
receiving prescription medications for their PHN. This finding may in part be attributed 
to the use of agents having no demonstrated efficacy for the treatment of neuropathic 
pain (e.g. 33% of patients were taking non-steroidal anti-inflammatory drugs or COX-2 
inhibitors for their PHN).
Similarly, suboptimal doses of neuropathic pain medications including gabapentin 
and carbamazepine may have contributed to inadequate pain management [9, 10]. Few 
patients reported adequate therapeutic efficacy of their prescribed medications, which 
may explain why non-prescription adjunctive treatments including over-the-counter 
analgesics, topicals and supplements were taken to obtain pain relief.
Twenty-one per cent of patients were taking amitriptyline, which has demonstrated 
efficacy in neuropathic pain, albeit at higher doses than the mean daily dose of 32.4±17.4 
mg observed here. According to the Beer’s modified criteria [28], amitriptyline is consid-
ered inappropriate for use in the age group represented in this analysis (≥65 years) and 
is not recommended for treatment of neuropathic pain in older patients [9]. Potentially 
inappropriate use of medications for painful neuropathic disorders was recently report-
ed in older adults, where 35% of patients with PHN were prescribed amitriptyline [29].
Our observation of inadequate pain control, pain interference with functioning and 
suboptimal treatment was consistent with a US postal survey of patients with PHN, 
where only half of patients reported taking prescription medication for PHN in the prior 
week, despite moderate levels of pain severity and pain interference [13]. The associa-
tion of pain severity with pain interference and EQ-5D health state valuation observed 
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in both the postal survey and current study suggest that suboptimal treatment of PHN 
is common.
Suboptimal pain management and patient burden were similarly reported by Gilron 
et al. [30] in a Canadian study of patients with neuropathic pain treated by general prac-
titioners. Seventy-three per cent of patients complained of inadequate pain control and 
only 16% tried any of the newer pharmacologic agents available for neuropathic pain. 
Approximately 30% of patients saw a pain specialist, similar to the present study, indi-
cating that few patients were being referred to and treated by physicians familiar with 
new and/or appropriate treatment options. In the current analysis, inadequate manage-
ment of PHN and increased resource utilisation were demonstrated by the significant 
association between pain severity and telephone consults and the trend towards more 
physician visits with increasing pain severity.
This study has several limitations. The small number of patients may limit the ability 
to detect potentially significant associations. Other limitations include the potential for 
selection and recall bias, where patients were actively seeking medical care (possible 
selection bias), and some information from the survey was collected by self report (pos-
sible recall bias). Furthermore, pain is a complex and multidimensional experience, and 
our focus on pain severity may not have captured the full impact of pain on patient 
burden. The use of >3 to distinguish between moderate and mild pain severity and 
interference was consistent with that reported in other studies. The cut-point correlated 
with resource utilisation and patient outcomes in diabetic peripheral neuropathy [20, 
24] and demonstrated agreement with activities of daily living and quality of life in an 
HZ-specific adaptation of the BPI [18].
In conclusion, this study demonstrates substantial patient burden associated with PHN. 
The burden was significantly greater when pain was less controlled and likely resulted 
from suboptimal or inappropriate management strategies. Our results demonstrate a 
need for more effective management strategies in patients presenting with PHN, such 
as physician education related to neuropathic pain mechanisms and treatment options, 
and familiarity with current neuropathic pain management guidelines.
key PoiNts
– Most patients with postherpetic neuralgia (PHN) reported moderate or severe pain 
and suboptimal health and functioning despite taking prescribed medications for 
the treatment of PHN.
– Patient burden was significantly associated with pain severity: health valuation was 
poorer and pain interference with functioning was greater with increasing pain 
levels.
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– Use of prescription medications with no known efficacy in neuropathic pain and 
in general lower than recommended doses of medications with neuropathic pain 
efficacy was reported.
– Better management strategies including physician education could reduce the 
burden of PHN.
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AbstrAct
background
The objective of this study is to use the pain numeric rating scale (NRS) to evaluate as-
sociations between change in pain severity and changes in sleep, function, and mood 
assessed via patient-reported outcomes (PROs) in patients with posttraumatic pain.
methods
This is a secondary analysis of a clinical trial evaluating pregabalin in patients with post-
traumatic peripheral neuropathic pain (N=254). Regression models were used to deter-
mine associations between changes in pain (0–10 NRS) as the predictor and scores on 
the following PRO measures as the outcome: Pain Interference Index; Hospital Anxiety 
and Depression Scale anxiety and depression subscales; Medical Outcomes Study–Sleep 
Scale 9-item Sleep Problems Index and Sleep Disturbance subscale; and Daily Sleep 
Interference Scale (0–10 NRS).
results
Change in pain severity showed clear, direct relationships with changes in function, 
anxiety, depression, and sleep PROs, all of which were statistically significant (P<.001). 
Results from subgroup analyses (≥30% or ≥50% pain responders, pregabalin or placebo 
treatment, age ≤ 51 years or >51 years) tended to be consistent with results from the 
overall sample.
conclusions
Overall, a direct relationship exists between pain and various aspects of patient’s well-
being and functioning, which can provide a quantitative assessment of how improve-
ments in pain may be expected to relate to other patient outcomes. (ClinicalTrials.gov 
Identifier number NCT00292188; EudraCT #2005-003048-78).
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bAckgrouNd
Because the complexity and subjective nature of pain complicates evaluation of its 
severity and impact, various patient self-report instruments have been developed to 
assess pain and other patient-reported outcomes (PROs) in the research and clinical 
settings [1]. The 11-point numeric rating scale (NRS), which ranges from 0 (no pain) to 
10 (worst possible pain), has become one of the most frequently used instruments for 
evaluating pain based on its simplicity and ease of comprehension by patients.
This NRS is recommended by the Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT) as one of the core outcomes for assessment in 
clinical trials of chronic pain [2]. Additionally, IMMPACT recommends that function and 
mood should be included as core outcomes. The presence and increased severity of pain 
often results in reduced function and increased mood disturbance [3, 4]. Although not 
included in the IMMPACT recommendations, sleep is another outcome that is affected 
adversely by pain, with consistent evidence endorsing this relationship [5–7].
When evaluating these outcomes, we believe that because the presence of pain 
generally interferes with daily functions, improvement in pain will be associated with 
improved functioning and other health benefits such as sleep and mood — specific out-
comes that can be quantified and expressed. Therefore, characterizing and quantifying 
the relationship between pain severity and corresponding levels of interference with 
daily function, sleep, and mood can inform treatment decisions and guide assessment 
of outcomes. Previous studies in painful diabetic peripheral neuropathy have evaluated 
the relationship between pain and other PROs to categorize patients with mild, moder-
ate, and severe pain [8, 9]. One of these studies suggested that changes across severity 
categories correlate with specific score changes in PROs [9]. The purpose of the current 
study is to use the pain NRS to characterize and quantify in a clinical and meaningful way 
the extent of the relationship between pain severity scores and scores on other PROs 
that measure sleep, pain interference on daily functions, and mood.
methods
This study is a secondary analysis using data derived from a placebo-controlled clini-
cal trial evaluating the efficacy of pregabalin in patients with posttraumatic peripheral 
neuropathic pain (N=254). The methodology and primary analysis of the trial have been 
reported elsewhere [10].
All patients gave written, informed consent. Institutional review boards reviewed and 
approved the protocol and the study was conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines and local laws and regulations. Patients 
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were eligible for participation if they received a diagnosis of posttraumatic peripheral 
neuropathic pain (including post-surgical neuropathic pain, neuropathic pain due to 
peripheral nerve injury, and phantom limb pain) that was confirmed by a qualified pain 
specialist and persisted for a minimum of three months following the traumatic event. 
Patients were enrolled if they had a score of ≥40 mm on the visual analog scale of the 
short-form McGill Pain Questionnaire and completed ≥ 4 daily pain diaries during the 
last week of the screening period prior to randomization, with the mean score being ≥4 
on the 11-point (0–10) NRS.
Patients with neuropathic pain that was not due to trauma (e.g. diabetic peripheral 
neuropathy, postherpetic neuralgia, radiculopathy, trigeminal neuralgia or carpal tun-
nel syndrome), was central rather than peripheral (e.g. spinal cord injury) or was due 
to Complex Regional Pain Syndrome (Type 1 or Type II) were excluded. Also, patients 
suffering from clinically significant or unstable conditions that, in the opinion of the 
investigators, would compromise participation in the study were excluded.
The current report focuses on the association between changes in pain severity and 
changes in PROs of pain interference on daily functions, sleep, and mood; these analyses 
are independent of the treatment allocation (pregabalin or placebo) and comparative 
results reported in the primary analysis.
We evaluated the association between change in pain, assessed daily using a 0-to-10 
NRS (0 = no pain, 10 = worst possible pain) and then averaged to give a weekly result, 
and several other PROs assessed at baseline and end of double-blind treatment at week 
8. These PROs included the following: the Pain Interference Index (PII) from the modified 
Brief Pain Inventory — short form (mBPI-sf ) [11], a composite score of the 7 interfer-
ence items assessed using a 0-to-10 NRS anchored at 0 = does not interfere and 10 = 
completely interferes (recall period of the past 24 hours); the anxiety and depression 
subscales of the Hospital Anxiety and Depression Scale (HADS) [12], with each subscale 
consisting of 7 items scored using a 4-point Likerttype scale (1-week recall period) and 
higher scores indicating greater severity; the Medical Outcomes Study–Sleep Scale 
(MOS-SS) 9-item Sleep Problems Index and 4-item Sleep Disturbance subscale [13], both 
based on a 1-week recall period with higher scores indicating greater sleep problems; 
and the Daily Sleep Interference Scale that uses an 11-point NRS to describe how pain 
has interfered with sleep during the past 24 hours (0 = no interference, 10 = completely 
interferes). Linear models were applied to evaluate the relationship between the change 
in each of these PROs as the outcome and the change in pain used as a continuous 
predictor.
The above-specified relationships between change in pain and PROs were examined 
using linear regression models. The changes in PRO scores were evaluated as a function 
of the change in pain NRS score (from baseline to end point).
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The model was populated with all available patients who provided data in the clinical 
trial regardless of treatment allocation or treatment effects. To evaluate the model for 
consistency and robustness, six sensitivity analyses were performed using subgroups 
from the clinical trial. These cohorts included patients achieving ≥30% pain response 
(30% responders), patients achieving ≥50% pain response (50% responders), pregab-
alin-treated patients, placebo-treated patients, patients aged ≤ 51 years and patients 
>51 years. Fifty-one years was chosen as the cut-off value since it is the median age of all 
patients. The 30% and 50% responders are those patients who achieved at least a 30% 
and 50% reduction in pain NRS scores, respectively, from baseline to endpoint.
All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, North 
Carolina, USA). A P value <.05 was taken to confer statistical significance.
results
The population consisted of 254 patients with a mean age of 51.7 years; 50.8% of the pa-
tients were female. In the original placebo-controlled clinical study [10], pregabalin was 
associated with a statistically significant improvement in pain compared to placebo, and 
significant improvements in other PRO scores that included pain-related sleep interfer-
ence, the MOS sleep scale (overall sleep problems index, as well as the sleep disturbance 
and sleep adequacy subscales), and the anxiety and depression subscales of the HADS.
In this secondary analysis, changes in PRO scores were evaluated as a function of 
change in pain severity. Regression models resulted in linear plots (see Table 1 for slope 
and intercept estimates) that showed significant associations (P<.001) between changes 
in pain and changes in patient-reported sleep disruption (Figure 1), pain interference 
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Tables 
Table 1  - Slope and intercept estimates from models predicting relationships between changes in pain severity and  
PROs for all patients 
ESTIMATE  (95% CI)  
 
MOS-SS 
DISTURBANCE 
MOS-SS 9-
ITEM SLEEP 
PROBLEMS 
INDEX 
SLEEP 
INTERFERENCE 
(NRS) 
HADS 
ANXIETY 
HADS 
DEPRESSION PII 
 Intercept 
 
–4.30 
(–7.31, –1.28) 
–2.07 
(–4.42,  0.27) 
–0.27 
(–0.49 ,–0.05) 
–0.76 
(–1.22 ,–0.30) 
–0.27 
(–0.63, 0.08) 
–0.32 
(–0.56, –0.08) 
       
Slope 
 
3.79 
(2.44, 5.13) 
2.76 
(1.71,  3.80) 
0.68 
(0.59, 0.78) 
0.38 
(0.17, 0.59) 
0.48 
(0.32, 0.64) 
0.58 
(0.47, 0.69) 
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on daily functions (Figure 2), and mood (anxiety and depression; Figure 3). For example, 
a 2-point decrease (improvement) in pain corresponded to an estimated 7.6-point 
decrease (improvement) in the MOS Sleep Problem Index 9, 11.9-point decrease in MOS 
Sleep Disturbance, and 1.6-point decrease in Sleep Interference (Figure 1). A 2-point 
decrease in pain was associated with an estimated 1.5-point decrease in pain interfer-
ence on daily function or PII (Figure 2). A 2-point decrease in pain was associated with 
an estimated 1.5-point decrease in HADS anxiety and a 1.2-point decrease in HADS 
depression (Figure 3). The derived plots can be interpreted as showing, at the individual 
patient level, the mean change in PRO score (y-axis) that can be expected with the vari-
ous incremental changes in pain severity (x-axis).
Table 2 presents the mean improvement (decrease) in PROs corresponding to a 
2-point improvement (decrease) in pain for the total sample. The mean improvement 
values were estimated as intercept + slope*(-2). For example, using data from Table 1, 
mean improvement in MOS-SS disturbance that corresponded to a 2-point improve-
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ment in pain is -4.3 + 3.79*(-2), which is equal to -11.87, taking into account rounding 
errors in intercept and slope (Table 2).
Table 2 also presents the results of the subgroup sensitivity analyses for 30% and 50% 
pain responders as well as for individuals in the pregabalin and placebo groups, and 
individuals aged ≤ 51 years and > 51 years. In general, these sensitivity analyses tended 
to support the results of the main analysis of the total sample, with some exceptions, 
for example, 50% responders on the PII scale, and placebo-treated patients as well as 
patients ≤ 51 years of age on the HADS depression subscale, the MOS-SS Disturbance 
subscale and the MOS-SS 9-item Sleep Problems Index.
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discussioN
It is well-recognized that pain affects patient function and may have a reciprocal rela-
tionship with specific outcomes such as sleep and mood [3–7]. The results of this study 
expand our knowledge of the relationship between pain and PRO by suggesting that 
a clear, direct relationship exists between change in pain and change in patients’ self-
report of daily function, sleep, and mood. To our knowledge, this is the first study that 
provides evidence for such a relationship. This study demonstrates a direct quantitative 
linkage of these relationships, whereby specific changes in pain severity can be mapped 
to the specific magnitude of a change in a PRO.
Pain severity is not necessarily linearly related to functional impairment [14]. Nev-
ertheless, our imposition of linearity on the relationship between change in pain and 
change in functional impairment is useful because it enables us to predict and quantify 
- 21 - 
Table 2  - Mean Improvement in PROs Corresponding to a 2-Point Improvement in Pain for Patients and Preselected Subgroups 
MEAN (95% CI) IMPROVEMENT IN PRO THAT CORRESPONDED TO A 2-POINT IMPROVEMENT IN PAIN 
GROUP 
MOS-SS 
DISTURBANCE 
MOS-SS 9-
ITEM SLEEP 
PROBLEMS 
INDEX 
SLEEP 
INTERFERENCE 
(NRS) 
HADS 
ANXIETY 
HADS 
DEPRESSION PII 
All patients 
(N=254) 
–11.87 
(–14.83, –8.91) 
–7.59 
(–9.91, –5.27) 
–1.64 
(–1.86 ,–1.43) 
–1.52 
(–1.97 ,–1.07) 
–1.23 
(–1.58,–0.88) 
–1.48 
(–1.72, –1.25) 
Subgroups       
30% responders  
(n=82)* 
–11.57 
(–19.17, –3.98) 
–7.41 
(–13.31, –1.50) 
–1.54 
(–2.05, –1.03) 
–1.57 
(–2.61, –0.53) 
–1.39 
(–2.13,–0.65) 
–1.68 
(–2.22 ,–1.14) 
50% responders 
(n=48)* 
–13.12 
(–25.04, –1.19) 
–8.37 
(–18.07,1.32) 
–1.70 
(–2.70,–0.70) 
–2.04 
(–3.88, –0.21) 
–1.25 
(–2.50,0) 
–2.21 
(–3.13,–1.28) 
Pregabalin- 
treated  patients  
(n=127) 
–15.79 
(–19.76, –11.83) 
–9.85 
(–13.14, –6.57) 
–1.67 
(–1.96, –1.38) 
–1.64 
(–2.25,–1.03) 
–1.56 
(–2.00,–1.12) 
–1.71 
(–2.05,–1.38) 
Placebo-treated  
patients (n=127) 
–7.09 
(–11.51,–2.68) 
–4.93 
(–8.22, –1.65) 
–1.62 
(–1.95, –1.29) 
–1.41 
(–2.09, –0.74) 
–0.83 
(–1.39,–0.27) 
–1.18 
(–1.51,–0.85) 
- 22 - 
Age ≤ 51 y  
(n=127) 
-8.12 
(-12.35, -3.89) 
-5.16 
(-8.41, -1.91) 
-1.59 
(-1.89, -1.30) 
-1.17 
(-1.83, -0.51) 
-0.75 
(-1.28, -0.22) 
-1.47 
(-1.79, -1.15) 
Age > 51 y 
(n=124) 
-15.64 
(-19.74, -11.54) 
-10.17 
(-13.48, -6.86) 
-1.69 
(-2.01, -1.38) 
-1.87 
(-2.48, -1.27) 
-1.71 
(-2.16, -1.26) 
-1.50 
(-1.85, -1.15) 
       
Mean Improvement = decrease; CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; MOS-SS, Medical Outcomes Study–
Sleep Scale; NRS, numeric rating scale; PII, Pain Interference Index; PROs, patient-reported outcomes. 
*30% and 50% responders are those patients who achieved at least a 30% and 50% reduction in pain, respectively, in the clinical trial on which 
this analysis was based. 
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the functional improvement that may be expected to result from successful analgesic 
treatments. The strength of our results is that they are hypothesis- and empirically-
driven findings that are independent of treatment allocation. This model for evaluating 
change in pain severity can be interpreted at the individual patient level over time, 
and can be used to determine the expected change in PRO score that corresponds to 
a particular incremental change in pain severity for a particular patient in the current 
study from baseline to week 8. This relationship can be explained to the patient and can 
help to convey the level of improvements that may be achievable, thereby enabling the 
patients to form more realistic and objective goals.
Even though there were fewer patients in the sensitivity analyses, the results were 
generally consistent with the main analysis, indicating the invariance of the observed 
relationships. The few exceptions may be owing to the smaller number of observations 
and the curtailment of distribution of responses, which resulted in a narrower range in 
change scores in the subgroups. While the reason for these exceptions warrants further 
investigation, the overall comparability of the values among the evaluated samples sug-
gests the model’s robustness.
Of particular interest is the observation that for some of the PROs, there was a change 
in score even with no change in pain severity. For example, individuals with no change 
in pain severity still showed a 4.3-point improvement on the MOS-SS Sleep Disturbance 
subscale. This can be taken to suggest that there may exist effects of treatment that are 
independent of the effects on pain, which in this case, can be specific effects on sleep.
Further support for this comes from the sensitivity analyses, for which pregabalin 
treated patients with no change in pain improved by 7.50 points on the MOS-SS Sleep 
Disturbance subscale, whereas placebo-treated patients with no pain change improved 
only by 1.35 points. Direct effects of pregabalin on sleep improvement have previously 
been suggested using mediation analysis in a study of patients with fibromyalgia [15]. 
The relationship between pain and sleep is considered to be bidirectional [6, 16], and 
while studies have suggested that sleep disruption may enhance the pain experience 
[17–19], it is not clear whether sleep improvement in itself can directly improve pain 
scores or if the improved sleep increases the patient’s ability to cope with the pain.
The data in the present study are consistent with results from a recent study by Hoff-
man et al. [9]. Using data from a randomized, placebo-controlled trial of pregabalin 
in patients with painful diabetic peripheral neuropathy, a different population from 
ours, researchers derived pain severity cutpoint categories on a 0–10 point pain nu-
merical rating scale (NRS), and compared the magnitude of within patient change in 
pain severity with corresponding changes in function and health status. The cutpoint 
analysis indicated that pain severity ratings of 1–3, 4–6, and 7–10 corresponded to mild, 
moderate and severe pain, respectively. For each change category, mean (± standard 
deviation, SD) score changes were examined for the mBPI-sf Pain Interference Index (PII) 
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and the Euro-Qol (EQ-5D). On the mBPI-sf PII (0–10 NRS), mean changes of -5.5 (± 2.1) 
corresponded to a shift from severe pain to no/mild pain; -3.3 (± 2.1), severe to moder-
ate; -3.2 (± 2.1), moderate to no/mild; -0.9 (± 2.0), no change; and 0.4 (± 2.6), worsening 
(P < .0001). Mean changes in the PII ranged from -4.5 (± 2.2) for patients with ≥ 50% 
NRS reduction and -0.2 (± 2.0) for patients with < 10% NRS reduction (P < .0001). Similar 
differences were observed for the EQ-5D. Thus, changes in pain severity were associated 
with changes in daily functioning and health status, findings similar to those reported 
in the presented study.
A two-point reduction on pain is taken to correspond to a clinically meaningful 
improvement on the other PROs. Psychometric studies on specific PRO scales provide 
evidence supporting the clinical importance of these changes. For example, a large 
study assessing the psychometric properties of the Daily Sleep Interference Scale 
demonstrated significant correlations between this scale and other outcome measures, 
including pain, and the results suggest that a 1–2 point change from baseline to end 
of treatment may be interpreted as clinically important [20], a change consistent with 
values reported in the present study.
In a similar study that evaluated the reliability and validity of the MOS Sleep Scale in 
patients with painful diabetic neuropathy [21], the MOS Sleep Problems Index was shown 
to be responsive to clinical changes, with improvements being greater as the pain and 
sleep of patients improved. Minimal improvement in health status (on measures of pain, 
sleep, patient or clinical global impression of change) corresponded to mean changes 
on the MOS Sleep Problems Index that ranged from -10 to -14, a range that overlaps with 
the mean ± 95% CI reported herein, particularly in pregabalin-treated patients.
A study evaluating the psychometric properties of the BPI for painful diabetic pe-
ripheral neuropathy showed that scores on the PII (subscale of BPI) correlate highly and 
significantly with other outcome measures related to pain, sleep, health status, quality 
of life and mood [11]. Furthermore, in patients with painful diabetic neuropathy treated 
with pregabalin, a one-grade reduction in pain level, either “severe-to-moderate” or 
“moderate-to-no/mild” corresponded to mean (± SD) reductions in the PII of -3.3 (± 
2.1) and -3.2 (± 2.1), respectively [9]. The PII values reported herein for all patients and 
subgroups are below these values but within the mean ± SD range, and therefore may 
be associated with clinically meaningful changes in pain levels. According to IMMPACT 
recommendations, a 1-point reduction in the PII may reflect minimally important im-
provement [22].
An important limitation of this study is that while it may be reasonable to expect that 
reductions in pain severity will result in improvements in other outcomes, the associa-
tions demonstrated by the reported data do not imply causation. Furthermore, these 
data are derived from patients with nonmalignant chronic pain and do not imply a 
general physiologic or pathophysiologic parallel regulation. For example, it has been 
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shown that change in depression scores are not necessarily paralleled by changes in 
pain thresholds in patients treated for major depression [23]. The use of other analytic 
techniques, such as path or mediation analysis, may help further characterize the causal 
relationship of these associations.
The generalizability of this study is another limitation that should be considered when 
interpreting the results within the context of clinical trials or clinical practice. Conse-
quently, these results should be used as a guide for further exploring the relationships 
underlying pain and pain interference with function.
Models with pain as a categorical predictor, which do not impose any functional 
relationship between outcome and predictor, were also investigated. Results of these 
models (not reported here) supported the results with pain as a continuous predictor. 
We believe that the best choice to depict the appropriateness of a model is through 
probability plots and residual plots. If the probability plot forms a linear pattern and the 
residual plot forms no pattern, then we can conclude that the fitted relationship (in this 
case linear) is appropriate. We extensively studied these two types of plots and found 
the model to be suitable. The use of pain as a continuous predictor not only increases 
the sensitivity of observed relationships but also lends a simplified and meaningful 
interpretation of the relationship through the slope as a measure of change.
coNclusioNs
In summary, the results reported here provide evidence of a direct and tangible rela-
tionship between pain and PROs in patients with chronic, nonmalignant neuropathic 
pain. Importantly, the data additionally demonstrate that pain responders show other 
benefits that are quantifiable in relation to the change in pain severity and are clinically 
significant. This novel analysis can be applied for determining individual responses that 
can be expected in patients being treated for pain, with the observed relationships 
providing a framework for quantitatively assessing how improvements in pain may be 
expected to result in improvement in other patient-centered outcomes. Such informa-
tion may be useful in the research setting for trial design and in the clinical setting for 
informing treatment decisions and enhancing assessment of outcomes. Additional 
confirmatory studies are encouraged.
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AbstrAct
objective
Postherpetic neuralgia and painful diabetic peripheral neuropathy are common chronic 
neuropathic pain conditions associated with sleep disturbances. Pregabalin is indicated 
in the treatment of neuropathic pain. The objective of this review is to summarize the 
efficacy and safety of pregabalin in painful diabetic peripheral neuropathy and posther-
petic neuralgia and the effect of pregabalin on sleep interference in these patients.
methods
MEDLINE and ISI Web of Knowledge databases were searched for randomized double-
blind, placebocontrolled clinical trials of pregabalin reporting sleep measures in ad-
dition to pain endpoints in patients with painful diabetic peripheral neuropathy and 
postherpetic neuralgia published from inception through March 2009.
results
Nine trials met the inclusion criteria, providing data for a total of 2399 patients with 
painful diabetic peripheral neuropathy or postherpetic neuralgia treated twice or three 
times per day with pregabalin (75–600 mg/day) or placebo on a fixed or flexible sched-
ule. Interpretation of sleep outcomes in two studies may be limited by trial inclusion 
criteria which permitted benzodiazepines for sleep problems. Also, none of the studies 
reported objective sleep measures. Pregabalin was well tolerated. Pregabalin (150–600 
mg/day) significantly reduced pain and improved pain-related sleep interference.
conclusions
In addition to an analgesic benefit, pregabalin may decrease pain-related sleep interfer-
ence in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia.
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iNtroductioN
Neuropathic pain results from a primary lesion or dysfunction in the nervous system1,2, 
with multiple mechanisms underlying painful symptoms, including changes in the 
peripheral nervous system, spinal cord, or brainstem3. Tricyclic antidepressants, opioids, 
selective serotonin reuptake inhibitors (SSRIs), selective serotonin–norepinephrine 
reuptake inhibitors, topical lidocaine, and antiepileptic drugs (AEDs) each have a dif-
ferent mode of action impacting neuropathic pain and are among the commonly used 
pharmacotherapies in painful diabetic peripheral neuropathy (DPN) or postherpetic 
neuralgia (PHN)2,4–6.
Patients with neuropathic pain often experience sleep interference described as dif-
ficulties in initiating sleep and remaining asleep7–10. Surveys of patients with painful DPN 
found that more than half of patients reported substantial interference with sleep11,12 
and greater sleep problems compared with the general US population (respective 
mean Sleep Problems Index scores, 47.1±21.1 vs. 25.8±18.6)13. Most patients reported 
suboptimal sleep (57 hours/night), and patients with severe pain reported greater sleep 
problems13. Sleep disturbance is also a comorbid disorder in patients with PHN and can 
lead to anxiety and depression, both of which can further exacerbate pain and sleep 
interference12,14.
Pharmacologic management of sleep disturbances in neuropathic pain is complex. 
AEDs have demonstrated both detrimental and beneficial effects on sleep quality and 
sleep architecture15,16. Pregabalin binds potently to the a2d subunit protein of voltage-
gated calcium channels in central nervous system (CNS) tissues17–19. High-affinity binding 
to the a2d subunit results in a reduction of calcium influx, modulates the release of sev-
eral excitatory neurotransmitters (including glutamate, noradrenaline, and substance 
P)20–24 from presynaptic neurons, and may lead to subsequent analgesia25. Awakening 
during nonrapid eye movement (NREM) sleep contributes to sleep disturbances 26,27. 
Pregabalin increases the duration of NREM sleep, and therefore, may consolidate sleep 
and reduce sleep interference.
Pregabalin has been shown to reduce awakenings and improve sleep dysfunction in 
patients with epilepsy and fibromyalgia28,29. The purpose of the present paper is to re-
view the efficacy and tolerability data from clinical trials of pregabalin in painful DPN or 
PHN and to summarize the effect of pregabalin on sleep interference in these patients.
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methods
literature search
A literature search was conducted in March 2009 using MEDLINE (PubMed) and ISI Web of 
Knowledge to identify publications where pregabalin was evaluated in randomized, pla-
cebo-controlled clinical trials in DPN or PHN. The search criteria were customized to each 
database. For PubMed, the following queries were used: pregabalin AND (diabetic neu-
ropath* OR postherpetic neuralgia OR post-herpetic neuralgia) AND (Clinical Trial[ptyp] 
OR Randomized Controlled Trial[ptyp] OR Multicenter Study[ptyp]) AND English[lang] 
NOT (‘anesthetics’[MeSH Terms] OR ‘anesthetics’[All Fields] OR ‘anesthetic’[All Fields] 
OR ‘anesthetics’ [Pharmacological Action]). For ISI Web of Knowledge, the search terms 
were: Title¼pregabalin AND (diabetic neuropath* OR postherpetic neuralgia OR post-
herpetic neuralgia) AND (study or trial) AND Language¼English. Literature searches 
were not restricted to specific dates.
inclusion criteria
Primary reports on randomized, double blind, placebo controlled clinical trials that 
evaluated pregabalin on pain and pain-related sleep interference in patients with DPN 
or PHN were included.
data extraction
Outcome measures on pain and pain-related sleep interference were extracted, along 
with demographics, adverse events and discontinuation rates.
results
The literature search yielded 27 publications, nine of which met the inclusion criteria 
(Table 1)30–38. Each of the nine clinical trials was conducted in accordance with good 
clinical practice guidelines and received Institutional Review Board approval. The trials 
were 5 to 13 weeks in duration, including the baseline phase. The mean age of patients 
ranged from 70 to 73 years in the PHN studies30,35,37, compared with a mean age of 56 
to 62 years in painful DPN studies32–34,36,38. Eligible patients receiving prohibited medica-
tions (e.g., benzodiazepines, skeletal muscle relaxants, steroids, local and topical agents, 
nonsteroidal anti-inflammatory drugs, and anticonvulsants) completed a washout 
period prior to randomization. Upon randomization, 2399 patients received pregabalin 
(75–600 mg/day) or placebo, twice-daily (BID) or three-times-a-day (TID) dosing on a 
fixed or flexible schedule (Table 1).
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Concomitant medications including aspirin 325 mg/day, acetaminophen ≤ 3 g/day, 
and SSRIs were allowed, provided the dosing was stable for 30 days prior to baseline 
and throughout the study. In two studies36,38, benzodiazepines were allowed for ‘sleep 
problems.’
efficacy
The primary efficacy measure in each study was the change from baseline of the least 
squares mean pain score at endpoint (defined as the last seven available daily scores 
while on study medication), which was rated on an 11-point numeric rating scale (0 = 
no pain to 10 = worst possible pain) and recorded by the patient in a daily diary. Across 
these studies, patients with painful DPN or PHN reported moderate-to-severe pain at 
baseline (mean pain scores ranged from 6.1 to 7.1)30–38. Each study reported endpoint 
least squares mean pain-related sleep interference scores as a secondary efficacy mea-
sure. Daily pain-related sleep interference scores were based on an 11-point numeric 
rating scale (0 = pain does not interfere with sleep to 10 = pain completely interferes 
with sleep) and recorded by the patient in a daily sleep diary30–38. In addition to the 
patient diary, two trials (one PHN and one trial with both PHN and DPN patients) also as-
sessed sleep interference using Medical Outcomes Study (MOS)–Sleep Scale scores30,31. 
The MOS–Sleep Scale is a validated, reliable, 12-item, self-administered instrument 
evaluating quantity of sleep, sleep disturbance, sleep adequacy, daytime somnolence, 
snoring, and awakening with shortness of breath or headache, with higher scores re-
flecting worse sleep39,40.
Pain
In patients with painful DPN, five randomized controlled trials assessed efficacy of prega-
balin administered TID or BID. Treatment with pregabalin 300 or 600 mg/day significantly 
decreased endpoint mean pain scores compared with placebo (Table 1)32–34,36,38. 
Doses of 75 and 150 mg/day (and 300 mg/day BID) did not produce significant pain 
relief vs. placebo32,33,36. Patients with PHN experienced significant reductions in mean 
pain scores with both TID and BID regimens across all pregabalin dosages (150–600 mg/
day; Table 1)30,35,37. One study included patients with either DPN or PHN. Both flexible-
dose (150–600 mg/day) and fixed-dose (600 mg/day) pregabalin significantly improved 
the mean pain score compared with placebo (Table 1)31.
sleep
Pregabalin 300 and 600 mg/day significantly decreased endpoint mean sleep interfer-
ence scores compared with placebo in patients with painful DPN32–34,36,38, while lower 
doses of pregabalin (75 and 150 mg/day) did not differ from placebo32,33,36 (Table 1 and 
Figure 1).
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Significant improvements in sleep interference scores were seen as early as week 
1 (Figure 1). In patients with PHN, compared with placebo, 150, 300 and 600 mg/day 
pregabalin significantly improved endpoint mean sleep interference scores30,35,37 and 
these effects were seen as early as week 1 (Figure 1). A significant improvement on the 
MOS-Sleep scale sleep problem index was alsoobserved30. In the study that included 
patients with either DPN or PHN31, flexible-dose (150–600 mg/day) and fixed-dose (600 
mg/day) pregabalin significantly improved endpoint mean sleep interference scores, 
and the improvements were observed as early as week 1 (Figure 1). Significant improve-
ments relative to placebo on sleep disturbance and overall sleep problem index of the 
MOS–Sleep scale were also observed.
discussioN
Pregabalin 150 to 600 mg/day is well tolerated and relieves pain and pain-related sleep 
disturbances associated with DPN or PHN30–38. Pregabalin 600 mg/day (TID or BID) was 
consistently superior to placebo in patients with PHN or DPN30–38. Doses ≤150 mg/day 
ranged from 6.1 to 7.1)30–38. Each study reported endpoint
least squares mean pain-related sleep interference scores as
a secondary efficacy measure. Daily pain-related sleep
interference scores were based on an 11-point numeric
rating scale (0¼ pain does not interfere with sleep to
10¼ pain completely interferes with sleep) and recorded
by the patient in a daily sleep diary30–38. In addition to the
patient diary, two trials (one PHN and one trial with both
PHN and DPN patients) also assessed sleep interference
using Medical Outcomes Study (MOS)–Sleep Scale
scores30,31. The MOS–Sleep Scale is a validated, reliable,
12-item, self-administered instrument evaluating quantity
of sleep, sleep disturbance, sleep adequacy, daytime som-
nolence, snoring, and awakening with shortness of breath
or headache, with higher scores reflecting worse sleep39,40.
Pain
In patients with painful DPN, five randomized controlled
trials assessed efficacy of pregabalin administered TID or
BID. Treatment with pregabalin 300 or 600mg/day signif-
icantly decreased endpoint mean pain scores compared
with placebo (Table 1)32–34,36,38. Doses of 75 and
150mg/day (and 300mg/day BID) did not produce signif-
icant pain relief vs. placebo32,33,36.
Patients with PHN experienced significant reductions
in mean pain scores with both TID and BID regi-
mens across all pregabalin dosages (150-600mg/day;
Table 1)30,35,37.
One study included patients with either DPN or PHN.
Both flexible-dose (150–600mg/day) and fixed-dose
(600mg/day) pregabalin significantly improved the mean
pain score compared with placebo (Table 1)31.
Sleep
Pregabalin 300 and 600mg/day significantly decreased
endpoint mean sleep interference scores compared with
placebo in patients with painful DPN32–34,36,38, while
lower doses of pregabalin (75 and 150mg/day) did not
differ from placebo32,33,36 (Table 1 and Figure 1).
Significant improvements in sleep interference scores
were seen as early as week 1 (Figure 1). In patients with
PHN, compared with placebo, 150, 300 and 600mg/day
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Figure 1. Difference from placebo in least squares mean sleep interference scores at week 1 and endpoint with pregabalin treatment for painful DPN and
PHN. Significant improvement in sleep interference was maintained in all nine trials at every time point from week 1 through endpoint. *p50.05; yp50.01;
zp50.001. aFlexible-dose pregabalin. bFixed-dose pregabalin.
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figure 1 Difference from placebo in least squares mean sleep interference scores at week 1 and endpoint 
with pregabalin treatment for painful DPN and PHN. Significant i provement in sleep interference was 
maintained in all nine trials at every time point from week 1 through endpoint. *p50.05; yp50.01; zp50.001. 
aFlexible-dose pregabalin. bFixed-dose pregabalin
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TID or ≤300 mg/day BID were not effective in the DPN studies32,33,36 while pregabalin 300 
mg/day TID showed statistically significant reductions in pain and sleep vs. placebo32,34. 
In the trial of pregabalin in patients with PHN or painful DPN, the BID flexible-dose 
regimen (150–600 mg/day) was superior to placebo31. Pregabalin (150–600 mg/day) 
demonstrated significant reductions in pain and pain-related sleep interference in PHN 
across all TID and BID dosages (150–600 mg/day).
All trials included in this review were randomized, double-blind, and placebo-con-
trolled, with sleep outcomes as secondary endpoints. From objective analyses, such as 
polysomnography, it is known that patients with DPN and PHN show reduced sleep effi-
ciency, more fragmented sleep, reductions in stages 3, 4, and REM sleep, and an increase 
in stage 1 sleep when compared with normal healthy volunteers41,42. However, none of 
the studies reviewed here included an objective sleep assessment30–38. Patient diaries 
were used as a subjective assessment of pain-related sleep interference; although these 
diaries are a reliable tool, they may have introduced self-report bias. One additional 
potential limitation was that not all studies prohibited the use of benzodiazepines for 
‘sleep problems’. The two trials that permitted benzodiazepines for ‘sleep problems’ did 
not assess the impact of concomitant medications on sleep quality36,38.
Somnolence was a commonly reported adverse event in the pregabalin treatment 
arms and may have contributed to the decreased pain-related sleep interference scores. 
Post hoc analysis suggested the presence of somnolence did not impact pain scores. 
However, an analysis of the effect of somnolence on sleep interference scores was not 
performed32.
While pregabalin improved both pain and pain-related sleep interference in patients 
with painful DPN and PHN, there have been studies that suggest the effects are indepen-
dent of each other. In patients with osteoarthritis, pain scores were similar for pregabalin 
and placebo immediately following total knee arthroplasty, but pregabalin significantly 
decreased pain-related sleep interference scores postoperatively43. This suggests that 
further examination of pregabalin is warranted to clarify its effect on sleep. Nonetheless, 
pregabalin’s ability to improve sleep may provide additional benefits as better sleep has 
been shown to decrease the prolongation of herpes zoster pain44 and improve glycemic 
control in diabetes45–49.
coNclusioNs
The results of these nine trials provide clinicians with safe and efficacious dosing 
regimens for pregabalin in the treatment of comorbid neuropathic pain and sleep 
disturbances in patients with painful DPN and PHN. Pregabalin 150 to 600 mg/day dem-
onstrated a statistically and clinically significant decrease in pain scores, pain-related 
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sleep interference scores, sleep disturbance, and overall sleep problems indices on the 
MOS-Sleep Scale. Because the mechanism of pregabalin on sleep in the reviewed trials 
of PHN and painful DPN remains unclear, future research on the effect of pregabalin in 
sleep disorders associated with DPN and PHN may also be indicated.
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geNerAl discussioN
Although neuropathic pain has been relatively well defined, it remains difficult to 
apply this definition in clinical practice. The wide variability in the neuropathic pain 
conditions, the different underlying etiologies, and differences in pain complaints and 
sensory findings all play a pivotal role. Due to lack of knowledge on the pathophysiology 
of neuropathic pain, it is almost impossible to make a reliable link between signs and 
symptoms and the underlying mechanisms. All these factors make neuropathic pain a 
difficult condition to manage.1
The challenge in both research and clinical practice is to translate the signs and symp-
toms into specific pathophysiologic mechanisms, each of which have implications for 
treatment. The development of specific and selective treatments may well depend on a 
mechanism-based classification. The assumption is that common mechanisms initiated 
by diverse etiologic factors may elicit common pain symptoms.2,3 However, what may 
appear to be the same lesion may induce pain complaints, or no pain at all. For example, 
in some patients the same etiology may result in complaints of numbness or an absence 
of sensation, and in others in painful spontaneous activity and hyperexcitability. A critical 
analysis of previous clinical trials showed that, despite the logic of a mechanism-based 
approach of therapy, evidence supporting its success remains inconclusive.4
Translational research should reduce the gap between the rapid progress made by 
basic science, which has revealed a multitude of underlying mechanisms, and the slow 
progress in clinical practice. One of the problems to be tackled is that standardized 
measurement approaches are either lacking or difficult to apply. 5
Attempting to apply a differentiation between ‘peripheral’ and ‘central’ neuropathic 
pain is questionable. Rather, the mechanisms and origins of the nerve damage or dys-
function are the main discriminative factors. It is not possible to determine the origin of 
neuropathic pain from clinical characteristics of the pain.6 Neuropathic pain is the result 
of activation, modulation and modification of the nervous system as a whole after nerve 
damage.7 It seems that current treatment needs to move away from merely suppressing 
‘peripherally’ or ‘centrally’ generated symptoms, to a disease-modifying strategy aimed 
at both preventing maladaptive plasticity and reducing intrinsic risk.8
Nowadays, neuropathic pain is mainly treated with antidepressants and anti-epilep-
tics; the ‘classic’ analgesics show no efficacy for this type of pain. However, patients suf-
fering from neuropathic pain may show a wide variation in response to one specific drug 
therapy. One reason for this is that neuropathic pain can co-exist with nociceptive and 
idiopathic types of pain. Therefore, patients may have different clinical pain components 
that need to be addressed, apart from the multiple neuropathic mechanisms involved.9
One step towards individually-tailored treatment strategies should be the use and 
validation of screening tools that can differentiate between the different types of pain. 
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Pain is a subjective phenomenon and therefore difficult to evaluate and/or measure with 
the currently available tools and equipment. The development of the DN4 questionnaire 
is a step towards clearly identifying patients with neuropathic pain. The questionnaire 
might also be used to determine neuropathic components in conditions such as malig-
nant pain, low back pain and post-traumatic disorders. The borderline between definite, 
probable, possible and unlikely with regard to different types of pain conditions, in 
particular nociceptive and neuropathic pain, still needs to be elucidated. In addition, 
the term ‘mixed pain’ should either be avoided or more clearly defined.
Most controlled trials have focused on the relief of pain, rather than on the highly 
distressing symptoms of allodynia or hyperalgesia, or the effect of treatment on the 
patient’s quality of life. This makes a comparative interpretation of the effects of the 
available treatments difficult. Monitoring treatment with questionnaires (such as 
the DN4) may help to measure the effect of treatment, and also make trial outcomes 
easier to compare. Moreover, because pain is generally not a static condition, the signs 
and symptoms may change during the course of the disease. A questionnaire might 
also allow to monitor these dynamic changes as well as the sometimes unpredictable 
responses to different types of treatment. Pain intensity scales (particularly the Visual 
Analogue Scale) and pain quality evaluation by monitoring specific pain symptoms (e.g. 
burning pain, pain paroxysms, or allodynia) may help to reveal preferential effects of 
different treatments. 10
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chAPter i iNtroductioN
It is important to discriminate between ‘nociceptive’ pain and ‘neuropathic’ pain due to 
the important therapeutic consequences of this classification.
Neuropathic pain may affect as much as 3% of the population.
Pregabalin is an α2-δ ligand with demonstrated efficacy in neuropathic pain disorders.
Neuropathic pain is under-diagnosed, which results in ineffective pain management. 
Therefore, the DN4 questionnaire was validated as a screening tool.
Neuropathic pain impairs patients’ mood, quality of life, activities of daily living and 
performance at work.
chAPter ii liNguistic VAlidAtioN of the dN4 for use iN 
iNterNAtioNAl studies
A French Neuropathic Pain Group has developed a specific questionnaire, the DN4, to 
help clinicians in the differential diagnosis of neuropathic and non-neuropathic pain. 
In order to allow this questionnaire to be used in international studies, it has been 
translated and linguistically validated into Dutch, German, Greek and Hungarian, using 
a well-established procedure.
The DN4 items were linguistically validated in each of the target languages, thus 
providing the means for standardising the diagnosis of neuropathic pain and pooling 
the data collected during clinical trials in the different countries involved.
chAPter iii VAlidAtioN of the dutch VersioN of the dN4: A 
diAgNostic QuestioNNAire for NeuroPAthic PAiN
From a therapeutic point of view, the most pragmatic classification of pain is a differen-
tiation in nociceptive and neuropathic pain.
Difficulties to diagnose neuropathic pain in routine clinical practice urge the need for 
validated and easy-to-use diagnostic tools.
DN4 stands for “Douleur Neuropathique 4 questions” and was developed by the 
French Neuropathic Pain Group. The DN4 was designed as an easy to fulfill diagnostic 
questionnaire and is composed of 10 yes/no items. This neuropathic pain diagnostic 
questionnaire is build in two parts. The first part is based on symptoms estimated in an 
interview of the patient; this part can also be self-administered. The second part is based 
on a standardized clinical examination.
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The interview part includes 7 items corresponding to 2 domains. The questions ad-
dress pain characteristics: burning, painful cold and electric shocks, and subsequently 
associated symptoms of abnormal sensations in the same area: tingling, pins and 
needles, numbness, itching.
The examination part includes 2 domains measured by 3 items that address to signs 
estimated with a neurological examination: touch hypoesthesia, pricking hypoesthesia 
and pain caused or increased by brushing. The DN4 neuropathic pain diagnostic ques-
tionnaire aims to discriminate neuropathic pain from nociceptive pain.
The primary objective of this study was to evaluate the diagnostic value of the Dutch 
version of the DN4 questionnaire.
Both the DN4 7-item and 10-item scores showed in a statistical analysis, using a receiver 
operating characteristic curve, a good ability to discriminate between patients’ type of 
pain, with an area under the curve (AUC) of 0.81 and 0.82, respectively. The cut-off point 
of 5/10 for the full questionnaire resulted in a sensitivity of 75% and a specificity of 79%, 
while the cut-off point of 4/7 for the partial questionnaire resulted in a sensitivity of 74% 
and a specificity of 79%.
The items “brushing”, “painful cold” and “numbness” were most discriminating.
chAPter iV efficAcy ANd tolerAbility of twice-dAily PregAbAliN 
for treAtiNg PAiN ANd relAted sleeP iNterfereNce iN PostherPetic 
NeurAlgiA: A 13-week, rANdomized triAl.
The 13-week, double-blind, placebo-controlled study randomized 370 patients with 
PHN to pregabalin (150, 300, or 600 mg/day BID) or placebo.
This international, multicenter trial evaluated the efficacy and safety of pregabalin 
dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic 
neuralgia (PHN).
Primary efficacy measure was endpoint mean pain score from daily pain diaries. Sec-
ondary efficacy measures included endpoint mean sleep-interference score from daily 
sleep diaries and Patient Global Impression of Change (PGIC).
Pregabalin provided significant, dose-proportional pain relief at endpoint: difference 
from placebo in mean pain score, 150 mg/day, -0.88, p = 0.0077; 300 mg/day, -1.07, p = 
0.0016; 600 mg/day, -1.79, p = 0.0003.
Sleep interference in all pregabalin groups was also significantly improved at end-
point, compared with placebo (p < 0.001).
Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well 
tolerated. It also reduced the extent to which pain interfered with sleep. Pregabalin’s 
effects were seen as early as week 1 and were sustained throughout the 13-week study.
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chAPter V PregAbAliN iN the treAtmeNt of Post-trAumAtic 
PeriPherAl NeuroPAthic PAiN: A rANdomized double-bliNd triAl
This study evaluated pregabalin in the treatment of post-traumatic peripheral neuro-
pathic pain (including post-surgical). The study was an international, multicenter, par-
allel-group, double-blind, randomized clinical trial comparing 8 weeks of flexible-dose 
pregabalin 150–600 mg/day with placebo, taken as two daily doses. Randomization was 
preceded by a 2-week, single blind, placebo run-in period; baseline data were collected 
at randomization. Patients who did not meet both pain entry criteria at randomization 
(i.e. NRS and VAS assessments) were not randomized. Of the 367 treated in the single-
blind run in, 254 were randomized and received either placebo (n=127) or pregabalin 
(n=127).
Pregabalin was associated with a significantly greater improvement in the mean 
endpoint pain score vs. placebo. Pregabalin was also associated with significant im-
provements from baseline in pain-related sleep interference, and was associated with 
a statistically significant improvement in the Hospital Anxiety and Depression Scale 
anxiety subscale.
It was concluded that a flexible-dose pregabalin 150–600 mg/day was effective in 
relieving neuropathic pain, improving disturbed sleep, and improving overall patient 
status and was generally well tolerated in patients with post-traumatic peripheral neu-
ropathic pain.
chAPter Vi A cross-sectioNAl surVey of heAlth stAte imPAirmeNt 
ANd treAtmeNt PAtterNs iN PAtieNts with PostherPetic NeurAlgiA.
Postherpetic neuralgia (PHN) develops in 8–24% of patients with herpes zoster. Few 
studies have evaluated the patient burden and treatment of PHN in general practice. 
The purpose of this study was to determine the patient burden of PHN with respect to 
pain intensity and impact on patient functioning and to characterize treatment patterns 
and health resource utilization in general practice.
Eighty-four patients with PHN were identified in general practice settings. Patients 
answered a questionnaire that included: pain severity and interference items from the 
modified short form brief pain inventory (mBPI-SF); EuroQol (EQ-5D) survey; and ques-
tions related to current treatment, health status and resource utilization. Physicians pro-
vided information on medications prescribed for PHN and pain-related co-morbidities 
(anxiety, depression and sleep disturbance).
It was concluded that PHN causes substantial patient burden expressed as interfer-
ence with daily functioning and reduced health status associated with pain severity. This 
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burden may result in part from suboptimal management strategies, increased health 
resource utilization and suggests a need for more effective pain management.
chAPter Vii relAtioNshiPs betweeN chANges iN PAiN seVerity ANd 
other PAtieNt-rePorted outcomes: AN ANAlysis iN PAtieNts with 
PosttrAumAtic PeriPherAl NeuroPAthic PAiN
This study is evaluating in patients a relationship between change in pain severity and 
changes on patient-reported outcomes (PROs) assessing sleep, function, and mood in 
patients with post-traumatic pain.
A secondary analysis is presented using data from a clinical trial evaluating pregabalin 
in patients with posttraumatic peripheral neuropathic pain (N=254). Regression models 
were used to determine the association between changes in pain (0–10 NRS) as the 
predictor and scores on patient-reported measures as the outcome.
Change in pain severity as a continuous predictor resulted in plots that showed clear 
and direct relationships with change in the other PROs, all of which were statistically 
significant (P<0.001). It was concluded that a direct relationship exists between pain and 
various aspects of patient’s well-being and functioning, which can provide a quantita-
tive assessment of how improvements in pain may be expected to relate to other patient 
outcomes.
chAPter Viii the effect of PregAbAliN oN PAiN-relAted sleeP 
iNterfereNce iN diAbetic PeriPherAl NeuroPAthy or PostherPetic 
NeurAlgiA: A reView of 9 Published cliNicAl triAls
Postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) are com-
mon chronic neuropathic pain conditions. Frequently, there is a complex relationship 
between chronic neuropathic pain and sleep; often with pain disturbing sleep, and poor 
sleep exacerbating pain. Pain and sleep can also have a significant impact on mood, and 
a greater benefit for patients with PHN or painful DPN is often found in treatments that 
both relieve pain and improve sleep quality.
This manuscript reviews efficacy and tolerability data from 9 published clinical trials 
of pregabalin for the treatment of DPN and PHN demonstrating the beneficial effect of 
pregabalin on pain and sleep disturbances in these patients.
Pregabalin was well tolerated and significantly reduced endpoint mean pain scores 
and also significantly improved pain-related sleep interference.
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chAPter iX geNerAl discussioN
In neuropathic pain it is almost impossible to make a reliable link between signs and 
symptoms and the underlying mechanisms. Translational research should reduce the 
gap between basic science, which has revealed a multitude of underlying mechanisms, 
and the application in clinical practice.
Treatment of neuropathic pain needs to aim at a disease-modifying strategy.
The validation of the DN4 questionnaire is a step towards clearly identifying patients 
with neuropathic pain. The borderline between definite, probable, possible and unlikely 
with regard to different types of pain conditions, still needs to be elucidated.
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hoofdstuk i iNleidiNg
Het is belangrijk om nociceptieve pijn te onderscheiden van neuropatische pijn wegens 
de verschillen in behandeling. 
Neuropathische pijn komt waarschijnlijk bij ongeveer 3% van de bevolking voor.
Pregabaline is als pijnstiller een geschikt middel bij de behandeling van neuropatische 
pijn en wordt over het algemeen goed verdragen door de patiënt.
De diagnose neuropatische pijn wordt te weinig gesteld, waardoor de behandeling te 
kort schiet. De DN4 vragenlijst werd gevalideerd om neuropatische pijn beter te kunnen 
opsporen.
Neuropatische pijn heeft een bijzonder negatieve invloed op het dagelijks functione-
ren en de kwaliteit van leven.
hoofdstuk ii tAAlkuNdige VAlidAtie VAN de dN4 Voor gebruik iN 
iNterNAtioNAle studies
Een Franse groep artsen die zich bezig houdt met neuropatische pijn heeft een specifieke 
vragenlijst ontwikkeld, de DN4, om clinici te helpen bij de differentiële diagnose van 
neuropathische en niet-neuropathische pijn. Om deze vragenlijst te kunnen gebruiken 
in internationale studies, is de vragenlijst vertaald en taalkundig gevalideerd in het Ne-
derlands, Duits, Grieks en Hongaars, met behulp van een goed vastgestelde procedure.
De DN4 vragen werden taalkundig gevalideerd in elk van de doeltalen, waardoor 
het vergelijken en bundelen van de gegevens over de diagnose en behandeling van 
neuropatische pijn, verzameld tijdens klinische proeven in de verschillende betrokken 
landen, mogelijk wordt.
hoofdstuk iii VAlidAtie VAN de NederlANdse Versie VAN de dN4: eeN 
diAgNostische VrAgeNlijst Voor NeuroPAthische PijN.
Vanuit een therapeutisch oogpunt is de meest pragmatische indeling van pijn een differ-
entiatie tussen nociceptieve en neuropathische pijn. De DN4 diagnostische vragenlijst 
is bedoeld om onderscheid te maken tussen neuropathische pijn en nociceptieve pijn.
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Het is lastig om neuropathische pijn in de dagelijkse praktijk te diagnostiseren. Er 
bestaat behoefte aan gevalideerde en eenvoudig te gebruiken diagnostische hulpmid-
delen.
De DN4 vragenlijst staat voor “Douleur Neuropathique 4 vragen” en is ontwikkeld door 
de Franse neuropathische pijngroep. De DN4 is ontworpen als een makkelijk in te vullen 
diagnostische vragenlijst en bestaat uit 10 ja / nee vragen. De vragenlijst is opgebouwd 
uit twee delen. Het eerste deel is gebaseerd op de symptomen uitgedrukt in de vorm 
van vragen aan de patiënt; dit deel kan ook zelf worden ingevuld door de patiënt. Het 
tweede deel is gebaseerd op een gestandaardiseerd klinisch onderzoek.
Het interview deel omvat 7 vragen overeenkomend met 2 domeinen. De vragen gaan 
over pijn kenmerken: branderig, pijnlijk koude gevoel en elektrische schokken, en ver-
volgens over bijbehorende symptomen van abnormale gewaarwordingen in hetzelfde 
gebied: tintelingen, prikken, doof gevoel, jeuk.
Het lichamelijk onderzoek deel omvat eveneens 2 domeinen gemeten door 3 items: 
hypo-esthesie bij aanraking, hypo-esthesie bij prikken en pijn veroorzaakt of verergerd 
door wrijven.
Het primaire doel van deze studie was het evalueren van de diagnostische waarde van 
de Nederlandse versie van de DN4 vragenlijst.
Zowel de DN4 7 vragen en 10 vragen uitkomsten toonden in een statistische analyse, 
met behulp van de ROC (Receiver Operating Characteristic), een duidelijk onderscheid 
tussen het type pijn bij patiënten, met een AUC (Area Under the Curve) respectievelijk 
van 0,81 en 0,82. De cut-off waarde van 5 uit 10 voor de volledige vragenlijst resulteerde 
in een gevoeligheid van 75% en een specificiteit van 79%, terwijl de cut-off waarde van 
4 uit 7 voor de gedeeltelijke vragenlijst resulteerde in een gevoeligheid van 74% en een 
specificiteit van 79%. De items “wrijven”, “pijnlijk koude gevoel” en “doof gevoel” waren 
de meest onderscheidende symptomen.
hoofdstuk iV de werkzAAmheid eN VerdrAAgbAArheid VAN 
tweemAAl dAAgs PregAbAliNe Voor de behANdeliNg VAN PijN eN 
AANVerwANte slAAPstoorNis iN PostherPetische NeurAlgie: eeN 13 
wekeN dureNde, gerANdomiseerde triAl.
Tijdens een 13 weken durend, dubbelblind, placebo-gecontroleerd gerandomiseerd en 
internationaal uitgevoerd onderzoek werden 370 patiënten met PHN (Post Herpetische 
Neuralgie) behandeld met pregabaline (150, 300, of 600 mg / dag tweemaal daags) of 
een placebo.
De werkzaamheid en veiligheid van pregabaline ter verlichting van postherpetische 
pijn werd geevalueerd.
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Het primaire eindpunt was de gemiddelde dagelijkse pijnscore genoteerd in een 
dagboekje. Secundaire eindpunten waren onder meer de dagelijkse slaaponderbreking 
of slaapstoornis en de Patient Global Impression of Change (PGIC). Daarnaast werden 
bijwerkingen geregistreerd.
Pregabaline verminderde significant en dosis-proportioneel de post herpetische pijn 
op eindpunt: verschil versus placebo in gemiddelde pijnscore: 150 mg / dag, -0,88, p = 
0,0077; 300 mg / dag, -1,07, p = 0,0016; 600 mg / dag, — 1,79, p = 0,0003.
Slaapstoornissen in alle groepen waren ook significant verbeterd op eindpunt bij in-
name van Pregabaline, vergeleken met placebo (p <0,001).
Pregabaline, tweemaal daags gedoceerd, verminderde neuropathische pijn als gevolg 
van PHN en werd goed verdragen. Het verminderde ook de slaapstoornissen ten ge-
volge van de pijn. De positieve effecten van Pregabaline werden in week 1 al duidelijk 
en vervolgens bleken deze effecten onverminderd meetbaar in de 13 weken durende 
studie.
hoofdstuk V PregAbAliNe bij de behANdeliNg VAN Post-
trAumAtische Perifere NeuroPAthische PijN: eeN gerANdomiseerde 
dubbelbliNde triAl
Deze studie evalueerde pregabaline bij de behandeling van post-traumatische perifere 
neuropathische pijn (met inbegrip van post-operatieve pijn). Het onderzoek was een 
internationaal, multicentrum uitgevoerde, met parallel-groep, dubbelblind, geran-
domiseerde klinische studie. Gedurende 8 weken werd een flexibele dosering prega-
baline 150–600 mg / dag met placebo vergeleken. De dosering was tweemaal daags. 
Randomisatie werd voorafgegaan door een twee weken durende, eenzijdig geblind-
eerde, placebo run-in periode; baseline gegevens werden verzameld bij randomisatie. 
Patiënten die niet voldeden aan de beide pijn criteria voor randomisatie (dwz NRS en 
de VAS evaluaties) werden niet in het onderzoek betrokken. Van de 367 behandelde in 
de single-blind run-in periode, werden 254 patiënten gerandomiseerd en deze kregen 
ofwel een placebo (n = 127) of pregabaline (n = 127).
Pregabaline groep toonde een significante verbetering in de gemiddelde pijnscore 
bij eindpunt versus de placebo groep. Patiënten die Pregabaline gebruikten toonden 
een significante verbetering ten opzichte van baseline bij pijn-gerelateerde slaapstoor-
nissen, en er werd een statistisch significante verbetering in de Hospital Anxiety and 
Depression Scale vastgesteld.
Er werd geconcludeerd dat een flexibele dosering pregabaline 150–600 mg / dag 
effectief was in het verlichten van neuropathische pijn, het verbeteren van verstoorde 
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slaap en algehele verbetering van de patiënt. Pregabaline werd over het algemeen goed 
verdragen door patiënten met post-traumatische perifere neuropathische pijn.
hoofdstuk Vi eeN cross-sectioNeel oNderzoek oVer de 
VermiNderde gezoNdheid eN de mANier VAN behANdeliNg bij 
PAtiëNteN met PostherPetische NeurAlgie.
Postherpetische neuralgie (PHN) komt voor bij 8–24% van de patiënten met herpes 
zoster. Weinig studies hebben de aan pijn gerelateerde problemen van de patiënt en 
de behandeling van PHN in de huisartspraktijk geevalueerd. Het doel van dit onderzoek 
was het bepalen van de functionele gevolgen bij de patiënt met PHN in samenhang met 
de pijn intensiteit. Getracht werd een beeld te krijgen van behandelingspatronen en 
benutting van gezondheidsvoorzieningen in de huisartspraktijk.
Vierentachtig patiënten met PHN werden geïdentificeerd in de huisartspraktijk. 
Patiënten beantwoorden een vragenlijst: Ernst van de pijn en interferentie items uit 
het aangepaste formulier korte pijn inventaris (mBPI-SF), EuroQol (EQ-5D) onderzoek, 
en vragen met betrekking tot de huidige behandeling, de gezondheidstoestand en de 
benutting van de zorg. Artsen verstrekten informatie over medicijnen voorgeschreven 
voor PHN en pijn-gerelateerde co-morbiditeit (angst, depressie en slaapstoornissen).
Er werd geconcludeerd dat PHN aanzienlijke last veroorzaakt voor de patiënt uitge-
drukt in verminderd dagelijks functioneren en een verminderde gezondheidstoestand 
geassocieerd met de ernst van de pijn. Deze last kan voor een deel het resultaat zijn van 
suboptimale behandelstrategieën. Ook wordt, mede hierdoor, een verhoogd beroep op 
zorg gedaan. Uit de studie blijkt dat er behoefte is aan effectievere pijnbehandeling.
hoofdstuk Vii relAties tusseN de VerANderiNgeN iN de erNst VAN 
de PijN eN ANdere door de PAtiëNt gerAPPorteerde uitkomsteN: 
eeN ANAlyse bij PAtiëNteN met PosttrAumAtische Perifere 
NeuroPAthische PijN
Deze studie evaluateert bij patiënten de relatie tussen verandering in de ernst van de 
pijn en veranderingen bij patiënt-gerapporteerde uitkomsten over de slaap, het functio-
neren en de stemming bij patiënten met post-traumatische pijn.
Een secundaire analyse wordt gepresenteerd met behulp van gegevens uit een 
klinisch onderzoek met pregabaline bij patiënten met een posttraumatische perifere 
neuropathische pijn (N = 254). Regressie modellen werden gebruikt om het verband te 
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bepalen tussen de veranderingen in pijn (0–10 NRS) als de voorspeller van veranderende 
scores op door de patiënt gerapporteerde uitkomsten.
Verandering in de ernst van de pijn als een continue voorspeller resulteerde in duide-
lijke en directe, aantoonbare relaties met veranderingen in de andere door de patient 
gerapporteerde uitkomsten, die alle statistisch significant (p <0,001) waren. Er werd 
geconcludeerd dat een directe relatie bestaat tussen de pijn en de diverse aspecten 
van het welzijn en functioneren van de patiënt. Misschien dat verandering van de ernst 
van de pijn kwantitatief beoordeelt kan worden door het meten van veranderingen van 
andere klachten van de patient.
hoofdstuk Viii het effect VAN PregAbAliNe oP PijN gerelAteerde 
slAAPoNderbrekiNg bij Perifere diAbetische NeuroPAthie of 
PostherPetische NeurAlgiA: eeN oVerzicht VAN 9 gePubliceerde 
kliNische oNderzoekeN
Postherpetische neuralgie (PHN) en pijnlijke diabetische perifere neuropathie (DPN) zijn 
vormen van neuropathische pijn die veel voorkomen. Vaak is er een complexe relatie 
tussen chronische neuropatische pijn en slaap, waarbij pijn de slaap verstoord en slecht 
slapen de pijn verergert. Pijn en slaap kunnen in belangrijke mate de stemming beïn-
vloeden. Patiënten lijdend aan PHN of DPN zouden beter behandeld kunnen worden 
indien tegelijkertijd de pijn en slaapstoornissen verminderen kunnen worden.
Dit artikel geeft een overzicht van gegevens en uitkomsten van negen gepubliceerde 
klinische studies over pregabaline voor de behandeling van DPN en PHN. Behandeling 
met pregabaline heeft een gunstig effect op de pijn en slaapstoornissen bij patiënten 
lijdend aan DPN of PHN.
Pregabaline werd goed verdragen en gemiddelde eindpunt pijnscores werden aan-
zienlijk verlaagd. Tevens verbeterde ook sterk de aan pijn gerelateerde slaapstoornissen 
tijdens de behandeling.
hoofdstuk iX AlgemeNe discussie
Het is bijna onmogelijk om een verband te leggen tussen klachten en symptomen en de 
veronderstelde mechanismen als oorzaak van neuropatische pijn.
De ontdekkingen uit de basiswetenschappen moeten worden vertaald in klinische 
toepasbaarheid.
Behandeling van neuropatische pijn moet gericht zijn op het resetten van het dys-
functionerende zenuwstelsel.
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De validatie van de DN4 vragenlijst is een stap vooruit om patienten met neuropati-
sche pijn duidelijk te onderscheiden. De grens tussen definitief, waarschijnlijk, mogelijk 
en onwaarschijnlijk met betrekking tot de verschillende soorten pijn moet nog vastge-
steld worden.
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Dankwoord
Op een bijzonder zonnige dag ergens in september 1975 bezocht ik als aankomend 
anesthesioloog het eerste wereldcongres over pijn (IASP, Florence). Ik werkte als AIO 
anesthesiologie in het academisch ziekenhuis te Leiden onder de bezielende leiding van 
Professor Dr. Johan Spierdijk. 
Pijn werd in die tijd alleen gezien als symptoom, zoiets als koorts, en toen Johan 
Spierdijk een afdeling pijnbehandeling wilde starten stuitte dat op meewarige hoog-
geleerde blikken en soms onverholen kritiek. Hoe juist was zijn zienswijze! Korte tijd 
na het congres in Florence werd met grote voortvarendheid in Nederland de NVBP 
(Nederlandse Vereniging ter Bestudering van Pijn) opgericht onder voorzitterschap van 
Paul Voorhoeve. Ik werd door Johan Spierdijk aangewezen als secretaris en ik moest de 
boekhouding doen. Johan Spierdijk zette mij aan het werk op de eerste Nederlandse 
pijnafdeling, zowaar ook bemand met een verpleegkundig pijnspecialist in de staf. 
En zo is het begonnen. Onder de inspirerende leiding van Johan leerde ik veelzijdige 
manieren om pijn te behandelen van Daniel Moore, Philip Bromage, Sam Lipton, Mark 
Swerdlow en andere coryfeeën. 
De kennis en inspiratie destijds opgedaan heeft mijn leven, mijn denken en werken 
bepaald. Helaas zijn deze briljante pioniers niet meer op deze wereld, maar ik draag mijn 
boekje graag op aan mijn leraren van kundige technieken en van de kunst om indicaties 
voor behandeling te stellen. Ik breng jullie waardevolle lessen nog steeds in de praktijk.
Mijn dank is zeer groot, want ik heb daardoor ook over de oorspronkelijke grenzen van 
de anesthesiologie heen, een bijzonder afwisselende loopbaan gehad. 
Van pijnbestrijding naar pijnbehandeling en uiteindelijk naar pijngeneeskunde.  De 
veel bredere kijk op chronische pijn als ziekte op zichzelf impliceerde dat ook meer we-
tenschap nodig was dan anesthesiologische vakkennis over zenuwblokkades en andere 
interventies om pijn te behandelen. Specifieke farmacotherapie en de behandeling van 
de gevolgen van pijn op het psychosociaal functioneren van de patiënt vergde nieuwe 
kennis. 
Beste Frank Huygen, hooggeachte promotor, we kennen elkaar al geruime tijd. Jij 
was het die mij, zelfs voordat  je tot hoogleraar werd benoemd, onmiddellijk aanmoe-
digde om ervaringen op schrift te stellen, om onderzoek te bundelen met de focus op 
neuropatische pijn. Je hebt mij enorm geholpen om mijn schroom te overwinnen. Mijn 
kwaliteiten lagen toch vooral op de ontwikkeling van interventie technieken. Er werden 
nieuwe onderzoeken geïnitieerd en met jou stuwende steun werden deze onderzoeken 
afgerond . Je werkte gewoon heel hard mee en daarnaast gaf je steeds positief en voor-
treffelijk commentaar. De laatste loodjes wogen het zwaarst, maar het resultaat ligt nu 
voor je. Ik ben er bijzonder trots op dat jij mijn promotor bent. Buitengewoon dank voor 
je acties als het nodig was en je vriendschappelijke en wetenschappelijke begeleiding.
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Dit proefschrift is het resultaat van uitsluitend klinisch onderzoek. Vele patiënten, 
waarvan ongeveer tweehonderd patiënten uit onze eigen praktijk in het Amphia zieken-
huis namen deel aan diverse onderzoekingen waarvoor toch aanzienlijke inspanningen 
op vrijwillige basis werden verricht. Er moesten vragenlijsten worden bijgehouden, vaak 
met elektronische hulpmiddelen, patiënten moesten beschikbaar zijn voor bloedonder-
zoek, nuchter blijven, regelmatig terugkomen en ook nog de kans op placebo behande-
ling lopen. De toewijding en trouwheid van praktisch alle patiënten aan de strikte regels 
van de onderzoekprotocollen was ongelooflijk en internationaal gezien opzienbarend. 
Mijn dank is bijzonder groot, want hoewel dit proefschrift natuurlijk nooit een doel op 
zich van enig onderzoek is geweest: zonder jullie medewerking had ik hier natuurlijk 
niet gestaan.
En dan Betty van Ginneken en José Verstijnen, research coördinatoren op en top. Wat 
hebben we toch veel meegemaakt, gelachen en ook wel eens een traantje weggepinkt. En 
altijd waren jullie er. Niet te beroerd om zelfs bij patiënten thuis het onderzoek te comple-
teren als dat noodzakelijk was. Voor jullie belangrijke bijdrage ben ik jullie erg dankbaar. 
Bedankt Peter Rosseel voor het voortdurend aandacht vestigen op het belang van weten-
schappelijk onderzoek binnen onze maatschap. We vormden een mooie commissie.
Ook Emile Houben en Juliette, verpleegkundig pijnspecialisten, en mijn medeonder-
zoekers Maarten van Eerd, Frank O’Connor en Vincent Hoffmann wil ik danken voor de 
geboden hulp in voorkomende gevallen. 
Beste Miryam, Cea, Annie, Arna en Tiny jullie stonden altijd klaar om het onmogelijke 
mogelijk te maken en om roosters aan te passen. Dank voor jullie steun, geduld en 
begrip.
Benoit Arnould, Flemming Bach, Didier Bouhassira, Andrew Bushmakin, Joe Cappel-
leri, Ellen Dukes, Hilary Feister, Frank Huygen, Maurice Giezeman, Le Gal, Melani Lucero, 
Susan Martin, Willem Jan Meerding, Bart Morlion, Kevin Murphy, Meryem Nimour, An-
toine Regnault, Laurence Rigaudy, Thomas Roth,  Alesia Sadosky, Michael Serpell, Mike 
Stoker, Jane Temple, Cory Toth, Maarten van Eerd, Mark Versavel, Kees Vos, James Young, 
Gergana Zlateva, mede auteurs in kille alfabetische volgorde: door  jullie belangrijke bij-
drage zijn de publicaties tot een goed einde gebracht. De raad en daad bij het opstellen 
van de manuscripten en het beantwoorden van reviewers om een publicatie acceptabel 
te maken was hartverwarmend. Oprecht hartelijk dank. En natuurlijk ook dank aan de 
vele onderzoekers in binnen- en buitenland die hun inspanningen leverden indien het 
onderzoek op verschillende locaties en in meerdere landen plaatsvond. 
Mevrouw Laraine Visser-Igles wil ik graag hartelijk danken voor het corrigeren van het 
Engels en het vergrootten van de leesbaarheid van de introductie, de discussie en ook 
de literatuurlijst! Anita van Toor: Bedankt voor je goede zorgen.
De kleine manuscriptcommissie, Prof. dr. S.E.R. Hovius, Prof. dr. R.J. Stolker, Prof. dr. 
K.C.P.Vissers hartelijk dank voor het kritisch beoordelen van het manuscript.
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En dan mijn huidige maatschap. Wat tien jaar geleden begonnen is als Buurt Overleg 
Anesthesiologen (BOA), later verbasterd tot Bredase - en Oosterhoutse  Anesthesio-
logen (BOA), is nu een volwassen solide groep collega’s en vrienden werkzaam op de 
meest vitale afdelingen van ons Amphia ziekenhuis. Ondanks of dankzij de grootte van 
onze club is toenemend duidelijk dat in de onderscheiden subspecialisaties, cardio- en 
algemene anesthesiologie, intensieve geneeskunde,  pijngeneeskunde en ziekenhuis 
management, ruimte is voor maten om te specialiseren en excelleren. Beste maten, zeer 
bedankt voor de geboden ruimte. Nardo van der Meer, Vincent Hoffmann, Anton Visser 
en Bas Gerritsen jullie zijn mij voorgegaan. Anton blijft mij maar “prefesser” noemen en 
ik denk met mijn boekje een kleine stap gemaakt te hebben naar iets hogers. Maar dat 
professorgedoe is veel te hoog gegrepen en moet nu echt afgelopen zijn Anton: ik heb 
mijn belofte waar gemaakt. In jou dankwoord van je proefschrift daag je ook Maarten 
van Eerd uit om zijn aspiraties waar te maken. Beste Maarten: Mijn goede vakvriend 
en toeverlaat, mijn wandelende bibliotheek, mijn voortdurende inspiratie, mijn steun 
in bange dagen, het gaat je zeker lukken! Ik geef daarom mijn promotiestokje door 
aan Gerhard van Gelder. Gerhard je hebt mij op koers weten te houden door als PC op 
bijzonder intelligente wijze het scheidend vermogen te herstellen na soms emotionele 
aberraties in het laatste seizoen van mijn werkzaam leven als anesthesioloog. Ik weet 
zeker dat je verworvenheden opgedaan bij je managementtaken de basis gaan vormen 
voor het volgende BOA boek.
Mijn paranimfen, Maarten van Eerd en Laut van Seventer, zeer hartelijk bedankt voor 
jullie steun. Maarten, decennia lang vriendschap en gelijke belangstelling en opvat-
tingen over pijn, wie anders had naast mij kunnen staan. En Laut, mijn oudste zoon, bij 
jou Delfts afstuderen al weer een tijd geleden, net voor het losbarsten van het jaarlijks 
carnaval heb ik mij een “Leids” grapje gepermitteerd over biervaten en drukverhoudin-
gen. De vraag hierover viel duidelijk niet in goede aarde bij de hooggeleerde commissie 
en ook niet bij jou overigens. Ik ben natuurlijk gewoon al levenslang heel erg trots op 
je en vind het geweldig dat je mijn paranimf bent.  Hopelijk heb ik toch ook weer iets 
rechtgezet en praktisch gezien heb ik je, met de voorgeschiedenis voor ogen, liever 
naast me dan tegenover mij staan.
En tot slot natuurlijk mijn lieve, altijd toegewijde Marijke, jij deelt al bijna 50 jaar lief 
en leed met mij. Je hebt met mij vele avonturen beleefd, meegemaakt is misschien een 
beter woord,  en dat was lang niet altijd zo leuk. Die vliegmaatschappij was mogelijk een 
dieptepunt, maar ik hoop dat je dit laatste avontuur als een hoogtepunt beschouwd. 
Dank voor je nooit aflatende steun en trouw, door dik en dun. Ik ben nu afgestudeerd en 
ik verheug me op nieuwe kleine avonturen met mijn kleinkinderen Milou en Florian en 
wie weet komen er nog meer. Dat zal helemaal afhangen van mijn lieve kinderen Anouk, 
Charita, Laut en Thijs. Bedankt voor jullie hartverwarmende belangstelling. Ik voel me 
een uiterst gelukkige echtgenoot, vader en grootvader. 
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Rob van Seventer werd geboren op 4 november 1946 te Dordrecht. Het HBS-B examen 
werd behaald in 1966 aan de Nassau HBS te Breda. In hetzelfde jaar werd de studie 
geneeskunde gestart aan de RU te Leiden. Na het artsexamen in 1973 begon hij, aanvan-
kelijk tijdens de vervulling van de militaire dienstplicht, de opleiding tot anesthesioloog 
in het AZL te Leiden, afdeling anesthesiologie (Hoofd Prof. Dr. Joh. Spierdijk). In 1976 
was hij mede oprichter van de Nederlandse Vereniging ter Bestudering van Pijn (NVBP) 
en een aantal jaren secretaris/penningmeester van deze vereniging. De opleiding tot 
anesthesioloog werd in 1977 afgerond. In 1977 werd hij maat in de maatschap anes-
thesiologie van het Diaconessenziekenhuis te Breda en tevens staflid van het Laurens-
ziekenhuis te Breda als pijnspecialist. Beide instellingen fuseerden in 1986 tot Baronie 
ziekenhuis. Van Seventer was, met korte onderbrekingen,  bijna tien jaar voorzitter van 
de medische staf. Na wederom een fusie met het Ignatius ziekenhuis te Breda in 2001 is 
hij thans, als lid van de maatschap anesthesiologie, werkzaam als pijnspecialist van het 
Amphia ziekenhuis te Breda. 
